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A B S T R A C T
Background
Risperidone is the ﬁrst new-generation antipsychotic drug made available in the market in its generic form.
Objectives
To determine the clinical effects, safety and cost-effectiveness of risperidone compared with placebo for treating schizophrenia.
Search methods
On19th October 2015, we searched the Cochrane Schizophrenia Group Trials Register, which is based on regular searches of CINAHL,
BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. We checked the references of all included
studies and contacted industry and authors of included studies for relevant studies and data.
Selection criteria
Randomised clinical trials (RCTs) comparing oral risperidone with placebo treatments for people with schizophrenia and/or schizophre-
nia-like psychoses.
Data collection and analysis
Two review authors independently screened studies, assessed the risk of bias of included studies and extracted data. For dichotomous data,
we calculated the risk ratio (RR), and the 95% conﬁdence interval (CI) on an intention-to-treat basis. For continuous data, we calculated
mean differences (MD) and the 95% CI. We created a ’Summary of ﬁndings table’ using GRADE (Grading of Recommendations
Assessment, Development and Evaluation).
Main results
The review includes 15 studies (N = 2428). Risk of selection bias is unclear in most of the studies, especially concerning allocation
concealment. Other areas of risk such as missing data and selective reporting also caused some concern, although not affected on the
direction of effect of our primary outcome, as demonstrated by sensitivity analysis. Many of the included trials have industry sponsorship
of involvement. Nonetheless, generally people in the risperidone group are more likely to achieve a signiﬁcant clinical improvement in
mental state (6 RCTs, N = 864, RR 0.64, CI 0.52 to 0.78, very low-quality evidence). The effect withstood, even when three studies
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with >50% attrition rate were removed from the analysis (3 RCTs, N = 589, RR 0.77, CI 0.67 to 0.88). Participants receiving placebo
were less likely to have a clinically signiﬁcant improvement on Clinical Global Impression scale (CGI) than those receiving risperidone
(4 RCTs, N = 594, RR 0.69, CI 0.57 to 0.83, very low-quality evidence). Overall, the risperidone group was 31% less likely to leave early
compared to placebo group (12 RCTs, N = 2261, RR 0.69, 95% CI 0.62 to 0.78, low-quality evidence), but Incidence of signiﬁcant
extrapyramidal side effect was more likely to occur in the risperidone group (7 RCTs, N = 1511, RR 1.56, 95% CI 1.13 to 2.15, very
low-quality evidence).
When risperidone and placebo were augmented with clozapine, there is no signiﬁcant differences between groups for clinical response
as deﬁned by a less than 20% reduction in PANSS/BPRS scores (2 RCTs, N = 98, RR 1.15, 95% CI 0.93 to 1.42, low-quality evidence)
and attrition (leaving the study early for any reason) (3 RCTs, N = 167, RR 1.13, 95% CI 0.53 to 2.42, low quality evidence). One
study measured clinically signiﬁcant responses using the CGI, no effect was evident (1 RCT, N = 68, RR 1.12 95% CI 0.87 to 1.44,
low quality evidence). No data were available for extrapyramidal adverse effects.
Authors’ conclusions
Based on low quality evidence, risperidone appears to be beneﬁtial in improving mental state compared with placebo, but it also causes
more adverse events. Eight out of the 15 included trials were funded by pharmaceutical companies. The currently available evidence
isvery low to low quality.
P L A I N L A N G U A G E S U M M A R Y
Risperidone versus placebo for schizophrenia
Review question
Is risperidone (tablet form) more effective than placebo in treating the symptoms of schizophrenia or schizophrenia-like illnesses?
Background
People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). These are called ‘positive
symptoms’. Mental illness also causes tiredness, apathy, emotional numbness, and withdrawal. These are called ‘negative symptoms’.
The main treatment for the symptoms of schizophrenia are antipsychotic drugs. Antipsychotic drugs can be classiﬁed into typical
(older) and atypical (newer) drugs. Typical antipsychotics such as chlorpromazine and haloperidol have been the mainstay of treatment
for decades, and have been effective in reducing the positive symptoms of schizophrenia. Negative symptoms, however, have been
fairly resistant to treatment. In addition, drug treatments are associated with unpleasant side effects that cause people to stop taking
medication, which may lead to relapse. It is thought that newer atypical antipsychotics, such as risperidone, are more effective than the
older antipsychotics as they reduce the positive symptoms but cause fewer side effects.
Study characteristics
Searches for high-quality randomised trials were carried out in 2008, 2013 and 2015. The review now includes 15 studies with 2428
participants. The studies randomised participants (in- and outpatients) with schizophrenia or schizophrenia-like illnesses into treatment
groups that received oral risperidone or placebo.
Key results
Results from limited data suggest that risperidone is more effective than placebo for reducing the overall symptoms of schizophrenia, and
participants receiving risperidone were more likely to comply with treatment. However, like the older typical antipsychotics, risperidone
was also associated with serious side effects, such as parkinsonism.
Quality of the evidence
The evidence available was very low quality. Information and data were limited, poorly reported, and probably biased in favour of
risperidone . Nearly half of the included trials were funded by drug companies. Firm conclusions are difﬁcult to make based on the
results of this review. Better conduct and reporting of trials could increase conﬁdence in the results.
Ben Gray, Senior Peer Researcher, McPin Foundation. http://mcpin.org/
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
RISPERIDONE compared to PLACEBO for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: inpat ient and outpat ient
Intervention: RISPERIDONE
Comparison: PLACEBO
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
PLACEBO RISPERIDONE
Mental state: no clin-
ically significant re-
sponse in psychotic
symptoms (defined by
various scale total
score change) - short
term (up to 12 weeks)
- defined by PANSS/
BPRS <20% decline
Follow-up: 12 weeks
Study population RR 0.64
(0.52 to 0.78)
864
(6 studies)
⊕©©©
Very Low1,2,3
692 per 1000 443 per 1000
(360 to 540)
Moderate
733 per 1000 469 per 1000
(381 to 572)
Leaving the study early
- short term (up to 12
weeks) - any reason
Follow-up: 12 weeks
Study population RR 0.69
(0.62 to 0.78)
2261
(12 studies)
⊕⊕©©
Low1,3
495 per 1000 342 per 1000
(307 to 386)
Moderate
486 per 1000 335 per 1000
(301 to 379)
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Global state: 2. no
significant clinical im-
provement - CGI, short
term (up to 12 weeks)
Follow-up: 12 weeks
Study population RR 0.69
(0.57 to 0.83)
594
(4 studies)
⊕©©©
very low1,2,3
744 per 1000 513 per 1000
(424 to 618)
Moderate
732 per 1000 505 per 1000
(417 to 608)
Adverse effects: 1a.
extrapyramidal - vari-
ous effects - short term
(up to 12 weeks) - gen-
eral - any significant
EPS
Follow-up: 12 weeks
Study population RR 1.56
(1.13 to 2.15)
1511
(7 studies)
⊕⊕©©
Low1,3
73 per 1000 113 per 1000
(82 to 156)
Moderate
106 per 1000 165 per 1000
(120 to 228)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to risk of bias: studies contribut ing data to this body of evidence have unclear or high risk of bias
in one or more domains, some were also sponsored by pharmaceut ical companies.
2 Downgraded one level due to inconsistency: some concerns of heterogeneity were ident if ied.
3 Downgraded one level due to publicat ion bias: ’strongly suspected’ - most studies were sponsored by pharmaceut ical
companies.
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B A C K G R O U N D
Risperidone (Figure 1) is the ﬁrst new-generation antipsychotic
drug made available in the market in its generic form. It has been
used in the treatment of schizophrenia and related psychotic dis-
orders for over a decade.
Figure 1. Risperidone
Description of the condition
Schizophrenia is a serious, chronic, and relapsing mental illness
with a worldwide lifetime prevalence of about 1%. It is char-
acterised by positive symptoms such as hallucinations and delu-
sions, and negative symptoms such as emotional numbness and
withdrawal. One-third of those who experience an episode of
schizophrenia recover and the illness does not recur. Another 30%
experience an unremitting illness. The remainder have a recurrent
illness but with long episodes of considerable recovery from the
positive symptoms. The overall cost of the illness to the individu-
als, their families, and the community is considerable.
Description of the intervention
Conventional antipsychotic drugs were introduced into
widespread use in the 1950s, and have since formed the mainstay
of drug treatment for schizophrenia. Although these drugs were
indeed a revolution, their early promise of complete recovery was
unfulﬁlled. Continued interests in further developments led to
the formulation of clozapine in the early 1960s, which, in turn,
paved the way for a series of new atypical antipsychotic drugs. This
disparate grouping was said to be ’atypical’ because they did not
seem to cause movement disorders to the same extent as the older
generation of drugs.
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This series of newer drugs appeared on the market in the early
1990s, risperidone being one of the ﬁrst. Initially, risperidone was
compared with placebo and then with the older-generation an-
tipsychotic drugs, especially haloperidol (Hunter 2003). More re-
cently, risperidone has been used as the control compound when
other new antipsychotic drugs are compared with a ’standard atyp-
ical’. In 2007 risperidone became off-licence, and it seems likely
that this drug will emerge as the new standard care comparator,
replacing the older and more problematic haloperidol (Joy 2006).
The absolute effects of a drug are often less well investigated when
a standard treatment is widely used, and it is seen as unethical not
to treat with drug therapy. With almost everyone having access to
older drug treatments for schizophrenia, placebo-controlled trials
in this area are now difﬁcult to justify (Carpenter 2003; Laughren
2001). Yet in many physical diseases, such as angina pectoris,
bronchial asthma, herpes simplex, and duodenal ulcers, placebo
effects can account for up to 33%of clinical improvement (Benson
1996).When it comes to new drugs such as risperidone, clinicians
and the public are often provided the evidence for the comparative
effects, but the newer drug has been compared with a less-than-
ideal drug (Hunter 2003). We argue that knowledge of the effects
of a drug compared with placebo assists development of a rational
therapeutic approach (Vallance 2006).
How the intervention might work
Risperidone (4-[2-[4-(6-ﬂuorobenzo[d]isoxazol-3-yl)-1-
piperidyl]ethyl]-
3-methyl-2,6-diazabicyclo[4.4.0]deca-1,3-dien-5-one) is a strong
postsynaptic dopamine receptor antagonist, but also acts as a 5-
HT2A antagonist and is called a serotonin/dopamine antagonist
(Leysen 1994). Risperidone is rapidly and very well absorbed after
administration orally, and less than 1% is excreted unchanged in
the faeces (Heykants 1994). It reaches peak plasma levels quickly
regardless of whether it is administered as a liquid or pill. It is
90% plasma protein bound (Darby 1997). Risperidone binds to
D2 and D3 receptors with 50 and 20 times greater afﬁnity than
clozapine and is only 2 to 3 times less potent than haloperidol.
Also, its afﬁnity for D1 receptors is 100 times lower than for D4
receptors (Leysen 1994).
Why it is important to do this review
Comparing any drug with a placebo has always been an intriguing
aspect of drug trials, and some authors, such as Vallance 2006, feel
that outcome measures are best measured when compared with a
placebo as it partly accounts for the philosophical obstacles such
as the mind/body dichotomy, which are inherent in conceptual-
ising these effects. In 60% to 90% of diseases, including angina
pectoris, bronchial asthma, herpes simples, and duodenal ulcers,
placebo effects can account for up to 33% of clinical improvement
and yield clinical results (Benson 1996). The placebo effect ulti-
mately allows a rationalised therapeutic approach to be developed
to maximise the clinical beneﬁt of the therapeutic encounter and
evaluate various outcome measures (Vallance 2006).
Cochrane reviews to date have evaluated the efﬁcacy of risperidone
for schizophrenia by comparing it with typical and other atypical
antipsychotics. This comparison of risperidone versus placebo is
one of a set of reviews on risperidone (Table 1).
O B J E C T I V E S
To determine the clinical effects, safety, and cost-effectiveness of
risperidone compared with placebo for treating schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all relevant RCTs. If a trial was described as ’double-
blind’, but only implied that the study is randomised, then we
included it in a sensitivity analysis. If in such a trial there was
no implied randomisation, we contacted the authors to clarify
the randomisation. We excluded trials where randomisation did
not occur. If there was no substantive difference within primary
outcomes (see Types of outcome measures) when these ’implied
randomisation’ studies were added, then we included these in the
ﬁnal analysis. If there was a substantive difference, we only used
clearly randomised trials and described the results of the sensitivity
analysis in the text. We excluded quasi-randomised studies, such
as those allocated by using alternate days of the week.
Types of participants
We included people (above 17 years of age) with schizophrenia
and other types of schizophrenia-like psychoses (schizophreniform
and schizoaffective disorders), as evidence suggests that they are
fundamentally not too dissimilar (Carpenter 1994).
Types of interventions
1. Oral risperidone: any dose or form
2. Placebo
Types of outcome measures
We grouped outcomes into short term (up to 12 weeks), medium
term (13 to 26 weeks), and long term (over 26 weeks).
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Primary outcomes
1. Mental state
1.1 Clinical response: no clinically signiﬁcant response in psy-
chotic symptoms, as deﬁned by each of the studies (short term)
2. Service utilisation
2.1 Hospital admission and/or re-admission
Secondary outcomes
1. Leaving the study early
2. Global state
2.1 Average score/change in global state
2.2 No clinically signiﬁcant response on global state, as deﬁned by
each of the studies
3. Mental state
3.1 Average score/change on psychotic symptoms
3.2 No clinically signiﬁcant response on positive symptoms, as
deﬁned by each of the studies
3.3 Average score/change in positive symptoms
3.4 No clinically signiﬁcant response on negative symptoms, as
deﬁned by each of the studies
3.5 Average score/change in negative symptoms
3.6 Use of additional medication (other than anticholinergics) for
psychiatric symptoms
4. Extrapyramidal adverse effects
4.1 Use of antiparkinson drugs
4.2 No clinically signiﬁcant extrapyramidal adverse effects, as de-
ﬁned by each of the studies
4.3 Average score/change in extrapyramidal adverse effects
5. Other adverse effects
5.1 General and speciﬁc (including deaths by suicide or natural
causes)
6. Service utilisation outcomes
6.1 Days in hospital
7. Economic outcomes
8. Quality of life/satisfaction with care for either recipients of
care or carers
8.1 Signiﬁcant change in quality of life/satisfaction, as deﬁned by
each of the studies
8.2 Average score/change in quality of life/satisfaction
9. ’Summary of findings’ table
We used the GRADE approach to interpret ﬁndings and used
GRADEpro to import data from RevMan 5.1 to create ’Summary
of ﬁndings’ tables (Schünemann 2008). These tables provide out-
come-speciﬁc information concerning the overall quality of evi-
dence from each included study in the comparison, themagnitude
of effect of the interventions examined, and the sum of available
data on all outcomes we rated as important to patient-care and
decision making. We selected the following main outcomes for
inclusion in the ’Summary of ﬁndings’ table:
1. Mental state - no clinically signiﬁcant response
2. Leaving the study early - for any reason
3. Global state - no signiﬁcant clinical improvement
4. Adverse events - extrapyramidal effects
Search methods for identiﬁcation of studies
Electronic searches
1. Cochrane Schizophrenia Group Trials Register
On 19th October 2015, the Trials Search Co-ordinator searched
the Cochrane Schizophrenia Group Trials Register using the fol-
lowing search strategy:
((risperidone* or Risperdal*) AND placebo*):ti,ab of REFER-
ENCES or ((risperidone* or Risperdal*) AND placebo*):sin of
STUDIES
The Cochrane Schizophrenia GroupTrials Register is compiled by
systematic searches ofmajor resources (includingAMED,BIOSIS,
CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and reg-
istries of clinical trials) and their monthly updates, handsearches,
grey literature, and conference proceedings (see Group Module).
There are no language, date, document type, or publication status
limitations for inclusion of records into the register.
For details of the previous search, please see Appendix 1.
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Searching other resources
1. Reference lists
We searched all references of the reports of included trials for
further relevant studies.
2. Authors of studies
Whennecessary, we contacted authors of studies to clarify data and
request additional studies, but received no response. We also con-
tacted authors for information on any published or unpublished
additional studies that they were aware of, but again, received no
response.
3. Pharmaceutical companies
We contacted relevant pharmaceutical companies for additional
studies and to clarify study data. However, we did not receive any
further information.
Data collection and analysis
We have updated some text of the methods to reﬂect changes
and updates in Cochrane methodology; please see Appendix 2 for
details of methods used in original version.
Selection of studies
Two review authors (RR, MJ) independently inspected all reports
of studies identiﬁed for the original search. Any disagreements
were resolved by consensus; where doubt remained, we acquired
the full article. Review authors (RR, BL and JX) independently
decided whether these studies met the review criteria. We did not
intend to blind the names of authors, institutions, and journal of
publication. Again, any disagreements were resolved by consensus.
When this was not possible, we sought further information and, in
the interim, added these trials to the Studies awaiting classiﬁcation
list.
SS screended results from 2013 search and review authors SZ
and BL independently inspected citations from the subsequent
updated search (19th October 2015) to identify relevant abstracts.
We obtained and inspected full reports of the abstracts meeting
the review criteria.
Data extraction and management
1. Extraction
Review authors RR, MJ (original search), SS (2013 search), SZ,
BL (2015 search) independently extracted data from all included
studies. In addition, to ensure reliability, JX independently ex-
tracted data from a random sample of these studies comprising
10% of the total. Again, we discussed any disagreements and doc-
umented decisions. The need did not arise, but we had planned
to extract data presented only in graphs and ﬁgures whenever pos-
sible, while only including the data if two review authors inde-
pendently reached the same result. We also attempted to contact
authors through an open-ended request in order to obtain missing
information or for clariﬁcation whenever necessary.
2. Management
2.1 Forms
We extracted data on to standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument was not written or modiﬁed by one
of the trialists for that particular trial.
2.3 Endpoint versus change data
Both endpoint and change data have advantages. Change data can
remove a component of between-person variability from the anal-
ysis. On the other hand, calculation of change needs two assess-
ments (baseline and endpoint), which can be difﬁcult in unsta-
ble and hard-to-measure conditions such as schizophrenia. We de-
cided to primarily use endpoint data, and only use change data if
the former were not available. We combined endpoint and change
data in the analysis, as we used mean differences (MD) rather than
standardised mean differences (SMD) throughout (Higgins 2011,
Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we aimed to apply the following
standards to all data before inclusion: a) standard deviations and
means are reported in the paper or obtainable from the authors;
b) when a scale starts from the ﬁnite number 0, the standard
deviation,whenmultiplied by 2, is less than themean (as otherwise
the mean is unlikely to be an appropriate measure of the centre of
the distribution (Altman 1996)); c) if a scale started from a positive
value (such as the Positive andNegative Syndrome Scale (PANSS),
which canhave values from30 to210), wemodiﬁed the calculation
described above to take the scale starting point into account. In
these cases, skew is present if 2 SD > (S - S min), where S is the
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mean score and S min is the minimum score. Endpoint scores
on scales often have a ﬁnite start and endpoint, and these rules
can be applied. We entered skewed endpoint data from studies of
fewer than 200 participants in ’other tables’ within the Data and
analyses section rather than into a statistical analysis. Skewed data
pose less of a problem when looking at mean if the sample size is
large; we entered such data from studies with over 200 participants
into syntheses.When continuous data are presented on a scale that
includes a possibility of negative values (such as change data), it is
difﬁcult to tell whether data are skewed or not, we entered skewed
change data into analyses.
2.5 Common measure
Had we identiﬁed such data, we intended to convert variables that
can be reported in differentmetrics, such as days in hospital (mean
days per year, per week, or per month) to a common metric (for
example mean days per month) to facilitate comparison between
trials. However, we did not identify such data.
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures to
dichotomous data. This can be done by identifying cutoff points
on rating scales and dividing participants accordingly into ’clini-
cally improved’ or ’not clinically improved’. It is generally assumed
that if there is a 50% reduction in a scale-derived score such as the
Brief Psychiatric Rating Scale, Overall 1962, or the PANSS, Kay
1986, this could be considered as a clinically signiﬁcant response
(Leucht 2005a; Leucht 2005b). If data based on these thresholds
were not available, we used the primary cutoff the original authors
presented. Some included studies provided a deﬁnition of response
as a reduction in PANSS or Clinical Global Impression scores, in
which case we employed the dichotomous data provided from the
primary study report.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicated a favourable outcome for
risperidone.
Assessment of risk of bias in included studies
For the update, two review authors (SZ, BL) independently used
the criteria described in the Cochrane Handbook for Systematic Re-
views of Interventions Higgins 2011to assess trial quality (Higgins
2011). This new set of criteria is based on evidence of associations
between overestimate of effect and high risk of bias of the article
such as sequence generation, allocation concealment, blinding, in-
complete outcome data, and selective reporting.
Where details of randomisation and other characteristics of trials
were inadequate, we contacted authors of the studies to obtain
additional information.
We have noted the level of risk of bias in both the text of the review
and in Summary of ﬁndings table 1 and Summary of ﬁndings 2.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% conﬁdence interval (CI). It has been
shown that RR is more intuitive than odds ratios and that clin-
icians tend to interpret odds ratios as RR (Boissel 1999; Deeks
2000). The number needed to treat to harm statistic with its CIs
is intuitively attractive to clinicians but is problematic both in
its accurate calculation in meta-analyses and in its interpretation
(Hutton 2009). For binary data presented in the ’Summary of
ﬁndings’ table/s, where possible, we calculated illustrative com-
parative risks.
2. Continuous data
For continuous outcomes, we estimated MD between groups. We
preferred not to calculate effect size measures (SMD). However,
if scales of very considerable similarity were used, we presumed
there was a small difference in measurement, and we calculated
effect size and transformed the effect back to the units of one or
more of the speciﬁc instruments.
Unit of analysis issues
To facilitate comparison between trials, we intended to convert
variables (such as days in hospital) that can be reported in different
metrics (mean days per year, per week, or permonth) to a common
metric (for examplemeandays permonth), but no studies reported
data for these types of outcomes.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data loses credibility (Xia
2009). For outcomes where more than 50% of data were unac-
counted for, we intended to not reproduce these data or use them
within analyses. If more than 50% of data in one arm of a study
were lost, but the total loss was less than 50%, we intended to
mark data with (*) to indicate that such a result may well be prone
to bias.
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2. Binary
In cases where attrition for a binary outcome was between 0% and
50% and where these data were not clearly described, we presented
data on a ’once-randomised-always-analyse’ basis wherever possi-
ble (an intention-to-treat (ITT) analysis). For every outcome with
the exception of the outcome of death, we had planned to assume
those participants leaving the study early to have the same rates of
negative outcome as those who completed. However, doing this
drastically changed the signiﬁcance of many outcomes and some-
times the direction of signiﬁcant results, so we only presented data
that was already available from the studies to reduce the risk of
making incorrect assumptions.
3. Continuous
3.1 Attrition
In cases where attrition for a continuous outcome was between 0%
and 50% and completer-only data were reported, we reproduced
these.
3.2 Standard deviations
We didn’t need to calculate any standard deviations (SD) in this
review, but our protocol stated that we would ﬁrst try to obtain
missing values from the authors. If not available, where measures
of variance for continuous data were missing but an exact stan-
dard error (SE) and CI were available for group means, and either
the P value or t value was available for differences in means, we
calculated SDs according to the rules described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
When only the SE was reported, we would calculate SDs using
the formula SD = SE * square root (n). Sections 7.7.3 and 16.1.3
of the Cochrane Handbook for Systematic Reviews of Interventions
Higgins 2011present detailed formulae for estimating SDs from P
values, t or F values, CIs, or other statistics (Higgins 2011). If these
formulae did not apply, we would calculate the SDs according to
a validated imputation method that is based on the SDs of the
other included studies (Furukawa 2006). Although some of these
imputation strategies can introduce error, the alternative would be
to exclude a given study’s outcome and thus to lose information.
We would nevertheless examine the validity of the imputations in
a sensitivity analysis excluding imputed values.
3.3 Last observation carried forward
We anticipated that some studies would employ the method of
last observation carried forward (LOCF). As with all methods of
imputation to deal with missing data, LOCF introduces uncer-
tainty about the reliability of the results. Therefore, where a trial
used LOCF data, if less than 50% of the data were assumed, we
reproduced these data and indicated that they were the product of
LOCF assumptions.
Assessment of heterogeneity
Firstly, we considered all the included studies within any compar-
ison to judge clinical heterogeneity. We then visually inspected
the graphs in order to investigate the possibility of statistical het-
erogeneity; to supplement this we used, primarily, the I2 statistic,
which provides an estimate of the percentage of variability due
to heterogeneity rather than due to chance alone. Where the I2
estimate was greater than or equal to 75%, we interpreted this as
indicating the presence of high levels of heterogeneity (Higgins
2003). If inconsistency became high, we did not summate data,
but presented it separately, and we investigated the reasons for
heterogeneity.
Assessment of reporting biases
In order to investigate the likelihood of overt publication bias, we
entered all data from all identiﬁed and selected trials into a funnel
graph (trial effect against trial size) (Egger 1997).
Data synthesis
We understand that there is no closed argument for preference for
use of ﬁxed-effect or random-effects models.We used the random-
effects model for all analyses due to the potential for heterogene-
ity between studies. The random-effects method incorporates an
assumption that the different studies are estimating different, yet
related, intervention effects. This often seems to be true to us, and
the random-effects model takes into account differences between
studies even if there is no statistically signiﬁcant heterogeneity.
However, there is a disadvantage to the random-effects model. It
puts added weight on to small studies, which are often the most
biased ones. Depending on the direction of effect, these studies
can either inﬂate or deﬂate the effect size.
Subgroup analysis and investigation of heterogeneity
If data were clearly heterogeneous, we checked that they had been
extracted and entered correctly, and that we had made no unit of
analysis errors. If the high levels of heterogeneity remained, we
did not undertake a meta-analysis at this point, because if there is
considerable variation in results, and particularly if there is incon-
sistency in the direction of effect, it may be misleading to quote
an average value for the intervention effect. We prespeciﬁed no
characteristics of studies that may be associated with heterogeneity
except quality of trial method.
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Sensitivity analysis
If studies had high attrition rates, we analysed the effect of includ-
ing these studies in a sensitivity analysis, but we did not include
any ﬁgures with more than 50% attrition in the analysis of efﬁcacy.
Where a trial was described as ’double-blind’, but it was implied
that the study was randomised, we had intended to include such
studies in the sensitivity analysis, but we did not come across any
such studies.
R E S U L T S
Description of studies
For a substantial description of each study, please refer to the
relevant tables:Characteristics of included studies, Characteristics
of excluded studies, Characteristics of ongoing studies.
Results of the search
The initial search resulted in 815 citations. We were able to in-
clude 42 references, relating to only 10 studies from which we
could extract useable data.We used information regarding unpub-
lished data from trials on risperidone available to the Cochrane
Schizophrenia Group from drug companies. The update searches
run in 2013 and 2015 yielded 94 citations, of which 5 new studies
were included.
In total up to the current update, 909 citations were identiﬁed
from the search process in total. After removing duplicates, 763
unique recordswere screenedby viewing titles and abstracts. A total
number of 116 studies with 406 full-text articles were screened for
eligibility. Finally, 86 studies with 337 references were excluded,
14 studies with 24 references are awaiting assessment due to lack
of full-texts and one study was onging trial, which resulted in 15
studies with 56 references being included in the data and analysis
(see Figure 2 for study ﬂow diagram).
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Figure 2. Study ﬂow diagram.
Included studies
1. Length of trials
Fourteen studies reported data on short-term follow-up, and only
1 study reported medium-term outcomes (Bachmann 2003), but
even that was only at 16 weeks. Two studies were of 4 weeks
duration (Potkin 1997; Potkin 2003), 6 studies were 6-weeks long
(Borison 1992; Geffen 2010; Heisterberg 2007; Potkin 2006;
Potkin 2007; Yagcioglu 2005), 3 studies were 8 weeks from start to
ﬁnish (Chouinard 1992; Honer 2006; Marder 1994a), 2 studies
were 9 weeks from start to ﬁnish (Downing 2014; Durgam 2014)
and 1 study was 12 weeks in duration (Pai 2002).
2. Participants
Amongst our included studies, two included participants with no
clear operational diagnostic criteria and simply stated “schizophre-
nia” (Potkin 1997; Potkin 2007). Nine studies included people
with a sole diagnosis of schizophrenia as per Diagnostic Statisti-
cal Manual of Mental Disorders (DSM) criteria (Borison 1992;
Chouinard 1992; Downing 2014; Durgam 2014; Geffen 2010;
Heisterberg 2007; Marder 1994a; Pai 2002; Yagcioglu 2005), and
the remaining four studies included participants with a diagnosis
of schizophrenia or schizoaffective disorder as per DSM criteria
(Bachmann 2003; Honer 2006; Potkin 2003; Potkin 2006).
Potkin 2007 did not report the sex of participants in the study. All
other studies included both men and women, but the majority of
participants were male. Most participants were aged between late
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30s and early 40s.
Two studies did not have deﬁnitive exclusion criteria (Heisterberg
2007; Potkin 1997). The remaining studies excluded people with
alcohol and substance misuse, as well as pregnant or breastfeeding
women. Yagcioglu 2005 excluded people who were intolerant to
risperidone in the past, Potkin 2003 excluded people being treated
with risperidone at baseline, and Potkin 2006 excluded people
who had received risperidone within the last seven days. Marder
1994a excluded people with schizoaffective disorder, and Potkin
2006 excluded people with borderline personality disorder. Potkin
2007 excluded people who had made a recent suicide attempt and
who had serious suicidal thoughts.
3. Setting
Eight of the included studies took place in the inpatient setting
(Borison 1992; Chouinard 1992; Downing 2014; Durgam 2014;
Geffen 2010; Marder 1994a; Potkin 2003; Potkin 2006). Three
studies involved both inpatients andoutpatients (Bachmann 2003;
Honer 2006; Yagcioglu 2005). We could not ﬁnd any explicit
information on setting for the remaining four studies (Heisterberg
2007; Pai 2002; Potkin 1997; Potkin 2007).
Studies were conducted in the USA (Bachmann 2003; Borison
1992; Geffen 2010; Marder 1994a; Potkin 1997; Potkin 2003;
Potkin 2006; Potkin 2007), Canada (Chouinard 1992; Honer
2006), India (Geffen 2010), Romania (Geffen 2010), Denmark
(Heisterberg 2007), and Turkey (Yagcioglu 2005). One studies
recruited participants internationally from 65 study centres in the
United States, India, Russia, Ukraine, and Malaysia.
4. Study size
The largest studywasDowning 2014, which randmised 1009 peo-
ple to four groups, amongwhich, 437 participants were assigned to
either resperidone or placebo group.Heisterberg 2007 randomised
303 people to receive either risperidone or placebo. Durgam 2014
randomised 729 people to ﬁve groups, however, only 291 partici-
pants were assigned to either resperidone or placebo group. Where
a study randomised different doses of risperidone in different arms,
as well as having a separate placebo arm, we tried to take data from
the risperidone arm that best ﬁtted with the average doses across
studies. For example, as the mean dose of risperidone for all the
other trials was 5.5 mg per day, we took the 6 mg arm from the
Marder 1994a and Chouinard 1992 trials for efﬁcacy measures
in the meta-analysis. In Potkin 1997, which had two risperidone
arms of 4 mg and 8 mg, we took the 4 mg arm for efﬁcacy mea-
sures in the meta-analysis, as this was closer than the 8 mg arm to
the mean of 5.5 mg. Potkin 2006 randomised 226 people, Potkin
2003 202, Marder 1994a 130, Chouinard 1992 44, and Potkin
1997 168. The rest of the studies ranged between 24 and 121
participants.
5. Interventions
5.1 Risperidone
The dose of risperidone administered by the trialists varied from
2 mg up to 10 mg per day.
5.2 Placebo
All studies had a placebo arm, and most had another arm with an
active treatment in addition to risperidone. Borison 1992, Marder
1994a, andChouinard 1992 had an arm for haloperidol. Downing
2014 had two arms for LY2140023with lowdosage or high dosage.
Durgam 2014 had three arms of cariprazine with low, medium
or high dosage. Geffen 2010 had two additional arms for a low
dose and a high dose of BL-1020. Marder 1994a and Chouinard
1992 also had four different risperidone arms with daily doses of
2 mg, 6 mg, 10 mg, and 16 mg. We used the 6 mg arm from the
Marder 1994a and Chouinard 1992 trials for efﬁcacy measures
in the meta-analysis and the 4 mg arm data from Potkin 1997.
Heisterberg 2007 used bifeprunox as the other arm, Potkin 2003
aripiprazole, Potkin 2006 quetiapine, and Potkin 2007 asenapine.
5.3 Augmentation
In three studies the risperidone and placebo arms were combined
with clozapine (Bachmann 2003; Honer 2006; Yagcioglu 2005).
6. Outcomes
Our primary outcomemeasures were mental state and service util-
isation; no data were available for service utilisation. Other out-
comes of interest were leaving the study early, global state, adverse
effects, and quality of life.
6.1 Mental state
The trials used several different rating scales to report on mental
state.Heisterberg 2007 didnot report useable data onmental state,
and we could not use the Positive and Negative Symptom Scale
(PANSS) data from Potkin 2007 as this trial had more than 50%
attrition. Downing 2014 only reported means of PANSS score
in each group, therefore we are unable to use the data. All other
trials used either the PANSS or the Brief Psychiatric Rating Scale
to measure this outcome. Wherever possible, we used the binary
data from these measures, but the validity of dichotomising these
measures, although widely accepted, is, nevertheless, unclear.
6.2 Leaving the study early
All included trials provided useable data on the number of partic-
ipants leaving the study early.
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6.3 Global state
Five of the included studies reported global change using the Clin-
ical Global Impression (CGI) scale (Durgam 2014, Honer 2006,
Marder 1994a, Potkin 2003, Potkin 2006). Yagcioglu 2005 used
both the CGI and the Global Assessment of Functioning Scale.
6.4 Adverse effects
Adverse effects are an important outcome measure from any trial.
We were able to pool data on adverse effects from the majority of
trials; some data was skewed and is presented in additional tables.
6.5 Quality of life
were only presented by Only Yagcioglu 2005 presented quality of
life data.
6.6 Missing outcomes
No data were available for service utilisation or economic out-
comes.
6.7 Outcome scales
6.7.1 Global state scales
6.7.1.1 Clinical Global Impression (Guy 1976)
The CGI scale was used to assess both severity of illness and clini-
cal improvement by comparing the conditions of the person stan-
dardised against other people with the same diagnosis. It is a seven-
point scoring system with low scores showing decreased severity
or overall improvement, or both.
6.7.1.2 Global Assessment of Functioning Scale (DSM-IV-TR)
The GAF scale is a numeric scale (0 through 100) used by mental-
health clinicians and doctors to rate the social, occupational, and
psychological functioning of adults. The scale is presented and
described in the DSM-IV-TR on page 32 (Table 2).
6.7.2 Mental state scales
6.7.2.1 Positive and Negative Syndrome Scale (Kay 1986)
The PANSS is used formeasuring symptom severity of people with
schizophrenia. It is widely used in the study of antipsychotic ther-
apy. The name refers to the two types of symptoms in schizophre-
nia, as deﬁned by the American Psychiatric Association: positive
symptoms, which refer to an excess or distortion of normal func-
tions, and negative symptoms, which represent a diminution or
loss of normal functions.
6.7.2.2 Brief Psychiatric Rating Scale (Overall 1962)
The BPRS consists of 18 items on a 7-point severity scale. Initially
published as a 16-item scale in 1962, the standard 18-item version
has been used since 1967 to successfully demonstrate efﬁcacy of
antidepressants, anti-anxiety drugs, and antipsychotics, including
the newer ’atypical’ antipsychotics. TheBPRShas also beenused in
epidemiological studies, geropsychiatric research, and to compare
diagnostic concepts between countries. It is most frequently used
in schizophrenia. When using BPRS, rater training is a must and
the use of a standardised interview is highly recommended in order
to ascertain consistent results.
6.7.2.3 Calgary Depression Scale for Schizophrenia (Addington
1993)
Developed at the University of Calgary, the CDSS speciﬁcally as-
sesses the level of depression in schizophrenia. It has been exten-
sively evaluated in both relapsed and remitted patients and appears
sensitive to change.
6.7.2.4 Scale for the Assessment of Negative Symptoms (
Andreasen 1981)
The SANS assesses affective blunting, alogia, avolition/apathy, an-
hedonia/asociality, and disturbance of attention to measure nega-
tive symptoms in schizophrenia.
6.7.3 Adverse effects scales
6.7.3.1 Barnes Akathisia Scale (Barnes 1989)
The Barnes Akathisia Scale (commonly known as BAS or BARS)
is a four-item rating scale administered by physicians to assess the
severity of drug-induced akathisia. The most widely used scale for
akathisia, it includes both objective items (e.g. observed restless-
ness) and subjective items (e.g. patient’s awareness of restlessness
and related distress), together with a global clinical assessment of
akathisia. Global assessment is made on a scale of 0 to 5, with
comprehensive deﬁnitions provided for each anchor point on the
scale: 0 = absent; 1 = questionable; 2 = mild akathisia; 3 = moder-
ate akathisia; 4 = marked akathisia; 5 = severe akathisia.
6.7.3.2 Extrapyramidal Symptom Rating Scale (Chouinard 1993)
The ESRS is a physician-rated scale for measuring extrapyramidal
adverse effects from antipsychotic medication. It takes approxi-
mately 10 minutes and involves 6 questions about the person’s
subjective experience of extrapyramidal features (slowness, stiff-
ness, and tremor); a standardised procedure for physical examina-
tion; and 7 rater-assessed items that address parkinsonian features
(rigidity and tremor). The instrument may not differentiate effec-
tively between dyskinesia and dystonia.
6.7.3.3 Simpson Angus Scale (Simpson 1970)
The SAS is a 10-item instrument used to evaluate the presence and
severity of parkinsonian symptomatology speciﬁcally in patients
who may be experiencing drug-induced parkinsonism and other
extrapyramidal effects. For the past 25 years it has been the most
commonly used rating scale for parkinsonism in clinical trials. The
10 items focus on rigidity rather than bradykinesia, and do not
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assess subjective rigidity or slowness. Items are rated for severity
on a 0 to 4 scale, with deﬁnitions given for each anchor point.
6.7.3.4 Abnormal Involuntary Movement Scale (Guy 1976)
The AIMS is a 12-item clinician-rated scale to assess severity of
dyskinesias including orofacial movements, extremity and truncal
movements in patients taking neuroleptic medications.
6.7.3.5 The UKU side effect rating scale (Lingjaerde 1987)
UKU is a 48 item clinician-rated scale to assess the side effects
of psychopharmacological medications. The interview takes any-
where from 10-30 minutes depending on the number of symp-
toms reported, the complexity of the symptoms, and the patient’s
ability to provide good report.
6.7.4 Quality of life scales
6.7.4.1 Quality of Life Scale (Carpenter 1994)
The QLS is a 21-item scale rated from a semistructured interview
providing information on symptoms and functioning during the
preceding 4 weeks. It is intended to be administered by a trained
clinician and requires about 45 minutes to complete. Each item is
rated on a 7-point scale and, in all but 2 cases, requires a judgement
by the clinician/interviewer. Each item is comprised of 3 parts:
(1) a brief descriptive statement to focus the interviewer on the
judgement to be made; (2) a set of suggested probes; and (3) the
7-point scale with descriptive anchors for every other point. The
speciﬁc descriptions vary among items, but the high end of the
scales (scores 5 and 6) reﬂects normal or unimpaired functioning,
and the low end of the scales (scores 0 and 1) reﬂects severe impair-
ment of the function in question. The interviewer is instructed to
probe around each item until he or she has an adequate basis for
making the required judgement, and is encouraged to go beyond
the suggested probes with questions tailored for the individual pa-
tient. Thus the experience of both the patient and interviewer is
similar to a careful clinical interview.
6.7.5 Cognitive function scales
6.7.5.1 Groton Maze Learning Test (Pietrzak 2008) (used in an
ongoing study)
The GMLT assesses processing speed, working memory, and as-
pects of executive function in healthy adults. Performance on
GMLT outcome measures can be compared to performance on
tests of psychomotor speed, working memory, and learning from
the Cogstate computerized cognitive test battery. Studies suggest
that the GMLT measures of spatial learning efﬁciency and error
monitoring correlate with Cogstate measures of attention, work-
ingmemory, and learning. Exploratory factor analyses have yielded
a two-factor solution of error monitoring and learning efﬁciency,
which have been stable across repeated assessments.
6.8 Of note
Borison 1992: In 1997 the ﬁrst author and his colleague, Dia-
mond, were convicted in the US courts (AHRP 2006; CBS News
2000CBS News 2000AHRP 2006). For example, one website
states: “Diamond, a Ph.D. pharmacologist who had performed
more than 300 trials over the course of his career on patients who
assumed he was an M.D., was convicted in 1997 on 53 crimi-
nal counts, including practicing medicine without a license, theft,
prescribing medications without a license, fraud, false statements,
tax evasion and bribery. Although he admitted to a growing greed
that led to some of his illegal practices, Diamond maintained that
the pair had never fabricated research data.” We have continued
to include data from this small study.
Excluded studies
We excluded 86 studies, 7 of which were not randomised (David
2000; Davis 2001; Baker 2012; Castle 2015; Kinon 2015;Marder
1991; Pikalov 2012). We excluded seven studies due to their
populations not including people with schizophrenia (Anwunah
1999; Ayd 2001; NCT00088075; NCT00305474; Siever 2002;
Anwunah 1999; Schmechtig2010). The remaining excluded stud-
ies did not directly compare oral risperidone with placebo.
Ongoing studies
We identiﬁed one ongoing study. NCT00174200 is assessing the
effects of risperidone (2 mg daily) on the differential sensitivity
of two spatial working memory tests in non-agitated, drug-naive
people suffering from ﬁrst-episode schizophrenia or schizophreni-
form disorder. They intend to enrol 20 patients for the trial. Pﬁzer
is sponsoring the study.
Awaiting assessment
Fourteen studies are awaiting assessment as sufﬁcient in-
formation is not currently available (Anon 2010; Litman
2014; NCT 00694707; Vanover 2014; Nisenbaum 2013;
Xu 2009; Bose 2010a; Cavazzoni 2002; DeMartinis 2012;
GlaxoSmithKline 2006; NCT01086748; NCT01175135;
NCT01363349; Rujescu 2009).
Risk of bias in included studies
Pharmaceutical companies funded 8 out of the 15 included tri-
als. We did our best to collect as much information as possible
from different sources about the types of biases that could have
occurred during these trials, and have presented the results of our
investigations in the following paragraphs. Figure 3 and Figure 4
presents the summary of risk of bias in included studies.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
All included studies were said to be randomised, but many did
not explicitly describe the method by which this was undertaken.
Bachmann 2003 utilised randomisation that was stratiﬁed by in-
patient status; no further details were provided. Honer 2006 used
a computer-generated schedule with a permuted-block design to
generate sequences. Marder 1994a and Chouinard 1992 under-
took randomisation in blocks of 12. Geffen 2010 and Potkin 2006
both used a centralised interactive voice response system for allo-
cation concealment. Although Yagcioglu 2005 used a pre-assigned
random sequence for each of their study sites that was developed
before the start of their study no further details were provided.
The rest of the studies provided no information about the process
of randomisation (Borison 1992; Downing 2014; Durgam 2014;
Heisterberg 2007; Pai 2002; Potkin 1997; Potkin 2003; Potkin
2007; Potkin 2003; Potkin 1997; Pai 2002; Heisterberg 2007;
Borison 1992), despite this having been repeatedly shown to be
of key importance in excluding selection biases (Juni 2001).
Blinding
All the included studies were described as double blind, with some
describing how this was achieved. Blinding is important for min-
imising observation bias and, because many of the outcomes were
subjective.
Incomplete outcome data
Bachmann 2003, Downing 2014, Durgam 2014, Geffen 2010,
Heisterberg 2007, Marder 1994a, Chouinard 1992, and Potkin
2006 used an intention-to-treat (ITT) analysis. Honer 2006,
Yagcioglu 2005 and Durgam 2014 used the ITT principle in a
mixed-model analysis. Potkin 2007 used ITT for the efﬁcacy data
and last observation carried forward (LOCF) for safety data.
We judged Pai 2002 andBorison 1992 to have a high risk of bias, as
they did not consider in their analysis the data of participants who
left early. We judged Potkin 1997 to be at unclear risk of bias, as
no information about loss to follow-up was provided. Potkin 2003
used the LOCF method to manage their loss to follow-up, but as
they had over 40% loss, we downgraded this category because such
a high attrition rate makes data prone to bias. None of the trials
attempted to validate assumptions by following up participants
who did leave early.
Selective reporting
We were unable to obtain original study protocol, however, the
included studies appear to have reported the results for all the out-
comes listed in their methods sections. Based on the information
available, we did not detect any obvious act of selective reporting.
Other potential sources of bias
1. Poor reporting
We could not use much data because of poor reporting. Findings
that are presented as graphs, in percentiles, or simply reported as
inexact P values were of little use to us as review authors. Many
studies failed to provide standard deviations (SDs) when reporting
mean changes. We are seeking further data from the ﬁrst authors
of relevant trials.
2. Industry
Pharmaceutical companies funded 8 out of the 13 included trials,
with the majority of these funded by a company that would proﬁt
from ﬁnding beneﬁcial effects of risperidone.
Effects of interventions
See: Summary of findings for the main comparison
RISPERIDONE compared to PLACEBO for schizophrenia;
Summary of findings 2 RISPERIDONE + CLOZAPINE
compared to PLACEBO + CLOZAPINE for schizophrenia
Studies relevant to this review fall into three comparisons. We
identiﬁed 15 randomised trials from which it is possible to extract
numerical data.
1. COMPARISON 1: RISPERIDONE versus
PLACEBO
This comparison has 20 outcomes.
1.1 Mental state: no clinically signiﬁcant response in
psychotic symptoms (deﬁned by various scale total
score change) - short term (up to 12 weeks)
1.1.1 deﬁned by PANSS < 30% decline
Three trials with a total of 707 participants provided data for this
subset .We did ﬁnd evidence that ’risperidone’ was clearly different
in its effects compared with ’placebo’ (RR 0.74, 95% CI 0.67 to
0.83) (Analysis 1.1).
1.1.2 deﬁned by PANSS/BPRS < 20% decline
Six trials with a total of 864 participants provided data for this
subset. We did ﬁnd evidence that ’risperidone’ was clearly different
in its effects compared with ’placebo’ (RR 0.64, 95% CI 0.52 to
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0.78). This subgroup had important levels of heterogeneity (Chi
2 = 12.27; df = 5.0; P = 0.03; I2 = 59%) (Analysis 1.1).
1.2 Leaving the study early - short term (up to 12
weeks)
1.2.1 any reason
There were 12 relevant trials, with a total of 2261 participants
providing data for numbers leaving the study early for any reason.
We did ﬁnd evidence that ’risperidone’ was clearly different in its
effects compared with ’placebo’ (RR 0.69, 95% CI 0.62 to 0.78).
There are moderate levels of heterogeneity (Chi2 = 14.73; df = 11;
P = 0.20; I2 = 25%) (Analysis 1.2).
1.2.2 due to adverse events
There were 10 relevant trials, with a total of 2081 participants,
providing data for this subset. There was not a clear difference
between ’risperidone’ and ’placebo’ (RR 0.78, 95% CI 0.59 to
1.03) (Analysis 1.2).
1.2.3 due to lack of efﬁcacy
Eleven trials, with a total of 2211 participants provided data for
this subsetWe found evidence of a clear difference between ’risperi-
done’ and ’placebo’ (RR 0.39, 95% CI 0.29 to 0.51). There are
moderate levels of heterogeneity (Chi2 = 14.70; df = 10; P = 0.14;
I2 = 32%) (Analysis 1.2).
1.2.4 due to non-compliance
We found 4 trials to be relevant to this subset, with a total of 534
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.15, 95% CI 0.33 to
4.05) (Analysis 1.2).
1.2.5 lost to follow-up
We found 6 trials to be relevant to this subset, with a total of 1545
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.79, 95% CI 0.25 to 2.56).
This subset had important levels of heterogeneity (Chi2 = 11.97;
df = 4.0; P = 0.02; I2 = 67%) (Analysis 1.2).
1.2.6 protocol violation
We found 4 trials to be relevant to this subset, with a total of 1257
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.79, 95% CI 0.39 to 1.62)
(Analysis 1.2).
1.2.7 reported death
There were 10 relevant trials in this subset, with a total of 1532
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 3.07, 95% CI 0.13 to 74.28)
(Analysis 1.2).
1.2.8 withdrawal of consent
We found 7 trials to be relevant to this subset, with a total of 1589
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.12, 95% CI 0.80 to 1.56)
(Analysis 1.2).
1.2.9 other
There were 3 relevant trials in this subset, with a total of 615
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.03, 95% CI 0.68 to
1.57) (Analysis 1.2).
1.3 Global state: 1. average endpoint scores of CGI
severity scale (high = poor) - short term (up to 12
weeks)
We identiﬁed 3 studies relevant to this outcome, with a total of 457
participants. This outcome had no subsets. We found evidence of
a clear difference between ’risperidone’ and ’placebo’ (MD -0.81,
95% CI -0.89 to -0.73) (Analysis 1.3).
1.4 Global state: 2. no signiﬁcant clinical
improvement - short term (up to 12 weeks)
For this outcome we found 4 relevant studies involving 594 partic-
ipants. There were no subsets in this outcome. We found evidence
of a clear difference between ’risperidone’ and ’placebo’ (RR 0.69,
95% CI 0.57 to 0.83). For this outcome heterogeneity was mod-
erately high (Chi2 = 5.43; df = 3.0; P = 0.14; I2 = 44%) (Analysis
1.4).
1.5 Global state: 3. needing additional medication -
short term (up to 12 weeks)
For this outcome we found six relevant studies, the data from
which we divided into seven subsets.
1.5.1 benzodiazepine
Therewas a single trial in this subset, with a total of 42 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 0.96, 95% CI 0.77 to 1.2) (
Analysis 1.5).
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1.5.2 benzodiazepine derivatives - lorazepam
There were 2 relevant trials in this subset, with a total of 228
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.93, 95% CI 0.68 to 1.27)
(Analysis 1.5).
1.5.3 benzodiazepine derivatives - Nitrazepam
There was a single trial in this subset, with a total of 184 partic-
ipants. For this subset, we did not ﬁnd evidence of a clear differ-
ence between the two treatments (RR 0.51, 95% CI 0.10 to 2.72)
(Analysis 1.5).
1.5.4 benzodiazepine related drugs - Zolpidem
We found 1 trial to be relevant to this subset, with a total of 184
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.81, 95% CI 0.53 to
1.23) (Analysis 1.5).
1.5.5 sedative/hypnotic
We found 2 trials to be relevant to this subset, with a total of 230
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.86, 95% CI 0.69 to
1.06) (Analysis 1.5).
1.5.6 antiparkinsonian
There were 2 relevant trials in this subset, with a total of 172
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.21, 95% CI 0.79 to 1.86)
(Analysis 1.5).
1.5.7 psychotropics
We found 1 trial to be relevant to this subset, with a total of
186 participants. We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 0.62, 95% CI
0.45 to 0.85) (Analysis 1.5).
1.6 Mental state: 1. average endpoint scores on
various scales on psychotic symptoms (high = poor) -
short term (up to 12 weeks)
We identiﬁed three studies relevant to this outcome, the data from
which we divided into ﬁve subsets.
1.6.1 BPRS total
We found 2 trials to be relevant to this subset, with a total of
171 participants. We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (MD -12.69, 95%
CI -17.06 to -8.32) (Analysis 1.6).
1.6.2 PANSS total
We found 3 trials to be relevant to this subset, with a total of
457 participants. For this outcome, within this subset, we did
ﬁnd evidence that ’risperidone’ was clearly different in its effects
compared with ’placebo’ (MD -17.81, 95% CI -18.17 to -17.45)
(Analysis 1.6).
1.6.3 PANSS general pathology
There was a single trial in this subset, with a total of 44 partici-
pants. For this outcome, within this subset, we did ﬁnd evidence
that ’risperidone’ was clearly different in its effects compared with
’placebo’ (MD -13.20, 95% CI -20.15 to -6.25) (Analysis 1.6).
1.6.4 PANSS negative symptom
There were 3 relevant trials in this subset, with a total of 457 par-
ticipants. We found evidence of a clear difference between ’risperi-
done’ and ’placebo’ within this subset (MD -3.10, 95% CI -3.19
to -3.01) (Analysis 1.6).
1.6.5 PANSS positive symptom
We found 3 trials to be relevant to this subset, with a total of
457 participants. For this outcome, within this subset, we did
ﬁnd evidence that ’risperidone’ was clearly different in its effects
compared with ’placebo’ (MD -5.49, 95% CI -6.18 to -4.80)
(Analysis 1.6).
1.7 Mental state: 2. skewed data - short term (up to
12 weeks)
These continuous data, from two trials were skewed. Therefore we
have reported these data in a separate data table (Analysis 1.7) .
1.8 Adverse effects: 1a. extrapyramidal - various
effects - short term (up to 12 weeks)
We identiﬁed 11 studies relevant to this outcome, the data from
which we divided into 12 subsets.
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1.8.1 general - any signiﬁcant extrapyramidal symptom
We found 7 trials to be relevant to this subset, with a total of
1511 participants.We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 1.56, 95% CI
1.13 to 2.15) (Analysis 1.8).
1.8.2 general - no improvement on AIMS score
Therewas a single trial in this subset, with a total of 42 participants.
We found evidence of a clear difference between ’risperidone’ and
’placebo’ within this subset (RR 0.30, 95% CI 0.15 to 0.61) (
Analysis 1.8).
1.8.3 general - no improvement on BAS score
There was a single trial in this subset, with a total of 226 partici-
pants. For this outcome, within this subset, we did ﬁnd evidence
that ’risperidone’ was clearly different in its effects compared with
’placebo’ (RR 1.14, 95% CI 1.01 to 1.28) (Analysis 1.8).
1.8.4 general - needing medication for EPS
We found 2 trials to be relevant to this subset, with a total of 94
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.14, 95% CI 0.78 to
1.67) (Analysis 1.8).
1.8.5 speciﬁc - akathisia
We found 5 trials to be relevant to this subset, with a total of
1204 participants.We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 2.58, 95% CI
1.41 to 4.72). For this subset heterogeneity was moderately high
(Chi2 = 5.63; df = 4.0; P = 0.23; I2 = 29%). (Analysis 1.8).
1.8.6 speciﬁc - bradykinesia
We found 2 trials to be relevant to this subset, with a total of 485
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.87, 95% CI 0.6 to
1.24) (Analysis 1.8).
1.8.7 speciﬁc - dyskinesia
We found 1 trial to be relevant to this subset, with a total of 303
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.32, 95% CI 0.01 to 7.86)
(Analysis 1.8).
1.8.8 speciﬁc - dystonia
There were 3 relevant trials in this subset, with a total of 687
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 3.40, 95% CI 0.26 to
44.46). This subset had important levels of heterogeneity (Chi2 =
13.09; df = 2.0; P = 0.001; I2 = 84%) (Analysis 1.8).
1.8.9 speciﬁc - hypertonia
There were 3 relevant trials in this subset, with a total of 505 par-
ticipants. We found evidence of a clear difference between ’risperi-
done’ and ’placebo’ within this subset (RR 2.98, 95% CI 1.35 to
6.59). For this subset heterogeneity was moderately high (Chi2 =
2.87; df = 2.0; P = 0.24; I2 = 30%) (Analysis 1.8).
1.8.10 speciﬁc - parkinsonism
We found 2 trials to be relevant to this subset, with a total of
485 participants. We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 7.64, 95% CI
1.4 to 41.59) (Analysis 1.8).
1.8.11 speciﬁc - tardive dyskinesia
There was a single trial in this subset, with a total of 303 partici-
pants. For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 6.77, 95% CI 0.35 to 130.03)
(Analysis 1.8).
1.8.12 speciﬁc - tremor
We found 5 trials to be relevant to this subset, with a total of 1204
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.60, 95% CI 0.89 to 2.88).
This subset had moderate levels of heterogeneity (Chi2 = 5.86; df
= 4.0; P = 0.21; I2 = 32%) (Analysis 1.8).
1.9 Adverse effects: 1b. extrapyramidal - AIMS
average endpoint score - short term (up to 12 weeks)
For this outcome we found a single study. A greater reduction in
AIMS scores were seen for people in the risperidone arm compared
to the placebo arm (1 RCT, N=42, MD -5.50 95% CI -8.60 to -
2.40) (Analysis 1.9).
1.10 Adverse effects: 1c. extrapyramidal - skewed
data (various scales) - short term (up to 12 weeks)
These continuous data (four RCTs) had such large SDs as to sug-
gest that analysis within RevMan would be inadvisable. Therefore,
we have reported these data in a separate table (Analysis 1.10).
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1.11 Adverse effects: 2. any adverse event - short
term (up to 12 weeks)
For this outcome we found 9 relevant studies and categorised data
into 16 subsets.
1.11.1 any adverse event
There were 7 relevant trials in this subset, with a total of 1610
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.05, 95% CI 0.96 to
1.15). This subset had important levels of heterogeneity (Chi2 =
14.46; df = 6.0; P = 0.02; I2 = 58%) (Analysis 1.11).
1.11.2 asthenia
There were 2 trials in this subset, with a total of 639 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 1.93, 95% CI 0.62 to 6.02)
(Analysis 1.11).
1.11.3 back pain
There was a single trial in this subset, with a total of 202 partic-
ipants. For this subset, we did not ﬁnd evidence of a clear differ-
ence between the two treatments (RR 1.04, 95% CI 0.38 to 2.86)
(Analysis 1.11).
1.11.4 blurred vision
There was a single trial in this subset, with a total of 202 partici-
pants. For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 4.16, 95% CI 0.47 to 36.59)
(Analysis 1.11).
1.11.5 cogwheel rigidity
We found 1 trial to be relevant to this subset, with a total of 226
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 5.25, 95% CI 0.69 to
39.88) (Analysis 1.11).
1.11.6 death
We found 1 trial to be relevant to this subset, with a total of 182
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 3.13, 95% CI 0.13 to
75.92) (Analysis 1.11).
1.11.7 dental disorder
There was a single trial in this subset, with a total of 202 par-
ticipants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 3.64, 95% CI 0.78 to 17.11)
(Analysis 1.11).
1.11.8 dysmenorrhoea
There were two trials in this subset, with a total of 495 participants.
There was not a clear difference between ’risperidone’ and ’placebo’
within this subset (RR 1.10, 95% CI 0.04 to 30.00) (Analysis
1.11).
1.11.9 fatigue
There were two trial in this subset, with a total of 558 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 2.23, 95% CI 0.69 to 7.22)
(Analysis 1.11).
1.11.10 fever
We found 1 trial to be relevant to this subset, with a total of 130
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 9.28, 95% CI 0.51 to 168.9)
(Analysis 1.11).
1.11.11 infection
We found 1 trial to be relevant to this subset, with a total of 202
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.52, 95% CI 0.10 to 2.78)
(Analysis 1.11).
1.11.12 salivation - increased
There was a single trial in this subset, with a total of 202 partici-
pants. For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 7.28, 95% CI 0.38 to 139.15)
(Analysis 1.11).
1.11.13 pyrexia
We found 1 trial to be relevant to this subset, with a total of 182
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.19, 95% CI 0.45 to
3.16) (Analysis 1.11).
22Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.11.14 pain
There was a single trial in this subset, with a total of 121 par-
ticipants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.58, 95% CI 0.47 to 5.31)
(Analysis 1.11).
1.11.15 rash (skin)
There was a single trial in this subset, with a total of 202 par-
ticipants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.19, 95% CI 0.45 to 3.16)
(Analysis 1.11).
1.11.16 vaginitis
Therewas a single trial in this subset, with a total of 58 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 1.07, 95% CI 0.07 to 16.32)
(Analysis 1.11).
1.12 Adverse effects: 3. cardiovascular - short term
(up to 12 weeks)
For this outcome we found four relevant studies and categorised
data into seven subsets.
1.12.1 dizziness - orthostatic
Therewas a single trial in this subset, with a total of 44 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 3.0, 95% CI 0.13 to 69.87)
(Analysis 1.12).
1.12.2 ECG abnormal
We found 1 trial to be relevant to this subset, with a total of 182
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR9.40, 95%CI 0.51 to 172.11)
(Analysis 1.12).
1.12.3 heart rate decreased
We found 1 trial to be relevant to this subset, with a total of 182
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.52, 95% CI 0.05 to 5.66)
(Analysis 1.12).
1.12.4 heart rate increased
There was a single trial in this subset, with a total of 182 par-
ticipants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.85, 95% CI 0.37 to 1.96)
(Analysis 1.12).
1.12.5 hypotension - postural
Therewas a single trial in this subset, with a total of 44 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 3.00, 95% CI 0.13 to 69.87)
(Analysis 1.12).
1.12.6 corrected QT interval > 450 milliseconds or > 10%
increase from baseline
We found 2 trials to be relevant to this subset, with a total of
380 participants. We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 8.46, 95% CI
1.07 to 67.07) (Analysis 1.12).
1.12.7 tachycardia
We found 2 trials to be relevant to this subset, with a total of
332 participants. We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 12.22, 95% CI
2.33 to 64.1) (Analysis 1.12).
1.13 Adverse effects: 4. central nervous system -
short term (up to 12 weeks)
We identiﬁed ten studies relevant to this outcome, the data from
which we divided into eight subsets.
1.13.1 agitation
There were 8 relevant trials in this subset, with a total of 1388
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.93, 95% CI 0.75 to
1.17) (Analysis 1.13).
1.13.2 anxiety
We found 6 trials to be relevant to this subset, with a total of 1225
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.04, 95% CI 0.73 to 1.48)
(Analysis 1.13).
1.13.3 dizziness
There were 5 relevant trials in this subset, with a total of 970
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.41, 95% CI 0.65 to 3.05).
This subset had moderate levels of heterogeneity (Chi2 = 7.37; df
= 4.0; P = 0.12; I2 = 46%) (Analysis 1.13).
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1.13.4 headache
We found 10 trials to be relevant to this subset, with a total of
1905 participants. For this subset, we did not ﬁnd evidence of a
clear difference between the two treatments (RR 0.99, 95% CI
0.81 to 1.21) (Analysis 1.13).
1.13.5 insomnia
We found 10 trials to be relevant to this subset, with a total of 1905
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.16, 95% CI 0.97 to 1.39)
(Analysis 1.13).
1.13.6 sedation
There were two trials in this subset, with a total of 517 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 1.84, 95% CI 0.52 to 6.50)
(Analysis 1.13).
1.13.7 somnolence
We found 6 trials to be relevant to this subset, with a total of
951 participants. We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 1.61, 95% CI
1.06 to 2.45) (Analysis 1.13).
1.13.8 restlessness
There were two trials in this subset, with a total of 619 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 1.16, 95% CI 0.49 to 2.74)
(Analysis 1.13).
1.14 Adverse effects: 5. endocrine - serum prolactin
increase above reference range (23 ng/ml) - short
term (up to 12 weeks)
For this outcome we found 2 relevant studies, with a total of 323
participants. There were no subsets in this outcome. We found
evidence of a clear difference between ’risperidone’ and ’placebo’
(RR 12.14, 95% CI 4.38 to 33.68). For this outcome heterogene-
ity was high (Chi2 = 2.14; df = 1.0; P = 0.14; I2 = 53%).
1.15 Adverse effects: 6. gastrointestinal system -
short term (up to 12 weeks)
For this outcome we found ten relevant studies and categorised
data into six subsets.
1.15.1 constipation
We found 8 trials to be relevant to this subset, with a total of
1695 participants.We found evidence of a clear difference between
’risperidone’ and ’placebo’ within this subset (RR 1.88, 95% CI
1.19 to 2.96) (Analysis 1.15).
1.15.2 diarrhoea
There was a single trial in this subset, with a total of 202 partic-
ipants. For this subset, we did not ﬁnd evidence of a clear differ-
ence between the two treatments (RR 0.92, 95% CI 0.37 to 2.3)
(Analysis 1.15).
1.15.3 dry mouth
We found 1 trial to be relevant to this subset, with a total of 202
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 2.43, 95% CI 0.65 to 9.12)
(Analysis 1.15).
1.15.4 dyspepsia
There were 5 relevant trials in this subset, with a total of 1058
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.24, 95% CI 0.64 to 2.40)
(Analysis 1.15).
1.15.5 nausea
There were 6 relevant trials in this subset, with a total of 1225
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.18, 95% CI 0.75 to 1.86)
(Analysis 1.15).
1.15.6 vomiting
There were 5 relevant trials in this subset, with a total of 1181
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.16, 95% CI 0.65 to 2.07)
(Analysis 1.15).
1.16 Adverse effects: 7a. metabolic - weight gain -
short term (up to 12 weeks)
For this outcome we found six relevant studies, the data from
which we divided into two subsets.
1.16.1 any gain
We found 3 trials to be relevant to this subset, with a total of 910
participants. For this outcome, within this subset, we did ﬁnd evi-
dence that ’risperidone’ was clearly different in its effects compared
with ’placebo’ (RR 3.77, 95% CI 1.34 to 10.63) (Analysis 1.16).
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1.16.2 > 7% increase from baseline
We found 3 trials to be relevant to this subset, with a total of
606 participants. For this outcome, within this subset, we did
ﬁnd evidence that ’risperidone’ was clearly different in its effects
comparedwith ’placebo’ (RR3.47, 95%CI 1.64 to 7.33) (Analysis
1.16).
1.17 Adverse effects: 7b. metabolic - skewed data -
average change value on lipid proﬁle - short term (up
to 12 weeks)
These continuous data (twoRCTs) had such large SDs as to suggest
that analysis within RevMan would be inadvisable. Therefore, we
presented them in an separate table (Analysis 1.17).
1.18 Adverse effects: 8. musculoskeletal system -
short term (up to 12 weeks)
We identiﬁed one study relevant to this outcome and categorised
data into two subsets.
1.18.1 myalgia
We found 1 trial to be relevant to this subset, with a total of 202
participants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 0.69, 95% CI 0.12 to 4.06).
(Analysis 1.18).
1.18.2 joint disorder
We found 1 trial to be relevant to this subset, with a total of 202
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 2.6, 95% CI 0.52 to
13.1) (Analysis 1.18).
1.19 Adverse effects: 9. physiology - short term (up to
12 weeks)
For this outcome we found two studies and categorised data into
four subsets.
1.19.1 alanine aminotransferase increased
There was a single trial in this subset, with a total of 182 partici-
pants. For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 1.04, 95% CI 0.07 to 16.45)
(Analysis 1.19).
1.19.2 aspartate aminotransferase increased
There was a single trial in this subset, with a total of 182 partici-
pants. No increase occured in either group. (Analysis 1.19).
1.19.3 blood creatine phosphokinase increased
We found 2 trials to be relevant to this subset, with a total of 619
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.67, 95% CI 0.23 to
1.95) (Analysis 1.19).
1.19.4 blood pressure increased
There was a single trial in this subset, with a total of 182 par-
ticipants. There was not a clear difference between ’risperidone’
and ’placebo’ within this subset (RR 1.04, 95% CI 0.15 to 7.26)
(Analysis 1.19).
1.20 Adverse effects: 10. respiratory system - short
term (up to 12 weeks)
For this outcome we found four relevant studies and categorised
data into three subsets.
1.20.1 upper respiratory infection
There were 2 relevant trials in this subset, with a total of 323 par-
ticipants. We found evidence of a clear difference between ’risperi-
done’ and ’placebo’ within this subset (RR 2.83, 95% CI 1.03 to
7.74) (Analysis 1.20).
1.20.2 pharyngitis
There was a single trial in this subset, with a total of 202 partic-
ipants. For this subset, we did not ﬁnd evidence of a clear differ-
ence between the two treatments (RR 0.42, 95% CI 0.08 to 2.1)
(Analysis 1.20).
1.20.3 rhinitis
There were 2 relevant trials in this subset, with a total of 306 par-
ticipants. For this outcome, within this subset, we found evidence
that ’risperidone’ was clearly different in its effects compared with
’placebo’ (RR 10.81, 95% CI 2.58 to 45.29) (Analysis 1.20).
1.20.4 Sinusitis
There were 1 relevant trial in this subset, with a total of 437
participants. For this outcome, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.04, 95% CI 0.09 to
11.36) (Analysis 1.20).
2. COMPARISON 2: RISPERIDONE plus
CLOZAPINE versus PLACEBO plus CLOZAPINE
This particular comparison had 23 outcomes.
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2.1 Mental state: no clinically signiﬁcant response in
psychotic symptoms (deﬁned by PANSS/BPRS < 20%
decline) - short term (up to 12 weeks)
For this outcome two relevant studies found no clear difference
between treatments (2 RCTS, N = 98, RR 1.15, 95% CI 0.93 to
1.42 Analysis 2.1 )
2.2 Leaving the study early - short term (up to 12
weeks)
For this outcome we found three relevant studies and categorised
data into nine subsets.
2.2.1 any reason
We found 3 trials to be relevant to this subset, with a total of 167
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.13, 95% CI 0.53 to
2.42) (Analysis 2.2).
2.2.2 due to adverse events
There were 2 relevant trials in this subset, with a total of 137
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
4.11, 95% CI 0.47 to 36.24) (Analysis 2.2).
2.2.3 due to lack of efﬁcacy
We found 1 trial to be relevant to this subset, with a total of 69
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
0.55, 95% CI 0.11 to 2.78) (Analysis 2.2).
2.2.4 due to noncompliance
We found 1 trial to be relevant to this subset, with a total of 69
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.36, 95% CI 0.02 to
8.61) (Analysis 2.2).
2.2.5 lost to follow-up
We found 1 trial to be relevant to this subset, with a total of 69
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.36, 95% CI 0.02 to
8.61) (Analysis 2.2).
2.2.6 reported death
Therewas a single trial in this subset, with a total of 68 participants.
No deaths were reported. (Analysis 2.2).
2.2.7 withdrawal of consent
There were 3 relevant trials in this subset, with a total of 167
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.41, 95% CI 0.28 to
7.09) (Analysis 2.2).
2.2.8 administrative reasons
We found 1 trial to be relevant to this subset, with a total of 69
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 5.44, 95% CI 0.27 to
109.34) (Analysis 2.2).
2.2.9 abnormal lab results
We found 1 trial to be relevant to this subset, with a total of 69
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.36, 95% CI 0.02 to
8.61) (Analysis 2.2).
2.3 Global state: 1. average endpoint scores of CGI
severity scale (high = poor) - short term (up to 12
weeks)
We identiﬁed 1 study relevant to this outcome involving 65 partic-
ipants. This outcome had no subsets. We did not ﬁnd evidence of
a clear difference between the two treatments in this comparison
(MD 0.51, 95% CI 0.02 to 1.00).
2.4 Global state: 2. no signiﬁcant clinical
improvement - short term (up to 12 weeks)
We identiﬁed 1 study relevant to this outcome, with a total of 68
participants. There were no subsets in this outcome. We did not
ﬁnd evidence of a clear difference between the two treatments in
this comparison (RR 1.12, 95% CI 0.87 to 1.44) (Analysis 2.4).
2.5 Global state: 3. general functioning - average
endpoint GAF score (high = good) - short term (up to
12 weeks)
We identiﬁed 1 study relevant to this outcome involving 30 par-
ticipants. This outcome had no subsets. We found evidence of a
clear difference between ’risperidone plus clozapine’ and ’placebo
plus clozapine’ (MD -4.50, 95% CI -8.38 to -0.62) (Analysis 2.5).
2.6 Mental state: 1. average endpoint scores on
various scales on psychotic symptoms (high = poor) -
short term (up to 12 weeks)
For this outcome we found two relevant studies and categorised
data into ﬁve subsets.
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2.6.1 PANSS total
We found 2 trials to be relevant to this subset, with a total of
95 participants. We found evidence of a clear difference between
’risperidone plus clozapine’ and ’placebo plus clozapine’ within
this subset (MD 5.56, 95% CI 1.59 to 9.53) (Analysis 2.6).
2.6.2 PANSS general pathology
There was a single trial in this subset, with a total of 30 partici-
pants. There was not a clear difference between ’risperidone plus
clozapine’ and ’placebo plus clozapine’ within this subset (MD
2.50, 95% CI 0.03 to 4.97) (Analysis 2.6).
2.6.3 PANSS delusion
We found 1 trial to be relevant to this subset, with a total of 30
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placeboplus clozapine’ within this subset (MD
0.70, 95% CI 0.09 to 1.31) (Analysis 2.6).
2.6.4 PANSS negative symptom
We found 2 trials to be relevant to this subset, with a total of 95
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (MD 0.69, 95% CI -0.68
to 2.05) (Analysis 2.6).
2.6.5 PANSS positive symptom
We found 2 trials to be relevant to this subset, with a total of 95
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (MD 2.30, 95% CI 0.98
to 3.62) (Analysis 2.6).
2.7 Mental state: 2. average endpoint scores on
various scales on psychotic symptoms (high = poor) -
medium term (up to 26 weeks)
For this outcome we found a single study, the data from which we
divided into four subsets.
2.7.1 BPRS total
We found 1 trial to be relevant to this subset, with a total of
53 participants. We found evidence of a clear difference between
’risperidone plus clozapine’ and ’placebo plus clozapine’ within
this subset (MD -4.60, 95% CI -9.88 to 0.68) (Analysis 2.7).
2.7.2 BPRS positive symptom
Therewas a single trial in this subset, with a total of 53 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (MD -0.90, 95% CI -2.81 to 1.01)
(Analysis 2.7).
2.7.3 BPRS anxiety/depression factor
Therewas a single trial in this subset, with a total of 53 participants.
We found evidence of a clear difference between ’risperidone plus
clozapine’ and ’placebo plus clozapine’ within this subset (MD -
1.00, 95% CI -2.80 to 0.80) (Analysis 2.7).
2.7.4 SANS total
We found 1 trial to be relevant to this subset, with a total of 53
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placeboplus clozapine’ within this subset (MD
-3.10, 95% CI -10.30 to 4.10) (Analysis 2.7).
2.8 Mental state: 3. skewed data - short term (up to
12 weeks)
These continuous data (twoRCTs) had such large SDs as to suggest
that analysis within RevMan would be inadvisable. Therefore, we
have presented them in a separate data table (Analysis 2.8).
2.9 Adverse effects: 1a. extrapyramidal - average
endpoint SAS score - short term (up to 12 weeks)
For this outcome we found a single study. People in the risperi-
done + clozapine arm were less likely to experience extrapyramidal
adverse events as reported on the SAS than those in the placebo +
clozapine arm (1 RCT, N=30, MD -0.90 95% CI -1.97 to 0.17)
(Analysis 2.9).
2.10 Adverse effects: 1b. extrapyramidal - skewed
data (various scales) - short term (up to 12 weeks)
These continuous data (twoRCTs) had such large SDs as to suggest
that analysis within RevMan would be inadvisable. Therefore, we
have presented them in a separate data table (Analysis 2.10).
2.11 Adverse effects: 1c. extrapyramidal - skewed
data (various scales) - medium term (up to 26 weeks)
These continuous data (one RCT) were too skewed to report in a
graphic. Therefore, we have reported these data in a separate data
table (Analysis 2.11).
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2.12 Adverse effects: 2. any adverse event - short
term (up to 12 weeks)
We identiﬁed one study relevant to this outcome and categorised
data into nine subsets.
2.12.1 any adverse event
We found 1 trial to be relevant to this subset, with a total of 64
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.14, 95% CI 0.83 to
1.58) (Analysis 2.12).
2.12.2 amenorrhoea
Therewas a single trial in this subset, with a total of 64 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 3.00, 95% CI 0.13 to 71.0)
(Analysis 2.12).
2.12.3 asthenia
Therewas a single trial in this subset, with a total of 64 participants.
There was not a clear difference between ’risperidone plus clozap-
ine’ and ’placebo plus clozapine’ within this subset (RR 1.08, 95%
CI 0.61 to 1.91) (Analysis 2.12).
2.12.4 depression
We found 1 trial to be relevant to this subset, with a total of 64
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
1.20, 95% CI 0.61 to 2.37) (Analysis 2.12).
2.12.5 emotional indifference
We found 1 trial to be relevant to this subset, with a total of 64
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
1.11, 95% CI 0.52 to 2.37) (Analysis 2.12).
2.12.6 fatigue
We found 1 trial to be relevant to this subset, with a total of 64
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.08, 95% CI 0.61 to
1.91) (Analysis 2.12).
2.12.7 failing memory
Therewas a single trial in this subset, with a total of 64 participants.
There was not a clear difference between ’risperidone plus clozap-
ine’ and ’placebo plus clozapine’ within this subset (RR 0.67, 95%
CI 0.32 to 1.41) (Analysis 2.12).
2.12.8 increased duration of sleep
We found 1 trial to be relevant to this subset, with a total of 64
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
1.00, 95% CI 0.51 to 1.97) (Analysis 2.12).
2.12.9 salivation - increased
We found 1 trial to be relevant to this subset, with a total of 64
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.25, 95% CI 0.81 to
1.94) (Analysis 2.12).
2.13 Adverse effects: 3a. cardiovascular - short term
(up to 12 weeks)
For this outcome we found a single study and categorised data
into three subsets (in keeping with our protocol).
2.13.1 dizziness - orthostatic
We found 1 trial to be relevant to this subset, with a total of 64
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
1.00, 95% CI 0.43 to 2.34) (Analysis 2.13).
2.13.2 palpitation
Therewas a single trial in this subset, with a total of 64 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 1.00, 95% CI 0.27 to 3.66)
(Analysis 2.13).
2.13.3 tachycardia
We found 1 trial to be relevant to this subset, with a total of 64
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
1.00, 95% CI 0.27 to 3.66) (Analysis 2.13).
2.14 Adverse effects: 3b. cardiovascular - corrected
QT interval - short term (up to 12 weeks)
For this outcome we found a single study, with a total of 30 par-
ticipants. There were no subsets in this outcome. We did not ﬁnd
evidence of a clear difference between the two treatments in this
comparison (MD -19.70, 95% CI -42.08 to 2.68).
2.15 Adverse effects: 4. central nervous system -
short term (up to 12 weeks)
For this outcome we found a single study and categorised data
into three subsets.
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2.15.1 sedation
Therewas a single trial in this subset, with a total of 64 participants.
There was not a clear difference between ’risperidone plus clozap-
ine’ and ’placebo plus clozapine’ within this subset (RR 1.46, 95%
CI 0.88 to 2.43) (Analysis 2.15).
2.15.2 somnolence
We found 1 trial to be relevant to this subset, with a total of 64
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.00, 95% CI 0.51 to
1.97) (Analysis 2.15).
2.15.3 tension
We found 1 trial to be relevant to this subset, with a total of 64
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 1.23, 95% CI 0.71 to
2.12) (Analysis 2.15).
2.16 Adverse effects: 5. gastrointestinal system -
short term (up to 12 weeks)
For this outcome we found a single study and categorised data
into one subset.
2.16.1 constipation
We found 1 trial to be relevant to this subset, with a total of 64
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (RR 0.71, 95% CI 0.25 to
2.02) (Analysis 2.16).
2.17 Adverse effects: 6a. haematological - short term
(up to 12 weeks)
We identiﬁed two studies relevant to this outcome and categorised
data into three subsets.
2.17.1 neutrophil count
Therewas a single trial in this subset, with a total of 57 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (MD 0.37, 95% CI -0.42 to 1.16)
(Analysis 2.17).
2.17.2 prolactin level, ng/mL
We found 1 trial to be relevant to this subset, with a total of 30
participants. For this outcome, within this subset, we did ﬁnd
evidence that ’risperidone plus clozapine’ was clearly different in
its effects compared with ’placebo plus clozapine’ (MD 60.1, 95%
CI 46.52 to 73.68) (Analysis 2.17).
2.17.3 white cell count
Therewas a single trial in this subset, with a total of 61 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (MD 0.66, 95% CI -0.20 to 1.52)
(Analysis 2.17).
2.18 Adverse effects: 6b. haematological - medium
term (up to 26 weeks)
For this outcome we found a single study, the data from which we
divided into two subsets.
2.18.1 prolactin level ng/mL
Therewas a single trial in this subset, with a total of 44 participants.
We found evidence of a clear difference between ’risperidone plus
clozapine’ and ’placebo plus clozapine’ within this subset (MD
34.1, 95% CI 17.63 to 50.57) (Analysis 2.18).
2.18.2 fasting glucose
There was a single trial in this subset, with a total of 40 partici-
pants. There was not a clear difference between ’risperidone plus
clozapine’ and ’placebo plus clozapine’ within this subset (MD -
4.60, 95% CI -17.09 to 7.89) (Analysis 2.18).
2.19 Adverse effects: 7a. metabolic - weight gain -
short term (up to 12 weeks)
Therewas a single trial in this subset, with a total of 64 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (RR 1.00, 95% CI 0.40 to 2.52)
(Analysis 2.19).
2.20 Adverse effects: 7a. metabolic - weight gain -
medium term (up to 26 weeks)
We found 1 trial to be relevant to this subset, with a total of 48
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placebo plus clozapine’ within this subset (RR
0.20, 95% CI 0.01 to 3.96) (Analysis 2.20).
2.21 Adverse effects: 7b. metabolic - average endpoint
value on lipid proﬁle - short term (up to 12 weeks)
For this outcome we found a single study and categorised data
into four subsets.
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2.21.1 cholesterol - total (mg/dl)
We found 1 trial to be relevant to this subset, with a total of 56
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (MD -6.60, 95%CI -29.05
to 15.85) (Analysis 2.21).
2.21.2 high-density lipoprotein cholesterol (mg/dl)
We found 1 trial to be relevant to this subset, with a total of 52
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (MD 0.00, 95% CI -8.44
to 8.44) (Analysis 2.21).
2.21.3 low-density lipoprotein cholesterol (mg/dl)
There was a single trial in this subset, with a total of 53 partici-
pants. There was not a clear difference between ’risperidone plus
clozapine’ and ’placebo plus clozapine’ within this subset (MD -
6.90, 95% CI -26.02 to 12.22) (Analysis 2.21).
2.21.4 triglycerides (mg/dl)
Therewas a single trial in this subset, with a total of 56 participants.
For this subset, we did not ﬁnd evidence of a clear difference
between the two treatments (MD 6.20, 95% CI -57.57 to 69.97)
(Analysis 2.21).
2.22 Adverse effects: 7c. metabolic - average endpoint
value - short term (up to 12 weeks)
We identiﬁed two studies relevant to this outcome, the data from
which we divided into four subsets.
2.22.1 body mass index
We found 1 trial to be relevant to this subset, with a total of 63
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placeboplus clozapine’ within this subset (MD
1.70, 95% CI -0.99 to 4.39) (Analysis 2.22).
2.22.2 fasting glucose (mg/dl)
We found 1 trial to be relevant to this subset, with a total of 51
participants. There was not a clear difference between ’risperidone
plus clozapine’ and ’placeboplus clozapine’ within this subset (MD
16.20 95% CI -3.12 to 35.52) (Analysis 2.22).
2.22.3 waist circumference (cm)
There was a single trial in this subset, with a total of 61 partici-
pants. There was not a clear difference between ’risperidone plus
clozapine’ and ’placebo plus clozapine’ within this subset (MD
5.10, 95% CI -4.14 to 14.34) (Analysis 2.22).
2.22.4 weight gain
We found 2 trials to be relevant to this subset, with a total of 94
participants. For this subset, we did not ﬁnd evidence of a clear
difference between the two treatments (MD 0.34, 95% CI -0.84
to 1.53) (Analysis 2.22).
2.23 Adverse effects: 8. sleep - skewed data - average
change score (UKU) - short term (up to 12 weeks)
These continuous data, from a single trial, had such large SDs as to
suggest that analysis within RevMan would be inadvisable. There-
fore, we have presented them in a separate data table (Analysis
2.23).
2.24 Quality of life: average endpoint score (QLS, high
= good) - short term (up to 12 weeks)
We identiﬁed 1 study relevant to this outcome involving 30 par-
ticipants. There were no subsets in this outcome. There was not a
clear difference between ’risperidone plus clozapine’ and ’placebo
plus clozapine’ (MD 0.80, 95% CI -5.44 to 7.04) (Analysis 2.24).
3. COMPARISON 3: SENSITIVITY ANALYSIS:
RISPERIDONE versus PLACEBO (based on attrition)
This particular comparison had only one outcome.
3.1 Mental state: 1. no clinically signiﬁcant response
(deﬁned by PANSS/BPRS) - short term (up to 12
weeks)
We identiﬁed six studies relevant to this outcome and categorised
data into two subsets (in keeping with our protocol).
3.1.1 deﬁned by PANSS/BPRS < 20% decline
We found 6 trials to be relevant to this subset, with a total of
864 participants. We found evidence of a clear difference between
’sensitivity analysis: risperidone’ and ’placebo (based on attrition)’
within this subset (RR 0.64, 95% CI 0.52 to 0.78). For this out-
come heterogeneity was high (Chi2 = 12.27; df = 5.0; P = 0.03; I
2 = 59%) (Analysis 3.1).
3.1.2 deﬁned by PANSS/BPRS < 20% decline (without studies
with > 50% leaving the study early)
There were 3 relevant trials in this subset, with a total of 589 partic-
ipants. We found evidence of a clear difference between ’sensitivity
analysis: risperidone’ and ’placebo (based on attrition)’ within this
subgroup (RR 0.77, CI 0.67 to 0.88) (Analysis 3.1).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia
Patient or population: people with schizophrenia
Settings: inpat ient and outpat ient
Intervention: RISPERIDONE + CLOZAPINE
Comparison: PLACEBO + CLOZAPINE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
PLACEBO + CLOZAP-
INE
RISPERIDONE +
CLOZAPINE
Mental state: no clin-
ically significant re-
sponse in psychotic
symptoms - short term
PANSS/ BPRS < 20%de-
cline
Follow-up: 6-8 weeks
Moderate1 RR 1.15
(0.93 to 1.42)
98
(2 studies)
⊕⊕©©
low1,2
725 per 1000 834 per 1000
(674 to 1000)
Leaving the study early
due to any reason -
short term
Follow-up: 12 weeks
119 per 1000 135 per 1000
(63 to 288)
RR1.13
(0.53 to 2.42)
167
(3 studies)
⊕©©©
very low1,2,3
Global state: no signif-
icant clinical improve-
ment - CGI short term
Follow-up: 8 weeks
735 per 10003 824 per 1000
(640 to 1000)
RR 1.12
(0.87 to 1.44)
68
(1 study)
⊕⊕©©
low1,2
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Adverse effects: ex-
trapyramidal - short
term
Follow-up: 12 weeks
See comment See comment Not est imable - See comment No study reported this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to risk of bias: studies contribut ing data to this body of evidence have unclear risk of bias in one
or more domains.
2 Downgraded one level due to imprecision: wide conf idence interval including no ef fect and appreciable harm, and less than
opt imal information size.
3 Downgraded one level due to publicat ion bias: ’strongly suspected’ - most studies were sponsored by pharmaceut ical
companies.
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D I S C U S S I O N
Summary of main results
1. COMPARISON 1: RISPERIDONE versus
PLACEBO
All of the included studies contributed data towards the compar-
ison of risperidone versus placebo. Despite there being data from
15 studies in total, more often than not only a few studies con-
tributed useable data towards each outcome. Most of the ﬁndings
were based on few data, which in the majority of cases was of poor
quality. The ratings within the Summary of ﬁndings table 1 reﬂect
this, as we have judged the overall quality of evidence to be low or
very low for each of the four main clinically relevant outcomes.
There is a clear difference in the treatment effect favouring risperi-
done group. Compared to placebo, people who received risperi-
done has a 36% risk reduction (very low quality of evidence)
in not achieving clinically signiﬁcant improvement in psychotic
symptoms. The effect withstood, even when three studies with
>50% attrition rate were removed from the analysis (3 RCTs, N =
589, RR 0.77, CI 0.67 to 0.88). Risperidone group also achieved
greater reduction on BPRS score (a reduction of 12.69 compared
to placebo group) and PANSS score (a reduction of 17.81 com-
pared to placebo group). However the quality of evidence is com-
promised due to risk of bias of included studies, the slight hetero-
geneity and the involvement of industry sponsorship. Similarly,
risperidone group are more likely to achieve signiﬁcant clinical im-
provement than placebo group (a risk reduction of 31% in risperi-
done group, very low quality of evidence).
A variety of reasons have caused people to leave the study early,
but most showed no clear difference between groups. However,
placebo group had signiﬁcantly more people left the study early
due to lack of efﬁcacy (a risk reduction of 61% if one receives
risperidone, low quality evidence). Overall, risperidone group is
31% less likely to drop out early compared to placebo group (low
quality evidence). The participants have also experienced a range
of adverse events, but most had similar incidence rate between
groups, but some clearly favoured placebo group including, EPS
(1.56 times less likely compared to risperidone group), akathisia
(2.58 times times less likely compared to risperidone group), hy-
pertonia (2.98 times times less likely compared to risperidone
group) and parkinsonism (7.64 times times less likely compared to
risperidone group), somnolence (1.61 times times less likely com-
pared to risperidone group), constipation (1.88 times less likely),
weight gain (3.77 times less likely), upper respiratory infection
(2.83 times less likely), rhinitis (10.81 times less likely).
2. COMPARISON 2: RISPERIDONE plus
CLOZAPINE versus PLACEBO plus CLOZAPINE
When combined with clozapine, there was no obvious difference
between groups in achieving clinically signiﬁcant response in psy-
chotic symptoms (low quality evidence). However, placebo plus
clozapine group achieved greater reduction in PANSS score (MD
= 5.56, 95% CI 1.59 to 9.53), while risperidone plus clozapine
group appeared to produce more improvement in general func-
tioning as assessed by GAF (MD = -4.5, 95% CI -8.38 to -0.62).
Participants left the study early for a variety of reasons, but none
of which discriminated against any interventions (very low quality
of evidence). Similarly, we did not ﬁnd any clear difference in the
adverse events experienced between groups.
Overall completeness and applicability of
evidence
The review included 15 studies (n = 2428) of relatively short dura-
tion, between 8 and 16 weeks, hence limiting the applicability of
the results of this review to long term use of risperidone. All par-
ticipants in included trials were adults diagnosed with schizophre-
nia or schizoaffective disorder. The studies took place in both pri-
mary and secondary care settings, however, most were conducted
in high income countries, hence the evidence should be applied
with care in developing countries. There was a lack of data in in-
cluded studies on the following outcome, including service utili-
sation and quality of life.
Issue of placebo-controlled trials
Placebo-controlled trials have been used as a licensing requirement
by the US Food and Drug Administration (FDA) and other regu-
latory authorities for some time. Since 1964, the Helsinki Ethical
Principles forMedical Research Involving Human Subjects WMA
2008 have been considered a benchmark for trialists around the
world (WMA 2008). However, recently it has been argued that
it is unethical to conduct trials involving placebo arms for condi-
tions that have an established standard treatment. Also recently,
the FDA has adopted the less rigorous Good Clinical Practice as
an alternative to the Helsinki declaration, although this has in-
vited numerous criticisms (Lurie 1997; Lurie 2005). Nevertheless,
placebo trials do still have an important place, and some ethical
bodies around the world do approve of trial methodologies with
placebo arms. We suggest that the ﬁndings of this review support
the continued need for placebo-controlled studies. risperidone is
a widely used drug. That many of the effects of this compound
are not that different from a placebo is important and would not
have been highlighted but for the use of this type of study.
Quality of the evidence
The quality of reporting in most studies could have been much
better (Figure 4). Well over half of the included studies have con-
cerns in sequence generation and allocation concealment. There
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has also been some controversy over the trials conducted by Bori-
son, with the author being accused of scientiﬁc fraud (see Included
studies). Although, the trialists have not been found to have fabri-
cated research data, this cast a shadow to the ﬁndings of his trials
(AHRP 2006; CBS News 2000CBS News 2000AHRP 2006).
Now, years after the ﬁrst Consolidated Standards of Reporting
Trials (CONSORT) statement (Begg 1996), it is expected that all
relevant details of methodology that are likely to inﬂuence out-
come, such as means of allocation and concealment of allocation,
are documented and reported. Only 5 out of 13 studies provided
information about sequence generation, and 3 out of 13 provided
any details about allocation concealment. Good randomisation
methodology is essential, and more so for smaller trials, as it en-
sures that confounding variables are as equally distributed as pos-
sible between the intervention and control groups. Poor quality
or inadequate randomisation procedures would instead produce
imbalance between groups in terms of participant selection and
could potentially bias the result.
Potential biases in the review process
The authors of this review made every effort to minimise bias in
the review process by strictly following the Cochrane Handbook
and conduct expectations. The majority of data in this review
were collected from published reports. Even though we identiﬁed
substantial number of conference proceedings and unpublished
reports, however, we were not able to extract much data from these
reports due to either poor reporting or lack of collection at trial
stage, therefore, could not be used in this review. For example, in
some studies trialists reported mean without standard deviation.
Our attempts to contact authors of trials for additional data were
unsuccessful. This directly results in
2. Omission of relevant data or studies
As deﬁned in our protocol, we had to omit efﬁcacy measures from
studies that had attrition rates of higher than 50% at study end-
point in a sensitivity analysis for our main outcomes. We are not
sure if this is correct, but have identiﬁed no ready solution to the
problem of missing data and when assumptions become too much
and undermine credibility (Xia 2009). Certainly, high attrition
rates, poor reporting, and poor methodology, combined with the
rules we had set ourselves within our protocol, limited the infor-
mation available for us to use. We feel that people can leave the
trials for several reasons, most of which are not speciﬁed in the
reports. Many studies carried the last observation of such people
to the end of the trial period and used those data as if things stayed
stable beyond leaving the study. This may or may not be correct
but has gone untested. We have taken a conservative approach in
presentation of the available data.
Agreements and disagreements with other
studies or reviews
This review substantially updates the previous work in the area of
risperidone. It also completes the series of direct comparison of
risperidonewith other drugs (Gilbody 2000;Hosalli 2003;Hunter
2003; Jayaram 2006; Kennedy 2000; Komossa 2007; Li 2009).
The ﬁndings of this review were similar to the ﬁndings of other
reviews involving risperidone.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Risperidone has a positive effect on themental state of people with
schizophrenia, but data in this review are of low to very low quality,
suggesting that future research is very likely to have an important
impact on our conﬁdence in the estimate of effect and is likely to
change the estimate.
2. For clinicians
While mental state and global state outcomes favoured risperi-
done, when used alone, there is a high amount of uncertainty re-
garding this these data and, even if credible, their direct clinical
meaning is unclear. Due in large part to poor reporting, we are
very uncertain about the effects of risperidone on adverse effects.
3. For managers/policymakers
We found some low quality evidence, which supported the efﬁcacy
of risperidone compared to placebo. Based on the same body of
evidence, it appears risperidone also causes more adverse events
than placebo, and from the available evidence, it is unclear if the
beneﬁt out weight the harm. In summary, there is insufﬁcient
evidence from this review to support preferential use of risperidone
over placebo. Policymakers are encouraged to allocate resources to
fund bigger trials with greater methodological quality.
Implications for research
1. General
Strict adherence to the CONSORT statement may well have re-
sulted in this review having more data. Full availability of all data
from each study could greatly help future review authors. Many of
the studies included in this review did not always clearly present
denominator data, did not mention allocation concealment, and
frequently described results as “signiﬁcant” without original data.
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Multiple publications is another concern. Authors of this review
inspectd a large number of publications, which eventually were
identiﬁed as salami publication of the same trial.Multiple publica-
tion poses a risk for reviewers, as if not discovered, the data could
be double counted which inadvertently results in biased summary.
If mutiple publication is unavoidable, quoting speciﬁc trial iden-
tiﬁers such as the International Standard Randomised Controlled
Trial Number would greatly reduce confusion over identiﬁcation
of the source of trial.
2. Speciﬁc
Many excluded trials could ﬁnd a place in new or existing system-
atic reviews, and although many of the ’risperidone versus (other
antipsychotic)’ reviews have been undertaken, there are many oth-
ers still to do before a full overview of the effects of risperidone in
every comparison is complete (Table 3).
More independent well-planned, well-conducted, and well-re-
ported RCTs of longer duration are needed to address important,
unanswered clinically relevant outcomes. In Table 4, we have a
recommended study design for future trials. Even though we in-
cluded 15 studies in this review, we could present few clinically
meaningful results. As a result, we are uncertain of the short-,
medium-, and long-term efﬁcacy of using this popular treatment.
A C K N OW L E D G E M E N T S
The Cochrane Schizophrenia Group Editorial Base in Notting-
ham, UK produces and maintains standard text for use in the
Methods sections of their reviews. We have used this text as the
basis of what appears here and adapted it as required. We wish to
thank Julia Shaw for helpful comments on a draft of this review,
and Michael Smith for carrying out the reliability checks of trial
selection for the original version of this review.
Parts of this review were generated using RevMan HAL v 4.2. You
can ﬁnd more information about RevMan HAL here.
R E F E R E N C E S
References to studies included in this review
Bachmann 2003 {published data only}
Bachmann M, Ramsey M, Buchanan RW, Conley
RC, Weiner E. Clozapine treatment of schizophrenic
patients. www.clinicaltrials.gov (accessed 9 October 2013).
NCT00056498]
Borison 1992 {published data only}
Borison R. Risperidone versus haloperidol versus placebo in
the treatment of schizophrenia. Clinical report 1991.
Chouinard 1992 {published and unpublished data}
Chouinard G. Effects of risperidone in tardive dyskinesia:
an analysis of the Canadian multicenter risperidone study.
Journal of Clinical Psychopharmacology 1995;15(Suppl 1):
S36–S44. MEDLINE: 7537286
Chouinard G, Albright PS. Economic and health state
utility determinations for schizophrenic patients treated
with risperidone or haloperidol. Journal of Clinical
Psychopharmacology 1997;17(4):298–307. MEDLINE:
9241010
Chouinard G, Arnott W. An antidyskinetic effect of
risperidone. 9th World Congress of Psychiatry; 1993 Jun 6-
12; Rio de Janeiro, Brazil. 1993:22. MEDLINE: 94350925
Chouinard G, Arnott W. Antidyskinetic effect of
risperidone in chronic schizophrenic patients. Clinical
Neuropharmacology 1992;15(Suppl 1 Pt B):266.
MEDLINE: 94350925
Chouinard G, Arnott W. The effect of risperidone on
extrapyramidal symptoms in chronic schizophrenic patients.
Biological Psychiatry 1992;31:158. MEDLINE: 94350925
∗ Chouinard G, Jones B, Remington G, Bloom D,
Addington D,MacEwan GW, et al. A Canadian multicenter
placebo-controlled study of ﬁxed doses of risperidone and
haloperidol in the treatment of chronic schizophrenic
patients. Journal of Clinical Psychopharmacology 1993;13(1):
25–40. MEDLINE: 93253120
Chouinard G, Vainer JL, Beauclair L. Dose regimens
of neuroleptics in negative symptoms. 19th Collegium
Internationale Neuro-Psychopharmacologicum Congress; 1994
Jun 27-Jul 1; Washington DC, USA 1994;10(3 Suppl 1):
S363. MEDLINE: 94350925
Downing 2014 {published data only}
Downing A M, Kinon B J, Millen B A, Zhang L, Liu L,
Morozova M A, et al. A double-blind, placebo-controlled
comparator study of LY2140023 monohydrate in patients
with schizophrenia. BMC Psychiatry 2014;14:351.
Durgam 2014 {published data only}
Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G,
et al. An evaluation of the safety and efﬁcacy of cariprazine
in patients with acute exacerbation of schizophrenia: a
phase II, randomized clinical trial. Schizophr Res 2014;152:
450–7.
Geffen 2010 {published data only}
Geffen Y, Anand R, Keefe R, Davidson M. Results of
phase 2b eagle trial; a double blind placebo control study
evaluating the efﬁcacy and safety of bl-1020, a gaba
enhanced antipsychotic for the treatment of schizophrenia.
Schizophrenia Research 2010;117(2-3):212.
Heisterberg 2007 {published data only}
Heisterberg J, Barbato LM, Yeung PP, Shapira NA. Lipid
proﬁle among patients with schizophrenia randomized
35Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
to bifeprunox, placebo, or risperidone: a comparison of
results. Schizophrenia Bulletin 2007;33(2):432–3.
Yeung PP, Barbato LM, Heisterberg J, Shapira NA. Changes
in safety parameters in patients with schizophrenia treated
with bifeprunox, placebo, or risperidone. Schizophrenia
Bulletin 2007;33(2):466–7.
Yeung PP, Shapira NA, Heisterberg J. Changes in safety
parameters in patients with schizophrenia treated with
bifeprunox, placebo, or risperidone. Proceedings of the 11th
International Congress on Schizophrenia Research; 2007
Mar 28-Apr 1, Colorado Springs, Colorado, USA. 2007.
Honer 2006 {published data only}
HonerW. International study of improving treatment for the
most severely ill with schizophrenia. www.clinicaltrials.gov
(accessed 9 October 2013). NCT00272584]
Marder 1994a {published and unpublished data}
Ereshefsky L, Anderson C, True J, Saklad SR, Reisenman
C, Toney G, et al. Plasma concentration of oral risperidone
and active metabolite in schizophrenics. Pharmacotherapy
1993;13(3):292. LMD96402]
Lindenmayer JP, The Risperidone Study Group. Incidence
of EPS with risperidone compared with haloperidol and
placebo in patients with chronic schizophrenia. 146th
Annual Meeting of the American Psychiatric Association;
1993 May 22-27; San Francisco, California, USA. 1993.
MEDLINE: 94350925
Marder S. Risperidone versus haloperidol versus placebo in
the treatment of chronic schizophrenia. Clinical Research
Report RIS-INT-3 1991. MEDLINE: 1375802
Marder SR. Risperidone: clinical development: North
American results. Clinical Neuropharmacology 1992;15
(Suppl 1 Pt A):92A–3A. MEDLINE: 92361850
Marder SR. Risperidone: efﬁcacy. Journal of Clinical
Psychiatry 1994;12:49–52. MEDLINE: 94350925
Marder SR, Davis JM, Chouinard G. The effects of
risperidone on the ﬁve dimensions of schizophrenia
derived by factor analysis: combined results of the North
American trials. Journal of Clinical Psychological Medicine
[ ] 1997;58(12):538–46.
∗ Marder SR, Meibach RC. Risperidone in the treatment of
schizophrenia. American Journal of Psychiatry 1994;151(6):
825–35. EMBASE 1994202181]
McEvoy JP. Efﬁcacy of risperidone on positive features of
schizophrenia. Journal of Clinical Psychiatry 1994;55(5
Suppl):18–21. EMBASE 1994182002]
Meibach R. Risperidone versus haloperidol in acute
exacerbations of chronic schizophrenia. 1st International
Risperidone Investigators’ Meeting; 1992 Mar 9-10; Paris,
France. USA, 1992:28–9. LMD94893]
Meibach RC, The Risperidone Study Group. A ﬁxed
dose, parallel group study of risperidone vs. haloperidol
vs. placebo. Schizophrenia Research 1993;9(2,3):245.
MEDLINE: 94350925
NCT00249132. Risperidone versus haloperidol versus
placebo in the treatment of chronic schizophrenia.
clinicaltrials.gov/show/NCT00249132 (2005).
Schooler NR. Negative symptoms in schizophrenia:
assessment of the effect of risperidone. Journal of Clinical
Psychiatry 1994;55(Suppl 5):22–8. MEDLINE: 94350925
Simpson GM, Lindenmayer JP. Extrapyramidal symptoms
in patients treated with risperidone. Journal of Clinical
Psychopharmacology 1997;17(3):194–201. MEDLINE:
97313564; PsycINFO 1997–06350–009
Pai 2002 {published data only}
Bai YM, Yu SC, Lin CC. Risperidone for severe tardive
dyskinesia: a 12-week randomized, double-blind, placebo-
controlled study. Journal of Clinical Psychiatry 2003;64(11):
1342–8.
Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive
dyskinesia: a double-blind, placebo-controlled study.
Proceedings of the 154th Annual Meeting of the American
Psychiatric Association; 2001 May 5-10; New Orleans,
Louisiana, USA. Marathon Multimedia, 2001.
Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive
dyskinesia: a double-blind, placebo-controlled study.
Proceedings of the 155th Annual Meeting of the American
Psychiatric Association; 2002 May 18-23; Philadelphia,
Pennsylvania, USA. 2002.
Potkin 1997 {published data only}
Potkin SG, Gutierrez R. Safety and efﬁcacy of once-daily
risperidone in the treatment of schizophrenia. Proceedings
of the 150th Annual Meeting of the American Psychiatric
Association; 1997 May 17-22; San Diego, California, USA.
1997.
Potkin 2003 {published data only}
Potkin SG, Kujawa M, Carson WH, Saha AR, Ali M,
Ingenito G. Aripiprazole and risperidone versus placebo in
schizophrenia and schizoaffective disorder. Schizophrenia
Research 2003;60(1):300.
∗ Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M,
Stock E, et al. Aripiprazole, an antipsychotic with a novel
mechanism of action, and risperidone vs placebo in patients
with schizophrenia and schizoaffective disorder. Archives of
General Psychiatry 2003;60(7):681–90.
Saha A, Carson W, Ali M, Dunbar G, Ingenito G. Efﬁcacy
and safety of aripiprazole and risperidone vs. placebo in
patients with schizophrenia and schizoaffective disorder.
Proceedings of the 7th World Congress of Biological
Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001.
Yeung P, Kujawa M, Carson WH, Saha A, Alid M,
Ingenito G. Aripiprazole and risperidone versus placebo in
schizophrenia and schizoaffective disorder. Schizophrenia
Research 2002;53(3 Suppl 1):185–6.
Yeung P, McQuade RD, Carson WH, Saha A, Ali MW,
Ingenito G. Aripiprazole and risperidone versus placebo in
schizophrenia. European Psychiatry 2002;17(Suppl 1):102s.
Yeung PP, Carson WH, Saha A, McQuade RD, Ali M,
Stringfellow JC, et al. Efﬁcacy of aripiprazole, a novel
antipsychotic, in schizophrenia and schizoaffective disorder:
results of a placebo-controlled trial with risperidone.
European Neuropsychopharmacology 2001;11(3):259.
36Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Potkin 2006 {published data only}
Gharabawi GM, Greenspan A, Rupnow MFT, Kosik-
Gonzalez C, Bossie CA, Zhu Y, et al. Reduction in
psychotic symptoms as a predictor of patient satisfaction
with antipsychotic medication in schizophrenia: data from
a randomized double-blind trial. BMC Psychiatry 2006;6
(45):1–7.
Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y,
McLemore J, Gharabawi G. Atypical antipsychotics in
patients with schizophrenia and comorbid substance abuse.
Proceedings of the 158th Annual Meeting of the American
Psychiatric Association; 2005 May 21-26; Atlanta, Georgia,
USA. 2005:Nr279.
Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie
CA, Rupnow MFT, Zhu Y, et al. Risperidone vs quetiapine
in inpatients with schizophrenia: a double-blind placebo-
controlled study. European Neuropsychopharmacology 2005;
15(Suppl 3):S503.
NCT00061802. A randomized, double blind study to
evaluate the efﬁcacy and safety of two atypical antipsychotics
vs placebo in patients with an acute exacerbation of either
schizophrenia or schizoaffective disorder. clinicaltrials.gov/
show/NCT00061802 (2003).
∗ Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud
R, Kosik-Gonzalez C, Rupnow MFT, et al. A double-
blind comparison of risperidone, quetiapine and placebo
in patients with schizophrenia experiencing an acute
exacerbation requiring hospitalization. Schizophrenia
Research 2006;85(1-3):254–65.
Potkin SG, Greenspan A, Kosik-Gonzalez C, Bossie C,
Rupnow M, Zhu Y, et al. A placebo-controlled study
of risperidone vs quetiapine for symptom response and
readiness for discharge among agitated inpatients with
schizophrenia. Schizophrenia Bulletin 2005;31:501.
Rupnow M, Greenspan A, Kosik-Gonzalez C, Bossie C,
Zhu Y, Gharabawi G, et al. Polypharmacy in schizophrenia:
data from a randomized, double-blind study. Proceedings
of the 158th Annual Meeting of the American Psychiatric
Association; 2005 May 21-26; Atlanta, Georgia, USA.
2005.
Stahl S, Rupnow M, Greenspan A, Kosik-Gonzalez C,
Zhu Y, Gharabawi G. Use and cost of polypharmacy in
schizophrenia: data from a randomized, double-blind study
of risperidone and quetiapine. Neuropsychopharmacology
2004;29(Suppl 1):S227.
Potkin 2007 {published data only}
Potkin S, Fleming K, Binneman B, Keller DS, Alphs L,
Panagides J. Asenapine improves cognitive function in acute
schizophrenia: a placebo- and risperidone-controlled trial.
Proceedings of the 160th Annual Meeting of the American
Psychiatric Association; 2007 May 19-24; San Diego, CA
2007.
Potkin S, Fleming K, Binneman B, Keller S. Asenapine
cognitive function effects in acute schizophrenia: a placebo-
and risperidone-controlled trial. Schizophrenia Bulletin
2007;33(2):454.
Potkin SG, Cohen M, Jina AS, Nettler S, Alphs L,
Panagides J. Asenapine efﬁcacy during acute episodes of
schizophrenia: a randomized placebo and risperidone
controlled trial. Proceedings of the 44th American College
of Neuropsychopharmacology; 2005 December 11-15,
Waikoloa, Hawaii 2005.
Potkin SG, Cohen M, Panagides J. Efﬁcacy and tolerability
of asenapine in acute schizophrenia: a placebo- and
risperidone-controlled trial. Journal of Clinical Psychiatry
2007;68(10):1492–500.
∗ Potkin SG, Cohen M, Panagides J, Jina A. Asenapine
safety and tolerability in acute schizophrenia: a
placebo- and risperidone-controlled trial. European
Neuropsychopharmacology 2006;16(Suppl 4):S401.
Potkin SG, Cohen M, Panagides J, Jina AS. Asenapine
efﬁcacy in acute schizophrenia: a randomized, placebo-
and risperidone-controlled trial. International Journal of
Neuropsychopharmacology 2006;9(Suppl 1):S275.
Potkin SG, Cohen M, Panagides J, Jina AS. Asenapine
efﬁcacy, safety, and tolerability in the treatment of acute
schizophrenia: a randomized, placebo- and risperidone-
controlled trial. Biological Psychiatry 2006;59(8 Suppl):
154S.
Yagcioglu 2005 {published data only}
Akdede BB, Anil Yaciolu AE, Alptekin K, Turgut TI,
Tumuklu M, Yazici MK, et al. A double-blind study of
combination of clozapine with risperidone in patients with
schizophrenia: effects on cognition. Journal of Clinical
Psychiatry 2006;67(12):1912–9.
Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu
M, Yazici MK, Alptekin K, et al. A double-blind
controlled study of adjunctive treatment with risperidone
in schizophrenic patients partially responsive to clozapine:
efﬁcacy and safety. Journal of Clinical Psychiatry 2005;66
(1):63–72.
References to studies excluded from this review
Adler 1999 {published data only}
Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann
R, et al. Vitamin E treatment for tardive dyskinesia.
Archives of General Psychiatry 1999;56(9):836–41.
Adler LA, Rotrosen J, Lavori P, Edson R. Vitamin E
treatment of TD: development of a VA cooperative study.
Biological Psychiatry 1994;35:730–1.
Caligiuri MP, Lohr JB, Rotrosen J, Adler L, Lavori P,
Edson R, et al. Reliability of an instrumental assessment of
tardive dyskinesia: results from VA Cooperative Study 394.
Psychopharmacology 1997;132(1):61–6.
Akhondzadeh 2005 {published data only}
Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, Alem
ZM. Does the addition of lamotrigine to risperidone
improve psychotic symptoms and cognitive impairments in
chronic schizophrenia?. Therapy 2005;2(3):399–406.
Akhondzadeh 2007 {published data only}
Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari
SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy
in schizophrenia: a double-blind, randomized and placebo-
37Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
controlled trial. Schizophrenia Research 2007;90(1-3):
179–85.
Anwunah 1999 {published data only}
Anwunah IJ, Mitropoulou V, Bushnoe L, Siever LJ.
Risperidone treatment for schizotypal personality disorder.
Proceedings of the 51st Institute on Psychiatric Services;
1999 Oct 25-Nov 2; New Orleans, Louisiana, USA. 1999.
Ayd 2001 {published data only}
Ayd FJ. Risperidone treatment for schizotypal personality
disorder. International Drug Therapy Newsletter 2001;36(8):
58.
Azorin 2002 {published data only}
Azorin J, Toumi M, Sloth-Nielsen M. Sertindole is well
tolerated and superior to risperidone with respect to efﬁcacy
in patients with schizophrenia. Schizophrenia Research 2003;
60(1):271–2.
Azorin JM, Toumi M, Sloth-Nielsen M. Sertindole is
well tolerated and superior to risperidone with respect
to efﬁcacy in patients with schizophrenia. European
Neuropsychopharmacology 2002;12(Suppl 3):S300.
Azorin 2006 {published data only}
Azorin J-M, Strub N, Loft H. A double-blind, controlled
study of sertindole versus risperidone in the treatment of
moderate-to-severe schizophrenia. International Clinical
Psychopharmacology 2006;21(1):49–56.
Bai 2005 {published data only}
Bai Y-M, Yu S-C, Chen J-Y, Lin C-Y, Chou P, Lin C-C.
Risperidone for pre-existing severe tardive dyskinesia: a 48-
week prospective follow-up study. International Clinical
Psychopharmacology 2005;20(2):79–85.
Bai Y-M, Yu S-C, Lin C-C. Risperidone for severe tardive
dyskinesia: a 12-week randomized, double-blind, placebo-
controlled study. Journal of Clinical Psychiatry 2003;64:
1342–8.
Baker 2012 {published data only}
Baker RA, Jin N, Ali MW, Forbes RA, Offord SJ, Carson
WH, Sanchez R, McQuade RD, Rahman Z. Long-term
effects (up to 4 years) of aripiprazole on maintenance
treatment for schizophrenia or schizoaffective disorder:
A pooled open-label extension of two clinical trials.
Schizophrenia research 2012;136:S154.
Basson 2001 {published data only}
Basson B, Kennedy J, Tollefson G, Tran P, Beasley C,
Bymaster F. The comparative anti muscarinic like adverse
event proﬁles of olanzapine and risperidone treatment in
patients with schizophrenia spectrum psychosis. Proceeding
of the 11th World Congress of Psychiatry; 1999 Aug 6-11;
Hamburg, Germany. 1999.
Basson B, Kinon BJ, Gilmore JA, Taylor CC, Tollefson
GD, Czekalla J. Factors inﬂuencing weight change in
patients with schizophrenia treated with olanzapine verus
haloperidol or risperidone. Journal of Psychopharmacology
2000;14(3 Suppl):A60.
Basson BR, Kennedy JS, Tran PV, Beasley CM, Bymaster
FP, Tollefson GD. The comparative anti-muscarinic like
side effect proﬁles of olanzapine and risperidone treatment
in patients with schizophrenia spectrum psychosis.
Schizophrenia Research 1999;36(1-3):270.
∗ Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore
JA, Tollefson GD. Factors inﬂuencing acute weight change
in patients with schizophrenia treated with olanzapine,
haloperidol, or risperidone. Journal of Clinical Psychiatry
2001;62(4):231–8.
Beasley 1996 {published data only}
Beasley C Jr, Tollefson GD, Beuzen JN, Dellva MA, Sanger
TM, Paul S. Acute and long-term results of the North
American double-blind olanzapine trial. Proceedings of the
4th International Conference on Schizophrenia: Breaking
Down the Barriers; 1996 Oct 6-9; Vancouver, Canada.
1996.
Beasley C, Tran P, Beuzen JN, Tamura R, Dellva MA, Bailey
J, et al. Olanzapine versus haloperidol: long-term results of
the multi-center international trial. Proceedings of the 20th
Collegium Internationale Neuro-Psychopharmacologicum
Congress; 1996 Jun 23-27; Melbourne, Australia. 1996.
∗ Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A,
et al. Olanzapine versus placebo, results of the United States
double-blind olanzapine trial. Proceedings of the 20th
Collegium Internationale Neuro-Psychopharmacologicum
Congress; 1996 Jun 23-27; Melbourne, Australia. 1996.
Beasley CM. Safety of olanzapine. Journal of Clinical
Psychiatry 1997;15(2):19–21.
Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P,
Hamilton S. Olanzapine versus placebo - results of a double-
blind, ﬁxed dose olanzapine trial. Psychopharmacology 1996;
124(1-2):159–67.
Beasley CM, Berg PH, Dananberg J, Kwong KC, Taylor
CCM, Breier A. Treatment-emergent potential impaired
glucose tolerance and potential diabetes with olanzapine
compared to other antipsychotic agents and placebo.
Biological Psychiatry 2001;49(8):121S.
Beasley CM, Dellva MA, Tamura RN, Morgenstern H,
Glazer WM, Ferguson K, et al. A randomised double-
blind comparison of the incidence of tardive dyskinesia in
patients with schizophrenia during long-term treatment
with olanzapine or haloperidol. British Journal of Psychiatry
1999;174:23–30.
Beasley CM, Hamilton SH, Crawford AM, Dellva
MA, Tollefson GD, Tran PV, et al. Olanzapine versus
haloperidol: acute phase results of the international double-
blind olanzapine trial. European Neuropsychopharmacology
1997;7(2):125–37.
Beasley CM, Sayler ME, Keisler GM, Potvin JH, Sanger
TM, Tollefson GD. The inﬂuence of pharamacotherapy
on self-directed and externally-directed aggression in
schizophrenia. Schizophrenia Research 1998;29(1-2):28.
Beasley CM, Sowell MO, Carlson C, Mukhopadhyay N,
Dananberg J, Henry R, et al. Prospective evaluation of
insulin sensitivity by the hyperinsulinemic, euglycemic
clamp in healthy volunteers treated with olanzapine,
risperidone or placebo. Schizophrenia Research 2003;60(1):
309.
Beasley CM, Sutton VK, Hamilton SH, Walker DJ,
38Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dossenbach M, Taylor CC, et al. A double-blind,
randomized, placebo-controlled trial of olanzapine in
the prevention of psychotic relapse. Journal of Clinical
Psychopharmacology 2003;23(6):582–94.
Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T,
Hamilton S. Olanzapine versus placebo and haloperidol:
acute phase results of the North American double-blind
olanzapine trial. Neuropyschopharmacology 1996;14(2):
111–23.
Beasley CM, Tollefson GD, Dellva MA, Tamura R, Glazer
WM, Morgenstern H. The differential risk of tardive
dyskinesia with olanzapine. Proceedings of the 151st
Annual Meeting of the American Psychiatric Association;
1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998.
Bondolfi 1998 {published data only}
Bondolﬁ G, Baumann P, Dufour H. Treatment-resistant
schizophrenia - clinical experience with new antipsychotics.
European Neuropsychopharmacology 1996;6(Suppl 2):S21–5.
Bondolﬁ G, Baumann P, Patris M, May J, Billeter U,
Dufour H, et al. A randomized double-bind trial of
risperidone versus clozapine for treatment-resistant chronic
schizophrenia. Proceedings of the 8th European College of
Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4;
Venice, Italy. 1995.
Bondolﬁ G, Baumann P, Patris M, May JP, Billeter
U, Dufour H. A randomised double-blind trial of
risperidone versus clozapine for treatment-resistant chronic
schizophrenia. Proceedings of the 148th Annual Meeting
of the American Psychiatric Association; 1995 May 20-25;
Miami, Florida, USA. 1995.
Bondolﬁ G, Baumann P, Patris M, May JP, Billeter
U, Dufour H. A randomized double-blind trial of
risperidone versus clozapine for treatment-resistant chronic
schizophrenia. Proceedings of the Workshop on Critical
Issues in the Treatment of Schizophrenia; 1995 Mar 10-12;
Florence, Italy. 1995.
∗ Bondolﬁ G, Dufour H, Patris M, May JP, Billeter U,
Eap CB, et al. Risperidone versus clozapine in treatment-
resistant chronic schizophrenia: a randomized double-blind
study. The Risperidone Study Group. American Journal of
Psychiatry 1998;155(4):499–504.
Borison 1992a {published data only}
∗ Borison R. Risperidone versus haloperidol in acute
exacerbations of chronic schizophrenia. Proceedings of the
1st International Risperidone Investigators’ Meeting; 1992
Mar 9-10; Paris, France. 1992.
Borison R, Pathiraja A, Diamond B, Meibach R.
Risperidone and schizophrenia. Biological Psychiatry 1991;
29:417.
Borison RL, Diamond BI, Augusta GA. Serotonin
modulation of dopaminergic-medicated extrapyramidal side
effects. Neurology 1991;41(Suppl 1):396.
Borison RL, Diamond BI, Pathiraja A, Meibach RC.
Clinical proﬁle of risperidone in chronic schizophrenia.
Proceedings of the 17th Collegium Internationale Neuro-
Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto,
Japan. 1991.
Borison RL, Pathiraja AP, Diamond BI, Meibach RC.
Risperidone - clinical safety and efﬁcacy in schizophrenia.
Psychopharmacology Bulletin 1992;28(2):213–8.
Borison RL, Pathiraja AP, Diamond BI, Meibach RC.
Risperidone in the treatment of acute exacerbation of
chronic schizophrenia. Schizophrenia Research 1991;4(3):
314–5.
Borison Rl, Pathiraja AP, Diamond BI, Meibach RC.
Antidopaminergic and antiserotonergic actions of
risperidone in schizophrenia. Biological Psychiatry 1991;29
(Suppl):114a.
Boyer 1995 {published data only}
Boyer P, Lecrubier Y, Puech AJ. Treatment of positive
and negative symptoms: pharmacologic approaches.
In: Andreasen NC editor(s). Modern problems of
pharmacopsychiatry. Vol. 24, Basel, Switzerland: S. Karger,
1990:152–74.
∗ Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F.
Treatment of negative symptoms in schizophrenia with
amisulpride. British Journal of Psychiatry 1995;166(1):
68–72.
Boyer P, Puech AJ. Determinants for clinical activity of
neuroleptic drugs: chemical substances, doses, assessment
tools [Modalities d’action clinique des neuroleptiques:
substances, doses, instruments de mesure utilises].
Psychiatrie and Psychobiologie 1987;2(4):296–305.
Boyer P, Puech AJ, Lecrubier Y. Double blind trial versus
placebo of low dose amisulpride (Solian 50) in schizophrenia
with exclusively negative symptoms. Preliminary analysis of
results [Etude en double insu contre placebo de l’amisulpride
(Solian (r) 50) a faible dose chez des schizophrenes purement
deﬁcitaires. Premiere analyse des resultats]. Annales de
Psychiatrie 1988;3(3):321–5.
Brecher 1998 {published data only}
Brecher M. Risperidone versus olanzapine in the
treatment of patients with schizophrenia or schizoaffective
disorder. Proceedings of the 11th European College of
Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4;
Paris, France. 1998.
Brecher M, The Risperidone Olanzapine Study Group.
Risperidone versus olanzapine in the treatment of
patients with schizophrenia or schizoaffective disorder.
Proceedings of the 21st Collegium Internationale Neuro-
Psychopharmacologicum Congress; 1998 Jul 12-16;
Glasgow, UK. 1998.
∗ Brecher M, The Risperidone-Olanzapine Study Group.
Risperidone versus olanzapine in the treatment of patients
with schizophrenia or schizoaffective disorder conference
abstract. Schizophrenia Research 1999;36(1-3):271.
Cada 2004 {published data only}
Cada DJ, Levien T, Baker DE. Risperidone long-acting
injection. Hospital Pharmacy 2004;39(4):353–62.
Carson 2002 {published data only}
Carson W, Cornblatt B, Saha A, Ali M, Kern R, Green M.
Neurocognitive beneﬁts of aripiprazole versus olanzapine in
39Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
stable psychosis. European Neuropsychopharmacology 2002;
12(Suppl 3):S291.
Carson W, McQuade R, Saha A, Torbeyns A, Stock
E. Aripiprazole versus placebo for relapse prevention
in patients with chronic schizophrenia. European
Neuropsychopharmacology 2002;12(Suppl 3):S288.
Carson W, Pigott T, Saha A, Ali M, McQuade RD,
Torbeyns AF, et al. Aripiprazole vs placebo in the treatment
of stable, chronic schizophrenia. Proceedings of the 156th
Annual Meeting of the American Psychiatric Association;
2003 May 17-22; San Francisco, California, USA. 2003.
Carson WH, Ali M, Dunbar G, Ingenito G, Saha AR. A
double-blind, placebo-controlled trial of aripiprazole and
haloperidol. Schizophrenia Research 2001;49(1,2):221–2.
Carson WH, Ali M, Saha AR, Dunbar GC, Ingenito G. A
double-blind, placebo-controlled trial of aripiprazole and
haloperidol in patients with schizophrenia or schizoaffective
disorder. Proceedings of the 39th Annual Meeting of the
American College of Neuropsychopharmacology; 2000 Dec
10-14; San Juan, Puerto Rico. 2000.
Carson WH, Ingenito GG, Mcquade RD, Stock EG,
Iwamoto T. Schizophrenia: safety / tolerability of
aripiprazole. Proceedings of the 12th World Congress of
Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002.
Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito
G. Efﬁcacy of aripiprazole in psychotic disorders:
comparison with haloperidol and placebo. European
Neuropsychopharmacology 2000;10(Suppl 3):S309.
Carson WH, Pigott TA, Saha AR, Ali MW, McQuade
RD, Torbeyns AF, et al. Aripiprazole vs placebo in the
treatment of chronic schizophrenia. International Journal of
Neuropsychopharmacology 2002;5(Suppl 1):S187.
Carson WH, Saha AR, Ali M, Dunbar GC, Ingenito G.
Aripiprazole and risperidone versus placebo in schizophrenia
and schizoaffective disorder. Proceedings of the 154th
Annual Meeting of the American Psychiatric Association;
2001 May 5-10; New Orleans, Louisiana, USA. 2001.
∗ Carson WHJ, Saha AR, Ali M, Dunbar GC, Ingenito G.
Aripiprazole and risperidone versus placebo in schizophrenia
and schizoaffective disorder. Proceedings of the 155th
Annual Meeting of the American Psychiatric Association;
2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002.
Casey 2003 {published data only}
Casey D, Barbato LM, Heisterberg J, Yeung PP, Shapira
NA. Results of a bifeprunox dose-ﬁnding study in patients
with acutely exacerbated schizophrenia. Schizophrenia
Bulletin 2007;33(2):425.
∗ Casey D, Saha A, Marcus R, Carson WH, McQuade
RD, Torbeyns AF, et al. Aripiprazole versus placebo for
relapse prevention in patients with chronic schizophrenia.
Schizophrenia Research 2003;60(1):276.
Casey D, Saha AR, Ali MW, Jody DN, Kujawa MJ,
Stock EG, et al. Switching to aripiprazole monotherapy.
International Journal of Neuropsychopharmacology 2002;5
(Suppl 1):S187.
Casey DE, Barbato LM, Heisterberg J, Yeung PP, Shapira
NA. Results of a bifeprunox dose-ﬁnding study in patients
with acutely exacerbated schizophrenia. Proceedings of the
11th International Congress on Schizophrenia Research;
2007 Mar 28-Apr 1, Colorado Springs, Colorado, USA
2007.
Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW,
Jody D, et al. Switching patients to aripiprazole from other
antipsychotic agents: A multicenter randomized study.
Psychopharmacology 2003;166(4):391–9.
Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak
P, Sommerville KW. Effect of divalproex combined with
olanzapine or risperidone in patients with an acute
exacerbation of schizophrenia. Neuropyschopharmacology
2003;28(1):182–92.
Casey DE, Saha AR, Ali MW, Jody D, Kujawa MJ,
Stock EG, et al. Switching to aripiprazole monotherapy.
Proceedings of the 155th Annual Meeting of the American
Psychiatric Association; 2002 May 18-23; Philadelphia,
Pennsylvania, USA. 2002.
Castle 2015 {published data only}
Castle DJ, Jensen JKS.Management of depressive symptoms
in schizophrenia: A pooled, post hoc analysis from the
asenapine development program. Clinical Schizophrenia
and Related Psychoses 2015;9:13–20.
Chan 2007 {published data only}
Chan H-Y, Lin W-W, Lin S-K, Hwang T-J, Su T-P,
Chiang S-C, et al. Efﬁcacy and safety of aripiprazole in the
acute treatment of schizophrenia in Chinese patients with
risperidone as an active control: a randomized trial. Journal
of Clinical Psychiatry 2007;68(1):29–36.
Chue 2002 {published data only}
Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P,
Eriksson L, et al. Comparative efﬁcacy and safety of long-
acting risperidone and risperidone oral tablets. European
Neuropsychopharmacology 2005;15(1):111–7.
∗ Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan
P, Eriksson L, et al. Efﬁcacy and safety of long-acting
risperidone microspheres and risperidone oral tables.
Schizophrenia Research 2002;53(3 Suppl 1):174.
Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan
P, Eriksson L, et al. Efﬁcacy and safety of long-acting
risperidone microspheres and risperidone oral tablets.
Proceedings of the 11th Biennial Winter Workshop on
Schizophrenia; 2002 Feb 24-Mar 1; Davos, Switzerland.
2002.
Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P,
Eriksson L, et al. Maintenance of efﬁcacy when switching
from oral risperdal to risperdal consta RIS-INT-61. Poster
supplied by Company 2002.
Ciliberto 2005 {published data only}
Ciliberto N, Bossie CA, Urioste R, Lasser RA. Lack of
impact of race on the efﬁcacy and safety of long-acting
risperidone versus placebo in patients with schizophrenia
or schizoaffective disorder. International Clinical
Psychopharmacology 2005;20(4):207–12.
40Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Citrome 2004 {published data only}
∗ Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan
LD, Tracy KA. Adjunctive divalproex and hostility among
patients with schizophrenia receiving olanzapine or
risperidone. Psychiatric Services 2004;55(3):290–4.
Citrome LL, Daniel DG, Wassef AA, Tracy KA, Wozniak P,
Casey DE. Antipsychotic monotherapy versus combination
treatment with valporate in hospitalized patients with
acute schizophrenia: a double-blind, multi-center study.
Proceedings of the 155th Annual Meeting of the American
Psychiatric Association; 2002 May 18-23; Philadelphia,
Pennsylvania, USA. 2002.
Claus 1992 {published data only}
Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid
M, Peuskens J, et al. Risperidone versus haloperidol
in the treatment of chronic schizophrenic inpatients:
a multicentre double-blind comparative study. Acta
Psychiatrica Scandinavica 1992;85(4):295–305.
Conley 1998 {published data only}
∗ Conley RR, Brecher M, The Risperidone/Olanzapine
Study Group. Risperidone versus olanzapine in patients
with schizophrenia or schizoaffective disorders. Proceedings
of the 11th European College of Neuropsychopharmacology
Congress; 1998 Oct 31-Nov 4; Paris, France. 1998.
Conley RR, Brecher MB, Olanzapine-Risperidone Study
Group. Risperidone versus olanzapine in the treatment
of patients with schizophrenia or schizoaffective disorder.
Proceedings of the 152nd Annual Meeting of the American
Psychiatric Association; 1999 May 15-20; Washington DC,
USA. 1999.
Conley RR, Mahmoud R. A randomized double-blind
study of risperidone and olanzapine in the treatment of
schizophrenia or schizoaffective disorder. American Journal
of Psychiatry 2001; Vol. 158, issue 5:765–74.
Conley RR, Mahmoud R. Efﬁcacy of risperidone vs.
olanzapine in the treatment of patients with schizophrenia or
schizoaffective disorder. European Neuropsychopharmacology
2000;10(Suppl 3):S343. 13th Congress of the European
College of Neuropsychopharmacology CD–ROM]:
Conifer, Excerpta Medica Medical Communications BV,
2000 P3021]
Conley RR, Mahmoud R. Efﬁcacy of risperidone vs.
olanzapine in the treatment of patients with schizophrenia
or schizoaffective disorder. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S151.
Conley RR, Mahmoud R. Risperidone and olanzapine
in people with schizophrenia or schizoaffective disorder:
a randomised double-blind study. Poster supplied by
Company 2001.
Conley RR, Mahmoud R. Risperidone vs olanzapine in
patients with schizophrenia & schizoaffective disorder.
Proceedings of the 40th Annual Meeting of the New
Clinical Drug Evaluation Unit; 2000 May 30-Jun 2; Boca
Raton, Florida, USA. 2000.
Conley RR, Mahmoud R. Risperidone vs. olanzapine
in the treatment of patients with schizophrenia
or schizoaffective disorder: safety comparisons.
European Neuropsychopharmacology 2000;10(Suppl 3):
S342. 13th Congress of the European College of
Neuropsychopharmacology CD–ROM]: Conifer, Excerpta
Medica Medical Communications BV, 2000 P3020]
Conley RR, Mahmoud R. Risperidone vs. olanzapine in the
treatment of patients with schizophrenia or schizoaffective
disorder: safety comparisons. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S151.
Conley RR, Mahmoud R, Risperidone Study Group.
Risperidone versus olanzapine in patients with schizophrenia
and schizoaffective disorder. Proceedings of the 10th
Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-
11; Davos, Switzerland. 2000.
Conley RR, Mahmoud R, Risperidone Study Group.
Risperidone versus olanzapine in patients with schizophrenia
and schizoaffective psychosis [Risperidon versus olanzapin
bei patienten mit schizophrenie und schizoaffektiven
psychosen]. Nervenheilkunde 2000;19(5):110–2.
Conley RR, Mahmoud R, Risperidone Study Group.
Risperidone vs. olanzapine in patients with schizophrenia
and schizoaffective disorder. Biological Psychiatry 2000;47:
32S.
Conley RR, Mahmoud RA. Risperidone versus olanzapine
in patients with schizophrenia and schizoaffective disorder.
155th Annual Meeting of the American Psychiatric
Association; 2002 May 18-23; Philadelphia, Pennsylvania,
USA. 2002. NR1 Monday, May 15, 9:00 a.m.–10:30 a.m]
Conley RR, Mahmoud RA. Risperidone versus olanzapine
in patients with schizophrenia and schizoaffective disorder.
Proceedings of the 153rd Annual Meeting of the American
Psychiatric Association; 2000 May 13-18; Chicago, Illinois,
USA. 2000.
Conley RR, Mahmoud RA. Risperidone vs olanzapine in
patients with schizophrenia and schizo-affective disorder.
International Drug Therapy Newsletter 2000;35(10):77–8.
Cooper 1997 {published data only}
∗ Cooper SJ, Butler A, Tweed J, Raniwalla J, Welch C.
Zotepine in the prevention of relapse. Proceedings of the
6th World Congress of Biological Psychiatry; 1997 Jun 22-
27; Nice, France. 1997.
Cooper SJ, Butler A, Tweed JA, Welch CP, Wighton
AJ, Appleby P, et al. Zotepine is effective in preventing
recurrence in patients with chronic schizophrenia.
Proceedings of the 11th European College of
Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4;
Paris, France. 1998.
Cooper SJ, Butler A, Tweed JA, Welch CP, Wighton
AJ, Appleby P, et al. Zotepine is effective in preventing
recurrence in patients with chronic schizophrenia.
Schizophrenia Research 2000;41(1):207–8.
Cooper TB, Volavka J, Czobor P. Plasma drug level and
clinical response. Journal of Clinical Psychopharmacology
1992;12(2):134–6.
Cornblatt 2002 {published data only}
Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X,
Green M. Neurocognitive effects of aripiprazole versus
41Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
olanzapine in stable psychosis. International Journal of
Neuropsychopharmacology 2002;5(Suppl 1):S185.
Cornblatt B, Kern RS, Carson WH, Stock E, Ali M,
Ingenito G, et al. Neurocognitive effects of aripiprazole
versus olanzapine in patients with stabile psychosis. Journal
of Psychopharmacology 2002;16(Suppl 3):A15.
∗ Cornblatt B, Kern RS, Carson WH, Stock E, Ali M,
Ingenito G, et al. Neurocognitive effects of aripiprazole
versus olanzapine in patients with stable psychosis.
Schizophrenia Research 2002;53(3 Suppl 1):27.
Crawford 1997 {published data only}
Crawford AM, Beasley CM, Tollefson GD. Olanzapine -
impact of an atypical antipsychotic candidate on prolactin
release. Proceedings of the 149th Annual Meeting of the
American Psychiatric Association; 1996 May 4-9, New
York, New York, USA. 1996.
Crawford AM, Beasley CM, Tollefson GD. The acute and
long-term effect of olanzapine compared with placebo and
haloperidol on serum prolactin concentrations. European
Neuropsychopharmacology 1997;7(Suppl 2):199.
∗ Crawford AM, Beasley CM, Tollefson GD. The acute
and long-term effect of olanzapine compared with placebo
and haloperidol on serum prolactin concentrations.
Schizophrenia Research 1997;26(1):41–54.
Crawford AMK, Beasley CM, Tollefson GD. The acute and
long-term effect of olanzapine compared with placebo and
haloperidol on serum prolactin concentration. Proceedings
of the 10th European College of Neuropsychopharmacology
Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
Crawford AMK, Gomez JC, Beasley CM Jr, Tollefson GD.
Olanzapine versus haloperidol: analysis of schizophrenic
patients from the multi-center international trial. European
Neuropsychopharmacology 1997;7:2.015.
Csernansky 1999 {published data only}
Csernansky J. Do novel antipsychotics optimize long
term outcomes in schizophrenia. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S1.
∗ Csernansky J, Brecher M, Okamoto A. Risperidone
vs haloperidol: relapse prevention in schizophrenia
and schizoaffective disorders: a long-term double-blind
comparison. Proceedings of the 11th World Congress of
Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999.
Csernansky J, Okamoto A. A long term double blind
comparison of risperidone and haloperidol in stable
outpatients with schizophrenia or schizoaffective disorder.
International Journal of Neuropsychopharmacology 2000;3
(Suppl 1):S155.
Csernansky J, Okamoto A. Risperidone versus haloperidol
for prevention of relapse in schizophrenia and schizoaffective
disorders: long term double blind comparison.
Proceedings of the 22nd Collegium Internationale Neuro-
Psychopharmacologicum Congress; 2000 Jul 9-13; Brussels,
Belgium. 2000.
Csernansky J, Okamoto A. Risperidone versus haloperidol
for prevention of relapse in schizophrenia and schizoaffective
disorders: long term double blind comparison.
Schizophrenia Research 2000;41(1):198.
Csernansky JG, Mahmoud R, Brenner R, The Risperidone-
USA-79 Study Group. A comparison of risperidone and
haloperidol for the prevention of relapse in patients with
schizophrenia. The New England Journal of Medicine 2002;
346(1):16–22.
Csernansky JG, Okamoto A. Risperidone versus haloperidol
for prevention of relapse in patients with schizophrenia
and schizoaffective disorder: a long-term double blind
comparison. Proceedings of the 38th Annual Meeting of
the American College of Neuropsychopharmacology; 1999
Dec 12-16; Acapulco, Mexico. 1999.
Csernansky JG, Okamoto A. Risperidone versus haloperidol
for relapse prevention in schizophrenia and schizoaffective
disorder: a long-term double-blind placebo controlled
comparison. Proceedings of the 40th Annual Meeting of
the New Clinical Drug Evaluation Unit; 2000 May 30-Jun
2; Boca Raton, Florida, USA. 2000.
Csernansky JG, Okamoto A. Risperidone vs haloperidol
for relapse prevention in schizophrenia and schizoaffective
disorder: a long-term double-blind comparison. Biological
Psychiatry 2000;47:31–2S.
Csernansky JG, Okamoto A, Brecher M. Risperidone
vs haloperidol: prevention of relapse in schizophrenia.
European Neuropsychopharmacology 1999;9:S268.
Csernansky JG, Okamoto A, Brecher MB. Risperidone
versus haloperidol for prevention of relapse in schizophrenia
and schizoaffective disorder: a long-term, double-blind
comparison. Proceedings of the 51st Institute on Psychiatric
Services; 1999 Oct 25-Nov 2; New Orleans, Louisiana,
USA. 1999.
David 2000 {published data only}
David S, Crawford AM, Breier A. Prolactin levels in
olanzapine versus typical and atypical antipsychotics.
European Neuropsychopharmacology 1998;8(Suppl 2):s229.
David SR, Meehan KM, Sutton VK, Taylor CC.
Treatment of negative symptoms with olanzapine in
comparison with other novel antipsychotic agents. European
Neuropsychopharmacology 1999;9:S292.
∗ David SR, Taylor CC, Kinon BJ, Breier A. The effects
of olanzapine, risperidone, and haloperidol on plasma
prolactin levels in patients with schizophrenia. Clinical
Therapeutics 2000;22(9):1085–96.
Davis 2001 {published data only}
∗ Davis JM, Chen N. Evidence of efﬁcacy of risperidone in
schizophrenia. Schizophrenia Research 2001;49(1-2):224–5.
Davis SM, Koch GG, Davis CE, La Vange LM. Statistical
approaches to effectiveness measurement and outcome-
driven re-randomizations in the clinical antipsychotic trials
of intervention effectiveness (CATIE) studies. Schizophrenia
Bulletin 2003;29(1):73–80.
Dossenbach 1997 {published data only}
∗ Dossenbach M, Friedel P, Jakovljevic M, Hotujac
L, Folnegovic V, Uglesic B, et al. Olanzapine
versus ﬂuphenazine - six weeks’ treatment of acute
schizophrenia. Proceedings of the 10th European College
42Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of Neuropsychopharmacology Congress; 1997 Sep 13-17;
Vienna, Austria. 1997.
Dossenbach M, Jakovljevic M, Folnegovic F, Uglesic B,
Dodig G, Friedel P, et al. Olanzapine versus ﬂuphenazine
- 6 weeks treatment of anxiety symptoms during acute
schizophrenia. Schizophrenia Research 1998;29(1,2):203.
Dubitsky 2002 {published data only}
∗ Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify
(aripiprazole) tablets; medical review part 1. www.fda.gov/
cder/foi/nda/2002/21-436 Abilify.htm 2002 (accessed 9
October 2013):1–50.
Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify
(aripiprazole) tablets; medical review part 2. www.fda.gov/
cder/foi/nda/2002/21-436 Abilify.htm. U.S. Food and
Drug Administration CDER, 2002 (accessed 9 October
2013):50–110.
Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify
(aripiprazole) tablets; medical review part 3. www.fda.gov/
cder/foi/nda/2002/21-436 Abilify.htm. U.S. Food and
Drug Administration CDER, 2002 (accessed 9 October
2013):111–75.
Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify
(aripiprazole) tablets; medical review part 4. www.fda.gov/
cder/foi/nda/2002/21-436 Abilify.htm. U.S. Food and
Drug Administration CDER, 2002 (accessed 9 October
2013):176–232.
Edgell 2000 {published data only}
Edgell ET, Andersen SW, Grainger D, Wang J. Resource use
and quality of life of olanzapine compared with risperidone:
results from an international randomized clinical trial.
Proceedings of the 21st Collegium Internationale Neuro-
Psychopharmacologicum Congress; 1998 Jul 12-16;
Glasgow, UK. 1998.
∗ Edgell ET, Andersen SW, Johnstone BM, Dulisse B,
Revicki D, Breier A. Olanzapine versus risperidone:
a prospective comparison of clinical and economic
outcomes in schizophrenia. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S92.
Edgell ET, Andersen SW, Johnstone BM, Dulisse B,
Revicki D, Breier A. Olanzapine versus risperidone: a
prospective comparison of clinical and economic outcomes
in schizophrenia. Pharmacoeconomics 2000;18(6):567–79.
Edgell ET, Andersen SW, Johnstone BM, Dulisse B,
Revicki D, Breier A, et al. Olanzapine versus risperidone: a
prospective comparison of clinical and economic outcomes
in schizophrenia. European Psychiatry 2000;15(Suppl 2):
408s.
Edgell ET, Grainger DL, Andersen SW, Wang J. Resource
use and quality of life associated with olanzapine compared
with risperidone. Proceedings of the 151st Annual Meeting
of the American Psychiatric Association; 1998 May 30-Jun
4; Toronto, Ontario, Canada. 1998.
Edgell ET, Hamilton SH, Revicki DA, Genduso LA,
Tollefson GD. Costs of olanzapine treatment compared
with haloperidol for schizophrenia: results from a
randomized clinical trial. Proceedings of the 21st Collegium
Internationale Neuro-Psychopharmacologicum Congress;
1998 Jul 12-6; Glasgow, UK. 1998.
Fleming 2007a {published data only}
Fleming K, Potkin SG, Binneman B, Keller D, Alphs L,
Panagides J. Effects of asenapine on cognitive function in
acute schizophrenia: a placebo- and risperidone-controlled
trial. European Neuropsychopharmacology 2007;17(Suppl 4):
S466.
Friedman 2000 {published data only}
∗ Friedman J, Adler D, Temporini H, Harvey P, Kemether
E, Davis K. Alpha2 agonists enhance cognition of
schizophrenia patients in combination with atypical
but not typical neuroleptics. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S155.
Friedman JI, Adler D, Temporini HD, Harvey PD,
Kemether EM, Davis KL. Alpha-2 agonists enhance
cognition of schizophrenia patients in combination with
atypical but not typical neuroleptics. Proceedings of
the 155th Annual Meeting of the American Psychiatric
Association; 2002 May 18-23; Philadelphia, Pennsylvania,
USA. 2002.
Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner
G, Temporini H, et al. A double blind placebo controlled
trial of donepezil adjunctive treatment to risperidone for the
cognitive impairment of schizophrenia. Biological Psychiatry
2002;51:349–57.
Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner
G, Temporini H, et al. A double blind placebo controlled
trial of donepezil adjunctive treatment to risperidone for
the cognitive impairment of schizophrenia. Schizophrenia
Research 2002;53(3 Suppl 1):9.
Friedman JI, Adler DN, Howanitz E, Temporini H,
Harvey PD, Davis KL. Effects of donepezil on cognition,
symptoms, and movement disorders in patients with chronic
schizophrenia. Proceedings of the 39th Annual Meeting of
the American College of Neuropsychopharmacology; 2000
Dec 10-14; San Juan, Puerto Rico. 2000.
Friedman JI, Adler DN, Temporini HD, Harvey PD, Davis
KL. Alpha-2 agonists enhance cognition of schizophrenic
patients in combination with atypical but not typical
neuroleptics. Proceedings of the 38th Annual Meeting of
the American College of Neuropsychopharmacology; 1999
Dec 12-16; Acapulco, Mexico. 1999.
Friedman JI, Adler DN, Temporini HD, Kemether
E, Harvey PD, White L, et al. Guanfacine
treatment of cognitive impairment in schizophrenia.
Neuropyschopharmacology 2001;25(3):402–9.
NCT00488163. Pilot study of atomoxetine to enhance
cognition in patients with schizophrenia. clinicaltrials.gov/
show/NCT00488163 (2007).
Gismondi 2004 {published data only}
Gismondi R, Meltzer H, Kujawa M, Carson W,
Stringfellow J, Iwamoto T, et al. Aripiprazole versus
perphenazine in treatment-resistant schizophrenia.
Proceedings of the XXIVth Collegium Internationale
Neuro-Psychopharmacologicum Congress; 2004 June 20-
24, Paris, France 2004.
43Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gregor 2000 {published data only}
Gregor K, Hamilton S, Edgell E. Functional outcomes in
schizophrenia: a European comparison of olanzapine and
haloperidol. Proceedings of the 11th World Congress of
Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999.
∗ Gregor KJ, Allicar MP, Lilliu H, Olivier V, Le Pen C,
Gavart S. An economic comparison of olanzapine versus
haloperidol in the treatment of schizophrenia in France.
International Journal of Neuropsychopharmacology 2000;3
(Suppl 1):S161.
Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes
in schizophrenia: a European comparison of olanzapine and
haloperidol. European Neuropsychopharmacology 1999;9
(Suppl 1):S11.
Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes
in schizophrenia: a European comparison of olanzapine and
haloperidol. European Neuropsychopharmacology 1999;9:
S289.
Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes
in schizophrenia: a European comparison of olanzapine and
haloperidol. Schizophrenia Research 2000;41(1):189.
Harvey 2001 {published data only}
Harvey K, Burns T, Sedgwick P, Higgitt A, Creed F, Fahy T.
Relatives of patients with severe psychotic disorders: factors
that inﬂuence contact frequency. Report from the UK700
trial. British Journal of Psychiatry 2001;178:248–54.
Harvey P, Meltzer H, Green M. Long term cognitive effects
of risperidone treatment in schizophrenia. International
Journal of Neuropsychopharmacology 2000;3(Suppl 1):S154.
Harvey P, Meltzer H, Green M. Risperidone cognitive effects
in schizophrenia and schizoaffective patients. International
Drug Therapy Newsletter 2001;36(8):59.
∗ Harvey P, Meltzer HY, Green MP. Cognitive effects of
risperidone versus olanzapine in patients with schizophrenia
or schizoaffective disorder. Proceedings of the 7th World
Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin,
Germany. 2001.
Harvey P, Melzer H, Green M. Cognitive effects of
risperidone and olanzapine in patients with schizophrenia
or schizoaffective disorder. Biological Psychiatry 2001;49(8):
123S.
Harvey PD. Cognitive effects of risperidone and olanzapine
in patients with schizophrenia. Proceedings of the
52nd Institute on Psychiatric Services; 2000 Oct 25-29;
Philadelphia, Pennsylvania, USA. 2000.
Harvey PD. Cognitive effects of risperidone and olanzapine
in patients with schizophrenia or schizoaffective disorder.
Proceedings of the 153rd Annual Meeting of the American
Psychiatric Association; 2000 May 13-18; Chicago, Illinois,
USA. 2000.
Harvey PD. Long-term cognitive effects of risperidone
treatment in schizophrenia. Proceedings of the 52nd
Institute on Psychiatric Services; 2000 Oct 25-29;
Philadelphia, Pennsylvania, USA. 2000.
Harvey PD, Gharabawi G. Risperidone and cognition
in schizophrenic elderly. Proceedings of the 12th World
Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan.
2002.
Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes
in cognitive functioning with risperidone and olanzapine
treatment: a large-scale, double-blind, randomized study.
Psychopharmacology 2003;169(3-4):404–11.
Harvey PD, Lyons BE, Mahmoud R. Long term cognitive
effects of risperidone. Schizophrenia Research 2000;41(1):
200–1.
Harvey PD, Mahmoud R, Meltzer HY, Green MP.
Cognitive effects of risperidone and olanzapine in patients
with schizophrenia or schizoaffective disorder. European
Neuropsychopharmacology 2001;11(3):257.
Harvey PD, Meltzer HY, Green M. Cognitive
effects of risperidone and olanzapine in patients with
schizophrenia or schizoaffective disorder. Proceedings of
the 39th Annual Meeting of the American College of
Neuropsychopharmacology; 2000 Dec 10-14; San Juan,
Puerto Rico. 2000.
Harvey PD, Meltzer HY, Green MF. Cognitive effects of
risperidone and olanzapine in patients with schizophrenia
or schizoaffective disorder. Proceedings of the 40th Annual
Meeting of the New Clinical Drug Evaluation Unit; 2000
May 30-Jun 2; Boca Raton, Florida, USA. 2000.
Harvey PD, Meltzer HY, Green MF. Long-term cognitive
effects of risperidone treatment in schizophrenia.
Proceedings of the 39th Annual Meeting of the American
College of Neuropsychopharmacology; 2000 Dec 10-14;
San Juan, Puerto Rico. 2000.
Hwang 2003 {published data only}
Hwang TJ, Lee S-M, Sun HJ, Lin H-N, Tsai S-J, Lee Y-
C, et al. Amisulpride versus risperidone in the treatment
of schizophrenic patients: a double-blind pilot study in
Taiwan. Journal of the Formosan Medical Association 2003;
102(1):30–6.
Hwang 2005 {published data only}
Hwang TJ, Chan HY, Lin WW, Lin SK, Hwu HG,
Cheng MY, et al. Aripiprazole versus risperidone in the
treatment of acutely relapsed patients with schizophrenia
in Taiwan: a randomized controlled trial. European
Neuropsychopharmacology 2005;15(Suppl 3):S497.
Kane 2005 {published data only}
Kane J, Carson Wh, Kujawa M, Stringfellow J, Marcus
R, Sanchez R, et al. Aripiprazole in treatment-resistant
schizophrenia: a 6-week double-blind comparison study
versus perphenazine. Schizophrenia Research 2004;67(1):
155–6.
Kane J, Eerdekens M, Keith S, Lesem M, Karcher K,
Lindenmayer J-P. Efﬁcacy and safety of Risperdal Consta,
a long-acting injection risperidone formulation RIS-USA-
121. Promotional slides on ﬁle from Janssen-Cilag UK Ltd
2002.
Kane J, Eerdekens M, Keith S, Lesem M, Karcher K,
Lindenmayer J-P. Efﬁcacy and safety of a novel long-acting
risperidone formulation. European Psychiatry 2002;17
(Suppl 1):S193.
Kane J, Eerdekens M, Keith S, Lesem M, Karcher K,
Lindenmayer J-P. Efﬁcacy and safety of a novel long-acting
44Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
risperidone microspheres formulation. Proceedings of the
11th Biennial Winter Workshop on Schizophrenia; 2002
Feb 24-Mar 1; Davos, Switzerland. 2002.
Kane J, Eerdekens M, Keith S, Lesem M, Karcher K,
Lindenmayer JP. Long-acting risperidone microspheres
for treatment of patients with schizophrenia. European
Neuropsychopharmacology 2001;11(3):291.
Kane J, Eerdekens M, Keith SJ, Lesem M, Karcher
K, Lindenmayer JP. Efﬁcacy and safety of risperdal
constatm, the long-acting injection risperidone formulation.
International Journal of Neuropsychopharmacology 2002;5
(Suppl 1):S188.
Kane J, Ingenito G, Ali M. Efﬁcacy of aripiprazole in
psychotic disorders: comparison with haloperidol and
placebo. Schizophrenia Research 2000;41(1):39.
Kane JM. Preventing morbidity in ﬁrst-episode
schizophrenia. clinicaltrials.gov/ct2/show/NCT00000374
(accessed 16 Feb 2001).
Kane JM. The latest advance in long-acting antipsychotic
therapy. Proceedings of the 156th Annual Meeting of the
American Psychiatric Association; 2003 May 17-22; San
Francisco, California, USA. 2003.
Kane JM, Carson WH, Saha AR, McQuade RD,
Ingenito GG, Zimbroff DL, et al. Efﬁcacy and safety of
aripiprazole and haloperidol versus placebo in patients
with schizophrenia and schizoaffective disorder. Journal of
Clinical Psychiatry 2002;63(9):763–71.
Kane JM, Conley RR, Keith SJ, Nasrallah HA, Turner M.
Guidelines for the use of long-acting injectable atypical
antipsychotics. Journal of Clinical Psychiatry 2004;65(1):
120–31.
Kane JM, Eerdekens M, Keith SJ, Lesem M, Karcher
K, Lindenmayer J-P. Efﬁcacy and safety of a novel long-
acting risperidone microspheres formulation. Schizophrenia
Research 2002;53(3 Suppl 1):174.
Kane JM, Eerdekens M, Keith SJ, Lesem M, Karcher
K, Lindenmayer JP. Long-acting injectable risperidone:
Efﬁcacy and safety. European Neuropsychopharmacology
2002;12(Suppl 3):S325.
Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem
M, Karcher K. Long-acting injectable risperidone: efﬁcacy
and safety of the ﬁrst long-acting atypical antipsychotic.
American Journal of Psychiatry 2003;160:1125–32.
Kane JM, Ingenito G, Ali M. Efﬁcacy of aripiprazole in
psychotic disorders: comparison with haloperidol and
placebo. 155th Annual Meeting of the American Psychiatric
Association; 2002 May 18-23; Philadelphia, Pennsylvania,
USA. 2002. NR345 Tuesday, May 16, 3:00 p.m.–5:00 p.m]
Kane JM, Ingenito G, Ali M. Efﬁcacy of aripiprazole in
psychotic disorders: comparison with haloperidol and
placebo. International Journal of Neuropsychopharmacology
2000;3(Suppl 1):S124.
Kane JM, Ingenito G, Ali M. Efﬁcacy of aripiprazole in
psychotic disorders: comparison with haloperidol and
placebo. Proceedings of the 153rd Annual Meeting of
the American Psychiatric Association; 2000 May 13-18;
Chicago, Illinois, USA. 2000.
∗ Kane JM, Potkin S, Buckley P, Daniel DG. Safety and
efﬁcacy of sertindole and risperidone in treatment resistant
patients with schizophrenia. Schizophrenia Bulletin 2005;
31:490.
Kane JM, William HCJ, Kujawa MJ, Stringfellow J, Marcus
RN, Sanchez R, et al. Aripiprazole vs perphenazine in
treatment-resistant schizophrenia. Proceedings of the 156th
Annual Meeting of the American Psychiatric Association;
2003 May 17-22; San Francisco, California, USA. 2003.
Kinon 1998 {published data only}
Kinon B, Basson B, Malcolm S, Breier A. Strategies
for switching from conventional antipsychotic drugs or
risperidone to olanzapine. Proceedings of the 39th Annual
Meeting of the New Clinical Drug Evaluation Unit; 1999
Jun 1-4; Boca Raton, Florida, USA. 1999.
Kinon B, Basson B, Tollefson GD. Gender-speciﬁc prolactin
olanzapine versus haloperidol in schizophrenia. 151st
Annual Meeting of the American Psychiatric Association;
1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998.
151st Annual Meeting of the American Psychiatric
Association CD–ROM]: MARATHONMultimedia, 1988
NR449; 151st Annual Meeting of the American Psychiatric
Association CD–ROM]: MARATHONMultimedia, 1988
NR739]
Kinon B, Basson B, Tollefson GD. Gender-speciﬁc prolactin
olanzapine versus haloperidol in schizophrenia. Proceedings
of the 151st Annual Meeting of the American Psychiatric
Association; 1998 May 30-Jun 4; Toronto, Ontario,
Canada. 1998.
Kinon B, Basson BR, Malcolm SK, Tollefson G. Strategies
for switching from conventional antipsychotic drugs to
olanzapine. Proceedings of the 152nd Annual Meeting of
the American Psychiatric Association; 1999 May 15-20;
Washington, DC, USA. 1999.
Kinon B, Breier A, Malcolm S, Basson B. Strategies
for switching from conventional antipsychotic drugs
or risperidone to olanzapine. Proceedings of the 11th
World Congress of Psychiatry; 1999 Aug 6-11; Hamburg,
Germany. 1999.
Kinon BJ, Basson B, Hill AL, Berg PH. Effective resolution
of acute presentation of behavioral agitation and positive
psychotic symptoms in schizophrenia with olanzapine.
European Neuropsychopharmacology 2000;10(Suppl 3):S305.
Kinon BJ, Basson B, Szymanski K, Tollefson GD. Predictors
of weight gain during olanzapine treatment. Proceedings of
the 11th European College of Neuropsychopharmacology
Congress; 1998 Oct 31-Nov 4; Paris, France. 1998.
Kinon BJ, Basson B, Wang J, Malcolm SK. Rapid
reduction in hyperprolactinemia upon switching treatment
to olanzapine from conventional antipsychotic drugs or
risperidone. Schizophrenia Research 2000;41(1):194–5.
Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL.
Rapid reduction in hyperprolactinemia upon switching
treatment to olanzapine from conventional antipsychotic
drugs or risperidone. European Neuropsychopharmacology
45Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2000;10(Suppl 3):S306.
Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer
VL. Rapid reduction in hyperprolactinemia upon
switching treatment to olanzapine from conventional
antipsychotic drugs or risperidone. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S155.
Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL.
Rapid reduction in hyperprolactinemia upon switching
treatment to olanzapine from conventional antipsychotic
drugs or risperidone. Proceedings of the 40th Annual
Meeting of the New Clinical Drug Evaluation Unit; 2000
May 30-Jun 2; Boca Raton, Florida, USA. 2000.
Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL.
Strategies for switching from conventional antipsychotic
drugs or risperidone to olanzapine. Journal of Clinical
Psychiatry 2000;61(11):833–40.
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-
term olanzapine treatment: weight change and weight-
related health factors in schizophrenia. Journal of Clinical
Psychiatry 2001;62(2):92–100.
Kinon BJ, Basson BR, Malcolm SK, Tollefson GD.
Strategies for switching from conventional antipsychotic
drugs or risperidone to olanzapine conference abstract.
Schizophrenia Research 1999;36(1-3):285–6.
Kinon BJ, Basson BR, Wang J. Rapid reduction in
hyperprolactinemia upon switching treatment to olanzapine
from conventional antipsychotic drugs or risperidone.
Proceedings of the 52nd Institute on Psychiatric Services;
2000 Oct 25-29; Philadelphia, Pennsylvania, USA. 2000.
Kinon BJ, Basson BR, Wang J, Malcolm SK, Stauffer VL.
Rapid reduction in hyperprolactinemia. Proceedings of
the 153rd Annual Meeting of the American Psychiatric
Association; 2000 May 13-18; Chicago, Illinois, USA.
2000.
∗ Kinon BJ, Basson MS, Tollefson GD. Gender-speciﬁc
prolactin response to treatment with olanzapine versus
haloperidol in schizophrenia. Proceedings of the 9th
Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-
13; Davos, Switzerland 1998.
Kinon BJ, Gilmore JA, Gottschalk LA. Continued
improvement in quality of life despite weight change
during olanzapine treatment. Proceedings of the
39th Annual Meeting of the American College of
Neuropsychopharmacology; 2000 Dec 10-14; San Juan,
Puerto Rico. 2000.
Kinon BJ, Liu-Seifert H, Ahl J, Ahmed S, Baker RW.
Longitudinal effect of olanzapine on fasting serum lipids: a
randomized, prospective, 4-month study. Annals of the New
York Academy of Sciences 2004;1032:295–6.
Kinon BJ, Milton DR, Gilmore JA. Continued
improvement in quality of life despite weight change
during olanzapine treatment. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S154.
Kinon BJ, Milton DR, Hill AL. Effective resolution of acute
presentation of behavioral agitation and positive psychotic
symptoms in schizophrenia with olanzapine. International
Journal of Neuropsychopharmacology 2000;3(Suppl 1):S154.
Kinon BJ, Milton DR, Hill AL, Williamson DJ. Effective
resolution of acute presentation of behavioral agitation
and positive psychotic symptoms in schizophrenia with
olanzapine. Journal of Psychopharmacology 2000;14(3
Suppl):A60.
Kinon BJ, Roychowdhury SM, Milton DR, Hill AL.
Effective resolution with olanzapine of acute presentation
of behavioral agitation and positive psychotic symptoms in
schizophrenia. Journal of Clinical Psychiatry 2001;62(Suppl
2):17–21.
Kinon 2015 {published data only}
Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory
analysis for a targeted patient population responsive to the
metabotropic glutamate 2/3 receptor agonist pomaglumetad
methionil in schizophrenia. Biological psychiatry 2015;
InPress:InPress.
Lauriello 2005 {published data only}
Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser
RA. Long-acting risperidone vs. placebo in the treatment
of hospital inpatients with schizophrenia. Schizophrenia
Research 2005;72(2-3):249–58.
Lemmens 1994 {published data only}
Lemmens P, de Smedt G, Gheuens J, Tritsmans L. Efﬁcacy of
risperidone in the treatment of schizophrenia. Proceedings
of the 7th Biennial Winter Workshop on Schizophrenia;
1994 Jan 23-28; Les Diablerets, Switzerland 1994; Vol. 11,
issue 2:106.
Lieberman 2005 {published data only}
Lieberman J, McEnvoy J, Stroup S. Protocol: comparative
effectiveness of antipsychotic medications in patients with
schizophrenia: revised in response to DSMB comments.
National Institute of Mental Health. Chapel Hill, USA:
University of North Carolina, 2000.
Lieberman J, McEvoy J, Stroup S. Trial design summary:
Comparative effectiveness of antipsychotic medications in
patients with schizophrenia: Draft. National Institute of
Mental Health. Chapel Hill, USA: University of North
Carolina, 2002.
Lieberman J, McEvoy JP, Perkins D, Hamer RH.
Comparison of atypicals in ﬁrst-episode psychosis: a
randomized, 52-week comparison of olanzapine, quetiapine,
and risperidone. European Neuropsychopharmacology 2005;
15(Suppl 3):S525.
Lieberman JA. Comparative effectiveness of antipsychotic
medications in patients with schizophrenia (CATIE
schizophrenia trial). clinicaltrials.gov/ct2/show/
NCT00014001 2001 (accessed 9 October 2013).
Lieberman JA. Research gaps and current research initiatives
to improve the treatment of schizophrenia. Proceedings
of the 156th Annual Meeting of the American Psychiatric
Association; 2003 May 17-22; San Francisco, California,
USA. 2003.
Lieberman JA, Schneider LS, McEroy J, Pariot P, Stroup
S, Adiao J, et al. Effectiveness trials of antipsychotic
drugs. 155th Annual Meeting of the American Psychiatric
46Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Association; 2002 May 18-23; Philadelphia, Pennsylvania,
USA. 2002. No. 103D]
Lieberman JA, Schneider LS, McEroy J, Pariot P, Stroup S,
Adiao J, et al. Effectiveness trials of antipsychotic drugs.
Proceeding of the 154th Annual Meeting of the American
Psychiatric Association; 2001 May 5-10; New Orleans,
Louisiana, USA. Marathon Multimedia, 2001.
Lieberman JA, Stroup TS. Schizophrenia, VI: treatments.
American Journal of Psychiatry 2003;160(10):1748.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Keefe
R, Perkins DO, et al. CATIE trial results. European
Neuropsychopharmacology 2006;16(Suppl 4):S184.
∗ Lieberman JA, Stroup TS, McEvoy JP, Swartz MS,
Rosenheck RA, Perkins DO, et al. Effectiveness of
antipsychotic drugs in patients with chronic schizophrenia.
The New England Journal of Medicine 2005;353(12):
1209–23.
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE,
Kahn R, et al. Comparative efﬁcacy and safety of atypical
and conventional antipsychotic drugs in ﬁrst-episode
psychosis: a randomized, double-blind trial of olanzapine
versus haloperidol. American Journal of Psychiatry 2003;160
(8):1396–404.
Lindstrom 1994 {published data only}
Lindstrom E, von Knorring L. Changes in single
symptoms and separate factors of the schizophrenic
syndrome after treatment with risperidone or haloperidol.
Pharmacopsychiatry 1994;27(3):108–13.
Loo 1997 {published data only}
Loo H, Poirier Littre MF, Theron M, Rein W, Fleurot O.
Amisulpride versus placebo in the medium-term treatment
of the negative symptoms of schizophrenia. British Journal
of Psychiatry 1997;170:18–22. MEDLINE: 9068769
Lopez 1996 {published data only}
Lopez Ibor JJ, Ayuso JL, Gutierrez M, Guimon J, Herraiz
ML, Chinchilla A, et al. Risperidone in the treatment
of chronic schizophrenia: multicenter study comparative
to haloperidol [Risperidona en el tratamiento de la
esquizofrenia cronica: estudio multicentrico comparativo
versus haloperidol]. Actas Luso Espanolas de Neurologia
Psiquiatria y Ciencias Afines 1996;24(4):165–72.
Lopez-Ibor 1992 {published data only}
Lopez-Ibor JJ. Safety proﬁle of risperidone in the multicentre
trials. Proceedings of the 1st International Risperidone
Investigators’ Meeting; 1992 Mar 9-10; Paris, France. 1992.
Luo 2011 {published data only}
. Palley risperidone sustained release tablets and
olanzapine tablets in the treatment of exacerbations and
readmission of patients with schizophrenia in a randomized
double-blind placebo-controlled study. Chinese Journal of
Mental Health [ ] 2011;23(05):560–3.
Marder 1991 {published data only}
Marder SR, Chouinard G, Davis JM. The clinical actions
of risperidone. Proceedings of the 6th World Congress of
Biological Psychiatry 1997;Jun 22-27:Nice, France.
McClellan 2009 {published data only}
McClellan J. Risperidone for schizophrenia. Stanley
Foundation Research Programs 2009.
McClure 2009 {published data only}
McClure MM, Koenigsberg HW, Reynolds D, Goodman
M, New A, Trestman R, Silverman J, Harvey PD, Siever LJ.
The effects of risperidone on the cognitive performance of
individuals with schizotypal personality disorder. Journal of
clinical psychopharmacology 2009;29:396–398.
McKenna 2004 {published data only}
McKenna PJ. An international study of improving treatment
for the most severely ill with schizophrenia. National
Research Register 2004.
Nasrallah 2004a {published data only}
Nasrallah HA, Duchesne I, Mehnert A, Janagap C,
Eerdekens M. Correction. Journal of Clinical Psychiatry
[linchuang jingshen yixue zazhi] [ ]
2004;65(8):1150.
Nasrallah HA, Duchesne I, Mehnert A, Janagap C,
Eerdekens M. Health-related quality of life in patients with
schizophrenia during treatment with long-acting, injectable
risperidone. Journal of Clinical Psychiatry 2004;65(4):
531–6.
NCT00034892 {published data only}
NCT00034892. Efﬁcacy and tolerability of olanzapine,
quetiapine and risperidone in the treatment of ﬁrst episode
psychosis: a randomized double blind 52-week comparison.
clinicaltrials.gov/ct2/show/NCT00034892 (2002) (accessed
9 October 2013).
NCT00088075 {published data only}
NCT00088075. A randomized, double-blind, placebo-
controlled clinical study of the efﬁcacy and safety
of risperidone for the treatment of schizophrenia in
adolescents. clinicaltrials.gov/ct2/show/NCT00088075
(2004) (accessed 9 October 2013).
NCT00202007 {published data only}
NCT00202007. A multi-center, randomized, double-blind
study, comparing with risperidone, to evaluate the efﬁcacy
and safety of aripiprazole in the treatment of patients with
schizophrenia. clinicaltrials.gov/ct2/show/NCT00202007
(2005) (accessed 9 October 2013).
NCT00249119 {published data only}
NCT00249119. Risperidone in the treatment of chronic
schizophrenic patients: an international multicentre double-
blind parallel-group comparative study versus haloperidol.
clinicaltrials.gov/ct2/show/NCT00249119 (2005) (accessed
9 October 2013).
NCT00253136 {published data only}
NCT00253136. Risperidone depot (microspheres) vs
placebo in the treatment of subjects with schizophrenia.
clinicaltrials.gov/ct2/show/NCT00253136 (2005) (accessed
9 October 2013).
NCT00305474 {published data only}
NCT00305474. Identiﬁcation and treatment of the
liability to develop schizophrenia. clinicaltrials.gov/ct2/
47Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
show/results/NCT00305474 (2006) (accessed 9 October
2013).
NCT 02109562 {published data only}
Nct02109562. A Phase 3, Randomized, Double-Blind,
Placebo-Controlled, Multicenter Study to Evaluate the
Efﬁcacy, Safety and Tolerability of RBP-7000 (90mg
and 120mg) as a Treatment in Subjects With Acute
Schizophrenia Over 8 Weeks (2 Subcutaneous Doses). http:
//Clinicaltrials.gov/show/NCT02109562.
Peuskens 1995 {published data only}
Peuskens J, Risperidone Study Group. Risperidone in the
treatment of patients with chronic schizophrenia: a multi-
national, multi-centre, double-blind, parallel-group study
versus haloperidol. British Journal of Psychiatry 1995;166:
712–26.
Peuskens 2001 {published data only}
Peuskens J, Kasper S. Amisulpride versus risperidone in
schizophrenia: comparing clinical and functional outcome
in a 6 months study. Proceedings of the 7th World Congress
of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany.
2001.
Peuskens 2001a {published data only}
Peuskens J, Moller HJ. Amisulpride improves depressive
symptoms in acute exacerbations of schizophrenia:
comparison with haloperidol and risperidone. European
Neuropsychopharmacology 2001;11(3):255.
Pikalov 2012 {published data only}
Pikalov A, Cucchiaro J, Ogasa M, Silva R, Hsu J,
Xu J, Loebel A. Effect of lurasidone on weight and
metabolic parameters: A comprehensive database analysis.
Schizophrenia research 2012;136:S278.
Rabinowitz 2001 {published data only}
Rabinowitz J, Davidson M. Risperidone versus haloperidol
in long-term hospitalized chronic patients in a double blind
randomized trial: a post hoc analysis. Schizophrenia Research
2001;50(1-2):89–93.
Rein 2002 {published data only}
Rein W, Fleurot O. Efﬁcacy of amisulpride vs risperidone
in the long-term treatment of chronic schizophrenia:
Results from a 12 month double-blind study. European
Neuropsychopharmacology 2002;12(Suppl 3):S302.
Rein W, Fleurot O. Safety of amisulpride vs risperidone
in the long-term treatment of chronic schizophrenia:
Results from a 12 month double-blind study. European
Neuropsychopharmacology 2002;12(Suppl 3):S309.
Revicki 1996 {published data only}
Revicki D, Genduso LA, Hamilton SL, Martin C, Reblando
J, Tran PV. Quality of life outcomes for olanzapine and
haloperidol treatment for schizophrenia and related
psychotic disorders. Proceedings of the 149th Annual
Meeting of the American Psychiatric Association; 1996 May
4-9, New York, New York, USA. 1996.
Riedel 2003 {published data only}
Riedel M, Mo ller HJ, Mu ller N. Rational and efﬁcacy
of cox-2-inhibitors as adjunctive therapy in schizophrenia.
European Neuropsychopharmacology 2003;13(4):S96.
Schmechtig 2010 {published data only}
Schmechtig A, Dourish C, Craig K, Dawson GR,
Williams S, Deakin W, Lees J, Wilkinson L, Ettinger U.
Effects of risperidone, amisulpride and nicotine on eye
movement control and their modulation by high schizotypy.
Pharmacopsychiatry 2011;21:A99.
Siever 2002 {published data only}
Siever LJ, Koenigsberg HW, Mitropoulou V, Goodman
M, Buchsbaum MS. Neurobiology and pharmacologic
treatment of schizotypal personality: implications for
pharmacology. Proceeding of the 155th Annual Meeting
of the American Psychiatric Association; 2002 May 18-23;
Philadelphia, Pennsylvania, USA. 2002.
Tollefson 1996 {published data only}
∗ Tollefson G, Beasley C, Tran P, Dellva MA, Krueger J,
Tamura R. Olanzapine versus haloperidol: acute results
of the multicenter international trial. Psychopharmacology
Bulletin 1996;32(3):401.
Tollefson G, Beasley C, Tran P, Sanger T. Olanzapine:
an exciting atypical antipsychotic; the clinical
experience. Proceedings of the 8th European College of
Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4;
Venice, Italy. 1995.
Tollefson G, Lu Y. Comorbid mood disturbance in
schizophrenia. Schizophrenia Research 1997;24:192.
Tollefson GD. Olanzapine: a novel antipsychotic with a
broad spectrum proﬁle. Neuropyschopharmacology 1994;10
(Suppl 3 Pt 1):805S.
Tollefson GD. The value of atypical antipsychotic
medications. Proceedings of the 150th Annual Meeting of
the American Psychiatric Association; 1997 May 17-22; San
Diego, California, USA. 1997.
Tollefson GD. Treatment consideration for comorbid mood
disorders in schizophrenic patients. Proceedings of the 6th
World Congress of Biological Psychiatry; 1997 Jun 22-27;
Nice, France. 1997.
Tollefson GD. Update on new atypical antipsychotics.
Proceedings of the 8th European College of
Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4;
Venice, Italy. 1995.
Tollefson GD, Andersen SW. Should we consider mood
disturbance in schizophrenia as an important determinant
of quality of life?. Journal of Clinical Psychiatry 1999;60
(Suppl 5):23–9.
Tollefson GD, Andersen SW, Tran PV. The course of
depressive symptoms in predicting relapse in schizophrenia:
a double blind, randomized comparison of olanzapine and
risperidone. Biological Psychiatry 1999;46(3):365–73.
Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin
JH. Blind, controlled, long term study of the comparative
incidence of treatment emergent tardive dyskinesia with
olanzapine or haloperidol. American Journal of Psychiatry
1997;154(9):1248–54.
Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger
JA, Tamura RN, et al. Olanzapine versus haloperidol in
the treatment of schizophrenia and schizoaffective and
schizophreniform disorders: results of an international
48Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
collaborative trial. American Journal of Psychiatry 1997;154
(4):457–65.
Tollefson GD, Lu Y. Comorbid mood disturbance in
schizophrenia. Biological Psychiatry 1997;41:101S.
Tollefson GD, Lu Y. Comorbid mood disturbance
in schizophrenia. Proceedings of the 20th Collegium
Internationale Neuro-Psychopharmacologicum Congress;
1996 Jun 23-27; Melbourne, Australia. 1996.
Tollefson GD, Lu Y. Comorbid mood disturbance in
schizophrenia. Proceedings of the 9th European College
of Neuropsychopharmacology Congress; 1996 Sep 21-25;
Amsterdam, Netherlands. 1996.
Tollefson GD, Lu Y, Sanger TM, Beasley CM, Tran PV.
Olanzapine in the treatment of schizoaffective disorder.
Schizophrenia Research 1997;24(1, 2):92–3.
Tollefson GD, Sanger TD, Lieberman JA. Olanzapine
versus haloperidol in the treatment of ﬁrst episode psychosis.
Biological Psychiatry 1997;41:73S.
Tollefson GD, Sanger TM. A blinded trial on the course
and relationship of depressive symptoms in schizophrenia.
Schizophrenia Research 1998;29(1, 2):205.
Tollefson GD, Sanger TM. Negative symptoms: a
path analytic approach to a double-blind, placebo- and
haloperidol-controlled clinical trial with olanzapine.
American Journal of Psychiatry 1997;154(4):466–74.
Tollefson GD, Sanger TM, Beasley CM. The course of
primary and secondary negative symptoms in a controlled
trial with olanzapine. 20th Collegium Internationale
Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27;
Melbourne, Australia. 1996. MEDLINE: 97245664
Tollefson GD, Sanger TM, Beasley CM. The course of
primary and secondary negative symptoms in a controlled
trial with olanzapine. Proceedings of the 149th Annual
Meeting of the American Psychiatric Association; 1996 May
4-9, New York, New York, USA. 1996.
Tollefson GD, Sanger TM, Beasley CM. The course of
primary and secondary negative symptoms in a controlled
trial with olanzapine. Schizophrenia Research 1997;24(1, 2):
192.
Tollefson GD, Sanger TM, Beasley CM. The course of
primary and secondary negative symptoms in a placebo-
and comparator-controlled trial of the typical antipsychotic
olanzapine. Proceedings of the 9th European College of
Neuropsychopharmacology Congress; 1996 Sep 21-25;
Amsterdam, Netherlands. 1996.
Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double
blind, controlled comparison of the novel antipsychotic
olanzapine versus haloperidol or placebo on anxious
and depressive symptoms accompanying schizophrenia.
Biological Psychiatry 1998;43(11):803–10.
Tollefson GD, Sanger TM, Leiberman JA. Olanzapine
versus haloperidol in the treatment of ﬁrst episode psychosis.
Schizophrenia Research 1997;24(1, 2):193.
Tollefson GD, Tran PV, Hamilton S, Kuntz A. Olanzapine
versus risperidone in the treatment of psychosis. Preliminary
report. Biological Psychiatry 1997;41:20S.
Tollefson GD, Tran PV, Hamilton S, Kuntz A. Olanzapine
versus risperidone in the treatment of psychosis. Preliminary
report. Schizophrenia Research 1997;24(1, 2):191–2.
Tran 1997 {published data only}
Tran P, Beasley C, Street J, Tamura R, Dellva MA, Graffeo
K, et al. Olanzapine versus haloperidol: acute results of the
multi-center international trial. Proceedings of the 20th
Collegium Internationale Neuro-Psychopharmacologicum
Congress; 1996 Jun 23-27; Melbourne, Australia. 1996.
Tran P, Beasley C, Tollefson G, Beuzen J, Dellva M, Sanger
T, et al. Acute and long-term results of the North American
double-blind olanzapine trial. Proceedings of the 8th
European College of Neuropsychopharmacology Congress;
1995 Sep 30-Oct 4; Venice, Italy. 1995.
Tran P, Beasley C, Tollefson G, Crawford A, Dellva
M, Gusman S, et al. Acute and long-term results
of the dose ranging double-blind olanzapine trial.
Proceedings of the 20th Collegium Internationale Neuro-
Psychopharmacologicum Congress; 1996 Jun 23-27;
Melbourne, Australia. 1996.
Tran P, Lu Y, Sanger T, Beasley C, Tollefson G.
Olanzapine in the treatment of schizoaffective disorder.
Proceedings of the 21st Collegium Internationale Neuro-
Psychopharmacologicum Congress; 1998 Jul 12-16;
Glasgow, UK. 1998.
Tran P, Sanger TM, Satterlee W, Beasley CJr, Tamura RN,
Tollefson GD. Olanzapine vs haloperidol - results of a
large multi-centre international trial. Proceedings of the
4th International Conference on Schizophrenia - 1996:
Breaking down the Barriers; 1996 Oct 6-9; Vancouver,
Canada. 1996.
Tran PV, Basson BR, Kennedy JS, Beasley Jr CM, Bymaster
FP, Tollefson GD. The comparative anti-muscarinic-like
side effect proﬁles of olanzapine and risperidone treatment
in patients with schizophrenia spectrum psychosis. European
Neuropsychopharmacology 1999;9:S290.
Tran PV, Beasley CM, Tollefosn GD, Sanger T, Satterlee
WG. Clinical efﬁcacy and safety of olanzapine, a new
atypical antipsychotic agent. Neuropsychopharmacology
1994;10(3S):267S.
Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Holman
SL, Sanger TM, et al. Olanzapine: a promising “atypical”
antipsychotic agent. Schizophrenia Research 1995;15(1, 2):
169.
Tran PV, Dellva MA, Beasley CM Jr, Satterlee WG, Cousins
LM, Tollefson GD. Clinical experience with long-term
continuation treatment with olanzapine. Proceedings of
the 149th Annual Meeting of the American Psychiatric
Association; 1996 May 4-9, New York, New York, USA.
1996.
Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin
JH, Kiesler GM. Extrapyramidal symptoms and tolerability
of olanzapine versus haloperidol in the acute treatment of
schizophrenia. Journal of Clinical Psychiatry 1997;58(5):
205–11.
Tran PV, Hamiliton SH, Kuntz AJ, Tollefson GD.
Olanzapine versus risperidone in the treatment of
psychosis disorders: a preliminary report. Proceedings
49Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of the 35th Annual Meeting of the American College of
Neuropsychopharmacology; 1996 Dec 9-13; San Juan,
Puerto Rico. 1996.
∗ Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen
SW, Beasley C, et al. Double-blind comparison of
olanzapine versus risperidone in the treatment of
schizophrenia and other psychotic disorders. Journal of
Clinical Psychopharmacology 1997;17(5):407–18.
Tran PV, Tollefson GD, Andersen SW, Kuntz AJ, Hamilton
SH. Olanzapine versus risperidone in the treatment of
schizophrenia and other psychotic disorders. Proceedings of
the 10th European College of Neuropsychopharmacology
Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
Tran PV, Tollefson GD, Anderson SW, Kuntz A, Hamilton
SH. Olanzapine versus risperidone in the treatment of
schizophrenia and other psychotic disorders. Schizophrenia
Research 1998;29(1, 2):205.
Tran PV, Tollefson GD, Crawford AM, Dossenbach
M, Friedel P, Folnegovic V, et al. Olanzapine versus
ﬂuphenazine in schizophrenia. Proceedings of the 151st
Annual Meeting of the American Psychiatric Association;
1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998.
Tran PV, Tollefson GD, Hamilton S. Olanzapine versus
risperidone in the treatment of schizophrenia and other
psychotic disorders. Proceedings of the 150th Annual
Meeting of the American Psychiatric Association; 1997 May
17-22; San Diego, California, USA. 1997.
Tran PV, Tollefson GD, Hamilton S, Kuntz A. Olanzapine
vs. risperidone in the treatment of psychosis. Proceedings
of the 6th World Congress of Biological Psychiatry; 1997
Jun 22-27; Nice, France. 1997.
Tsai 2004 {published data only}
Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine
transporter I inhibitor, N-Methylglycine (sarcosine), added
to antipsychotics for the treatment of schizophrenia.
Biological Psychiatry 2004;55(5):452–6.
Tsai 2006 {published data only}
Tsai GE, Yang P, Chang Y-C, Chong M-Y. D-alanine
added to antipsychotics for the treatment of schizophrenia.
Biological Psychiatry 2006;59(3):230–4.
Urioste 2004 {published data only}
Urioste R, Bossie C, Zhu Y, Ciliberto N, Trinh B, Lasser
R. Clinical improvement with long-acting risperidone: no
impact of race. Proceedings of the 157th Annual Meeting
of the American Psychiatric Association; 2004 May 1-6;
New York, New York, USA. 2004.
Wang 2003 {published data only}
Wang G. 60 week, randomized, double-blind, placebo-
controlled trial of valproate added to risperidone in 200
treatment-naive, ﬁrst-episode patients with schizophrenia.
Stanley Foundation Research Programs 2003.
Weickert 2003 {published data only}
Weickert TW, Goldberg TE, Marenco S, Bigelow LB,
Egan MF, Weinberger DR. Comparison of cognitive
performances during a placebo period and an atypical
antipsychotic treatment period in schizophrenia: critical
examination of confounds. Neuropsychopharmacology 2003;
28(8):1491–500.
Weiden 2005 {unpublished data only}
Weiden P, Radulovic L, Wang C, Allison D. Sibutramine
for the treatment of obesity in schizophrenia: randomized,
placebo controlled pilot study. 2005.
Wirshing 1995 {published data only}
Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder
SR, Wirshing WC. Risperidone in treatment-refractory
schizophrenia. American Journal of Psychiatry 1999;156(9):
1374–9.
∗ Wirshing WC, Ames D, Green M, Marshall BD, Marder
SR. Risperidone versus haloperidol in treatment-refractory
schizophrenia: preliminary results. Psychopharmacology
Bulletin 1995;31(3):633.
Wirshing WC, Ames D, Marder SR, Marshall BD, Green
MF, McGurk S. Risperidone vs haloperidol in treatment
resistant schizophrenia: preliminary results. Schizophrenia
Research 1996;18(2, 3):130.
Wirshing WC, Ames D, Marder SR, Marshall BD, Green
MF, McGurk SR. Risperidone in treatment resistant
schizophrenia. Proceedings of the 34th Annual Meeting of
the American College of Neuropsychopharmacology; 1995
Dec 11-15; San Juan, Puerto Rico. 1995.
Wirshing WC, Ames D, Marshall BD, Green MF, McGurk
S. Risperidone in treatment resistant schizophrenia.
Proceeding of the 8th Biennial Winter Workshop on
Schizophrenia; 1996 Mar 16-22; Crans Montana,
Switzerland. 1996.
Wirshing WC, Ames D, Palmer Bray M, Marshall BD,
Green MF, Marder SR. Risperidone versus haloperidol in
treatment refractory schizophrenia: preliminary results.
Proceeding of the 148th Annual Meeting of the American
Psychiatric Association; 1995 May 20-25; Miami, Florida,
USA. 1995.
Wirshing WC, Green MF, Ames D, Marshall BD, McGurk
SR, Mintz J, et al. Risperidone vs. haloperidol in treatment-
resistant schizophrenia. Proceedings of the 6th World
Congress of Biological Psychiatry; 1997 Jun 22-27; Nice,
France. 1997.
Yamawaki 1996 {published data only}
Yamawaki S, Hayashi T, Yokota N, Takahashi T, Sato
G, Tahara Y. Serotonin-dopamine antagonists in elderly
schizophrenics. Proceedings of the 20th Collegium
Internationale Neuro-Psychopharmacologicum Congress;
1996 Jun 23-27; Melbourne, Australia. 1996.
Zhang 2002 {published data only}
Zhang CZ. A study of the therapeutic effectiveness of
risperidone in combination with antioxidants in the
treatment of schizophrenia. Herald of Medicine 2002;21
(10):629–30.
Zhong 2006 {published data only}
Zhong Z-Y, Tao J, Wang X-L, Wu X-L, Zhang J-B. Effect of
antipsychotic plus buﬂomedil hydrochloride in ameliorating
the negative symptoms of patients with schizophrenia.
Chinese Journal of Clinical Rehabilitation [Zhongguo lin
chuang kang fu] 2006;10(2):30–2.
50Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
References to studies awaiting assessment
Anon 2010 {published data only}
Anon. An assessment of the long-term efﬁcacy and safety
of org 5222, risperidone and placebo in subjects with
schizophrenia. http://www.clinicalstudyresults.org/ (2010).
Bose 2010a {published data only}
Bose A, Li D, Migliore R, Werner P, Nemeth G, Laszlovsky
I. The efﬁcacy and safety of the novel antipsychotic
cariprazine in acute exacerbation of schizophrenia. European
Psychiatry 2011;26(1):1354.
Bose A, Li D, Migliore R, Werner P, Nemeth G, Laszlovszky
I. The efﬁcacy and safety of the novel antipsychotic
cariprazine in acute exacerbation of schizophrenia.
European Neuropsychopharmacology 2010:493–4.
Cavazzoni 2002 {published data only}
Cavazzoni P, Berg P, Millikan M, Carlson C, Beasley C. An
integrated analysis of treatment-emergent extrapyramidal
syndrome in schizophrenic patients during olanzapine
clinical trials versus placebo, haloperidol, risperidone or
clozapine. International Journal of Neuropsychopharmacology
2002;5(Suppl 1):S164.
∗ Cavazzoni P, Berg PH, Millikan M, Carlson C, Beasley
CM. An integrated analysis of treatment-emergent
extrapyramidal syndrome in schizophrenic patients during
olanzapine clinical trials versus placebo, haloperidol,
risperidone or clozapine. Schizophrenia Research 2002;53(3
Suppl 1):171.
DeMartinis 2012 {published data only}
DeMartinis NA. Results of a phase 2a proof-of-concept
trial with a pde10a inhibitor in the treatment of acute
exacerbation of schizophrenia. Biological Psychiatry 2012;8
(Suppl 1):17S–8S.
GlaxoSmithKline 2006 {published data only}
NCT00049946. A multicenter, double-blind, double-
dummy, placebo-controlled, randomized, parallel group
evaluation of the efﬁcacy and safety of a ﬁxed-dose of
talnetant versus placebo versus risperidone in subjects with
schizophrenia. clinicaltrials.gov/show/NCT00049946
(2002).
NCT00103727. A multicenter, double-blind, double-
dummy, placebo-controlled, randomized, parallel group
evaluation of the efﬁcacy and safety of a ﬁxed-dose of
talnetant versus placebo versus risperidone in subjects with
schizophrenia. clinicaltrials.gov/show/NCT00103727
(2005). NCT00103727]
NCT00300963. A multicenter, double-blind, double-
dummy, placebo-controlled, randomized, parallel group
evaluation of the efﬁcacy and safety of a ﬁxed-dose of
talnetant versus placebo versus risperidone in subjects with
schizophrenia. clinicaltrials.gov/show/NCT00300963
(2006). NCT00300963]
Litman 2014 {published data only}
Litman R, Smith M, Doherty J, Cross A, Raines S,
Zukin S. AZD8529, a positive allosteric modulator at
the MGGLUR2 receptor, does not improve symptoms
in schizophrenia: A proof of principle study. European
neuropsychopharmacology 2014;24:S508–S509.
Litman RE, Smith MA, Doherty J, Cross A, Raines S,
Zukin S. AZD8529, a positive allosteric modulator at
the mGLuR2 receptor, does not improve symptoms in
schizophrenia: A proof of principle study. Schizophrenia
research 2014;153:S176.
NCT00921804. Study to assess the efﬁcacy, safety, and
tolerability of AZD8529 in adult schizophrenia patients.
clinicaltrials.gov/show/NCT00921804 (2009).
NCT 00694707 {published data only}
Debelle M, Faradzs-zade S, Szatmari B, Nagy K, Nemeth
G, Durgam S, Laszlovszky I. Cariprazine in negative
symptoms of schizophrenia: Post hoc analyses of a ﬁxed-
dose, placebo-and active-controlled trial. European
neuropsychopharmacology 2014;24:S534.
NCT01086748 {published data only}
NCT01086748. A study in schizophrenia patients.
ClinicalTrials.gov/show/NCT01086748 (2010).
NCT01175135 {published data only}
NCT01175135. An inpatient study of the efﬁcacy, safety,
and tolerability of pf-02545920 in the treatment of acute
exacerbation of schizophrenia. ClinicalTrials.gov/show/
NCT01175135 (2010).
NCT01363349 {published data only}
NCT01363349. Phase iib-iii study of bl-1020 small
molecule for schizophrenia. ClinicalTrials.gov/show/
NCT01363349 (2011).
Nisenbaum 2013 {published data only}
Nisenbaum L, Millen B A, Zhao F, Downing A, Quigley A,
Kohler J, et al. LY 2140023 monohydrate in the treatment
of patients with schizophrenia: Pharmacogenetic analysis
within a clinical trial assessing efﬁcacy in treating acutely ill
patients. Schizophrenia Bulletin 2013;39:S105.
Rujescu 2009 {published data only}
Rujescu D. Riluzole for schizophrenia. Stanley Foundation
Research Programs 2009.
Vanover 2014 {published data only}
Nct02469155. A Trial to Assess the Antipsychotic
Efﬁcacy of ITI-007 Over 6 Weeks of Treatment. https://
ClinicalTrials.gov/show/NCT02469155 2015.
Vanover K, Davis RE, Ereshefsky L, Mates S. Positive
results with ITI-007 for the treatment of schizophrenia: A
randomized double-blind placebo- and active-controlled
phase 2 study. Schizophrenia research 2014;153:S278–S279.
Vanover KE, Davis RE, Mates S. ITI-007 for the treatment
of schizophrenia: A differentiating response proﬁle.
Biological psychiatry 2014;1:325S.
Vanover KE, Davis RE, Mates S. ITI-007, a new approach
to the treatment of schizophrenia. Schizophrenia research
2014;153:S21.
Vanover KE, Mates S, Greengard P, Davis RE. Phase 2
evaluation of ITI-007, a novel approach to the treatment
of schizophrenia. Neuropsychopharmacology 2013;38:
S386–S387.
51Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Xu 2009 {published data only}
Xu Z. LDXGW for schizophrenia. Stanley Foundation
Research Programs 2009.
References to ongoing studies
NCT00174200 {published data only}
NCT00174200. A randomized, double-blind, crossover
add-on study to assess the differential sensitivity of 2 spatial
working memory tests (the groton maze learning test [gmlt]
and the motor delayed response test [mdr]) in non-agitated,
antipsychotic drug-naive ﬁrst-episode schizophrenic or
schizophreniform patients treated with risperidone 2 mg
daily or placebo. clinicaltrials.gov/show/NCT00174200
(2005). Date accessed: 9/10/2013.
Additional references
Adams 2013
Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol
versus placebo for schizophrenia. Cochrane Database
of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/
14651858.CD003082.pub3; PUBMED: 24242360
Addington 1993
Addington D, Addington J, Maticka-Tyndale E. Assessing
depression in schizophrenia: the Calgary Depression Scale.
British Journal of Psychiatry 1993;22:39–44.
Ahmed 2011
Ahmed U, Rehman F, Jones H, Adams Clive E. Risperidone
for psychosis induced aggression or agitation. Cochrane
Database of Systematic Reviews 2011, Issue 11. [DOI:
10.1002/14651858.CD009412; CD009412
AHRP 2006
Hassner VS. Scientiﬁc fraud: Eric Poehlman / Richard
Borison. Alliance for Human Research Protection (http:/
/www.ahrp.org/cms/content/view/370/29/) 29 Oct 2006
(accessed 5 Nov 2009).
Altman 1996
Altman DG, Bland JM. Detecting skewness from summary
information. BMJ 1996;313(7066):1200.
Andreasen 1981
Andreasen, NC. Scale for the assessment of negative
symptoms: SANS. Lowa: the University of Lowa. 1981.
Asmal 2013
Asmal L, Flegar SJ, Wang J, Rummel-Kluge C,
Komossa K, Leucht S. Quetiapine versus other atypical
antipsychotics for schizophrenia. Cochrane Database
of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/
14651858.CD006625.pub3; PUBMED: 24249315
Bagnall 2007
Bagnall A, Fenton M, Kleijnen J, Lewis R. Molindone for
schizophrenia and severe mental illness. Cochrane Database
of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/
14651858.CD002083.pub2; PUBMED: 17253473
Barnes 1989
Barnes TR. A rating scale for drug-induced akathisia. British
Journal of Psychiatry 1989;154:672–6.
Begg 1996
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin
I, et al. Improving the quality of reporting of randomized
controlled trials. The CONSORT statement. JAMA 1996;
276(8):637–9.
Belgamwar 2011
Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo
for schizophrenia. Cochrane Database of Systematic Reviews
2011, Issue 8. [DOI: 10.1002/14651858.CD006622.pub2;
PUBMED: 21833956
Benson 1996
Benson H, Friedman R. Harnessing the power of the
placebo effect and renaming it “remembered wellness”.
Annual Review of Medicine 1996;47:193–9.
Bhattacharjee 2008
Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical
antipsychotic drugs for schizophrenia. Cochrane Database
of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/
14651858.CD006617.pub3; PUBMED: 18646161
Bland 1997
Bland JM. Statistics notes. Trials randomised in clusters.
BMJ 1997;315:600.
Boissel 1999
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyfﬁer F,
Buyse M, et al. The problem of therapeutic efﬁcacy indices.
3. Comparison of the indices and their use [Apercu sur
la problematique des indices d’efﬁcacite therapeutique, 3:
comparaison des indices et utilisation. Groupe d’Etude
des Indices D’efﬁcacite]. Therapie 1999;54(4):405–11.
[PUBMED: 10667106]
Carpenter 1994
Carpenter WT Jr, Buchanan RW. Schizophrenia. The New
England Journal of Medicine 1994;330(10):681–90.
Carpenter 2003
Carpenter WT, Appelbaum PS, Levine RJ. The Decleration
of Helsinki and clinical trials: a focus on placebo-controlled
trials in schizophrenia. American Journal of Psychiatry 2003;
160(2):356–62.
CBS News 2000
Augusta G. Drug money: Patients worsened; little oversight
provided. CBS News (http://www.cbsnews.com/stories/
2000/07/31/48hours/main220233.shtml) 31 Jul 2000
(accessed 5 November 2009).
Chouinard 1993
Chouinard G, Arnott W. Clinical review of risperidone.
Canadian Journal of Psychiatry 1993;38(Suppl 3):89–95.
Darby 1997
Darby JK, Pasta DJ, Elfand L, Dabiri L, Clark L, Herbert J.
Risperidone dose and blood level variability: accumulation
effects and interindividual and intraindividual variability in
the nonresponder patient in the clinical practice setting.
Journal of Clinical Psychopharmacology 1997;17(6):478–84.
Deeks 2000
Deeks J. Issues in the selection for meta-analyses of binary
data. Proceedings of the 8th International Cochrane
52Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Colloquium; 2000 Oct 25-28; Cape Town. Cape Town:
The Cochrane Collaboration, 2000.
Divine 1992
Divine GW, Brown JT, Frazier LM. The unit of analysis
error in studies about physicians’ patient care behavior.
Journal of General Internal Medicine 1992;7(6):623–9.
Donner 2002
Donner A, Klar N. Issues in the meta-analysis of cluster
randomized trials. Statistics in Medicine 2002;21:2971–80.
DSM-IV-TR
American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. Washington, DC: American
Psychiatric Association, 1994.
Duggan 2005
Duggan L, Fenton M, Rathbone J, Dardennes R, El-
Dosoky A, Indran S. Olanzapine for schizophrenia.
Cochrane Database of Systematic Reviews 2005, Issue 2.
[DOI: 10.1002/14651858.CD001359.pub2; PUBMED:
15846619
Egger 1997
Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias
in meta-analysis detected by a simple, graphical test. BMJ
1997;13:629–34.
Furukawa 2006
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe
N. Imputing missing standard deviations in meta-analyses
can provide accurate results. Journal of Clinical Epidemiology
2006;59(7):7–10.
Gilbody 2000
Gilbody SM, Bagnall AM, Duggan L, Tuunainen A.
Risperidone versus other atypical antipsychotic medication
for schizophrenia. Cochrane Database of Systematic Reviews
2000, Issue 3. [DOI: 10.1002/14651858.CD002306
Gulliford 1999
Gulliford MC. Components of variance and intraclass
correlations for the design of community-based surveys
and intervention studies: data from the Health Survey for
England 1994. American Journal of Epidemiology 1999;149:
876–83.
Guy 1976
Guy U. ECDEU assessment manual for psychopharmacology.
Revised. Rockville: National Institute of Mental Health,
1976.
Heykants 1994
Heykants J, Huang ML, Mannens G, Meuldermans W,
Snoeck E, Van Beijsterveldt L, et al. The pharmacokinetics
of risperidone in humans: a summary. Journal of Clinical
Psychiatry 1994;55(Suppl):13–7.
Higgins 2003
Higgins JP, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2008
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions. Chichester: John Wiley
& Sons, 2008.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0. Available
from www.cochrane-handbook.org: The Cochrane
Collaboration, 2011.
Hosalli 2003
Hosalli P, Davies JM. Depot risperidone for schizophrenia.
Cochrane Database of Systematic Reviews 2003, Issue 4.
[DOI: 10.1002/14651858.CD004161
Hunter 2003
Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F.
Risperidone versus typical antipsychotic medication for
schizophrenia. Cochrane Database of Systematic Reviews
2003, Issue 2. [DOI: 10.1002/14651858.CD000440
Hutton 2009
Hutton JL. Number needed to treat and number needed to
harm are not the best way to report and assess the results
of randomised clinical trials. British Journal of Haematology
2009;146(1):27–30.
Hutton 2012
Hutton P, Morrison AP, Yung AR, Taylor PJ, French
P, Dunn G. Effects of drop-out on efﬁcacy estimates
in ﬁve Cochrane reviews of popular antipsychotics for
schizophrenia. Acta Psychiatrica Scandinavicia 2012;126
(1):1–11. [DOI: 10.1111/j.1600-0447.2012.01858.x;
PUBMED: 22486554
Jayaram 2006
Jayaram MB, Hosalli P, Stroup S. Risperidone versus
olanzapine for schizophrenia. Cochrane Database of
Systematic Reviews 2006, Issue 2. [DOI: 10.1002/
14651858.CD005237
Jayaram 2007
Jayaram MB, Hosalli PM, Stroup TS. Risperidone versus
olanzapine for treatment of schizophrenia. Schizophrenia
Bulletin 2007;33(6):1274–6. [PUBMED: 17921477]
Joy 2006
Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo
for schizophrenia. Cochrane Database of Systematic Reviews
2006, Issue 4. [DOI: 10.1002/14651858.CD003082.pub2
Juni 2001
Juni P, Altman DG, Egger M. Systematic reviews in health
care: Assessing the quality of controlled clinical trials. BMJ
2001;323:42–6.
Kay 1986
Kay SR, Opler LA, Fiszbein A. Positive and Negative
Syndrome Scale (PANSS) Manual. North Tonawanda, NY:
Multi-Health Systems, 1986.
Kennedy 2000
Kennedy E, Song F, Hunter R, Clarke A, Gilbody S.
Risperidone versus typical antipsychotic medication for
53Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
schizophrenia. Cochrane Database of Systematic Reviews
2000, Issue 2. [DOI: 10.1002/14651858.CD002306
Khanna 2014
Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C,
El-Sayeh HG, et al. Aripiprazole versus other atypical
antipsychotics for schizophrenia. Cochrane Database
of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/
14651858.CD006569.pub5; PUBMED: 24385408
Komossa 2007
Komossa K, Rummel C, Hunger H, Schmidt F, Schwarz S,
Leucht S. Risperidone versus other atypical antipsychotics
for schizophrenia. Cochrane Database of Systematic Reviews
2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2
Komossa 2009
Komossa K, Rummel-Kluge C, Hunger H, Schwarz S,
Schmidt F, Lewis R, et al. Sertindole versus other atypical
antipsychotics for schizophrenia. Cochrane Database
of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/
14651858.CD006752.pub2; PUBMED: 19370652
Komossa 2010
Komossa K, Rummel-Kluge C, Hunger H, Schmid F,
Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride
versus other atypical antipsychotics for schizophrenia.
Cochrane Database of Systematic Reviews 2010, Issue 1.
[DOI: 10.1002/14651858.CD006624.pub2; PUBMED:
20091599
Kumar 2005
Kumar A, Strech D. Zuclopenthixol dihydrochloride for
schizophrenia. Cochrane Database of Systematic Reviews
2005, Issue 4. [DOI: 10.1002/14651858.CD005474;
PUBMED: 16235403
Laughren 2001
Laughren TP. The scientiﬁc and ethical basis for placebo-
controlled trials in depression and schizophrenia: an FDA
perspective. European Psychiatry 2001;16(7):418–23.
Leucht 2005a
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E,
Engel R. Clinical implications of brief psychiatric rating
scale scores. British Journal of Psychiatry 2005;187:366–71.
Leucht 2005b
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E,
Engel RR. What does the PANSS mean?. Schizophrenia
Research 2005;79(2-3):231–8.
Leysen 1994
Leysen JE, Janssen PM,Megens AA, Schotte A. Risperidone:
a novel antipsychotic with balanced serotonin-dopamine
antagonism, receptor occupancy proﬁle, and pharmacologic
activity. Journal of Clinical Psychiatry 1994;55(Suppl):5–12.
Li 2009
Li C, Xia J, Wang J. Risperidone dose for schizophrenia.
Cochrane Database of Systematic Reviews 2009, Issue 4.
[DOI: 10.1002/14651858.CD007474.pub2
Lingjaerde 1987
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K.
The UKU side effect rating scale. A new comprehensive
rating scale for psychotropic drugs and a crosssectional
study of side effects in neuroleptic-treated patients. Acta
Psychiatr Scand 1987;76((suppl. 334)):1–100.
Lurie 1997
Lurie P,Wolfe SM.Unethical trials of interventions to reduce
perinatal transmission of the human immunodeﬁciency
virus in developing countries. The New England Journal of
Medicine 1997;337:853–6.
Lurie 2005
Lurie P, Greco DB. US exceptionalism comes to research
ethics. The Lancet 2005;365:1117–9.
Marshall 2000
Marshall M, Lockwood A, Bradley C, Adams C, Joy C,
Fenton M. Unpublished rating scales: a major source
of bias in randomised controlled trials of treatments for
schizophrenia. British Journal of Psychiatry 2000;176:
249–52.
Mota 2002
Mota NE, Lima MS, Soares BG. Amisulpride for
schizophrenia. Cochrane Database of Systematic Reviews
2002, Issue 2. [DOI: 10.1002/14651858.CD001357;
PUBMED: 12076408
Nussbaum 2012
Nussbaum AM, Stroup TS. Paliperidone palmitate for
schizophrenia. Cochrane Database of Systematic Reviews
2012, Issue 6. [DOI: 10.1002/14651858.CD008296.pub2;
PUBMED: 22696377
Overall 1962
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale.
Psychological Reports 1962;10:799–812.
Pietrzak 2008
Pietrzak RH, Maruffb P, Mayesc LC, Romand SA, Sosad
JA, Snyde PJ. An examination of the construct validity and
factor structure of the Groton Maze Learning Test, a new
measure of spatial working memory, learning efﬁciency, and
error monitoring. Archives of Clinical Neuropsychology 2008;
23(4):433–45.
Schünemann 2008
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT,
Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results
and drawing conclusions. Higgins JPT, Green S editor(s).
Cochrane Handbook for Systematic Reviews of Interventions.
The Cochrane Collaboration, 2008:359–83.
Simpson 1970
Simpson GM, Angus JWS. A rating scale for extrapyramidal
side-effects. Acta Psychiatrica Scandinavica Supplementum
1970;212:11–9.
Vallance 2006
Vallance AK. Something out of nothing: the placebo effect.
Advances in Psychiatric Treatment 2006;12:287–96.
WMA 2008
World Medical Association. Ethical principles for medical
research involving human subjects. World Medical
Association 2008.
54Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Xia 2009
Xia J, Adams C, Bhagat N, Bhagat V, Bhoopathy P, El-Sayeh
H, et al. Losing participants before the trial ends erodes
credibility of ﬁndings. Psychiatric Bulletin 2009;33:254–7.
∗ Indicates the major publication for the study
55Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bachmann 2003
Methods Allocation: randomised.
Blindness: double.
Duration: 16 weeks.
Setting: inpatients and outpatients, USA.
Design: parallel groups.
Participants Diagnosis: people with schizophrenia or schizoaffective (DSM-IV).
N = 69
Age: 18-65 years.
Sex: male and female (data only available for completers).
Inclusion criteria: Those who met DSM-IV criteria for schizophrenia or schizoaffective
disorder were selected for study entry. BPRS total score of > 45 or CGI severity of illness
item score of > 4; and BPRS positive symptom item total score of > 8, with 1 or more
item rated > 4. They were required to have had an adequate clozapine trial, deﬁned as
clozapine treatment for > 6 months on a dose that produced a clozapine plasma level of
X350 ng/ml or a clozapine + norclozapine plasma level of X450 ng/ml.
Exclusion criteria: Participants whometDSM-IV diagnosis of alcohol or substance abuse
(other than nicotine) within the past month, alcohol or substance dependence (other
than nicotine) within the past 6months, mental retardation, unstable medical condition,
or those treated previously with adjunctive risperidone at X8 mg/day for at least 6 weeks
Interventions 1. Risperidone (dose 4 mg) plus clozapine (dose not reported). N = 33.
2. Placebo plus clozapine (dose not reported). N =36.
Outcomes Mental state: BPRS, SANS.
Leaving the study early (the week that participants left the study early were reported; all
left before 12 weeks)
Adverse effects: metabolic, extrapyramidal, haematological.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was stratiﬁed by in-pa-
tient status” (p2276).
Allocation concealment (selection bias) Unclear risk No information available.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All raters were blind to treatment assign-
ment” (p2275). “Risperidone 4mg (two
2mg capsules) or placebo (two capsules)”
(p2276)
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Bachmann 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis and completers-only analysis
undertaken.
Selective reporting (reporting bias) Low risk Outcomes listed in paper all reported.
Other bias High risk Double-blind medications were provided
by
Ortho-McNeil-Janssen Scientiﬁc Affairs,
LLC. Authors have associations with Eli
Lilly, Astra-Zeneca, Pﬁzer, GlaxoSmithK-
line, Cephalon, Otsuka, Bioscience, Ab-
bott, Cypress, Merck, Organon, Sanoﬁ-
Aventis, Bristol-Myers Squibb, Janssen,
Solvay, Wyeth, Zeneca, and Roche either
as employees, stockholders, or members of
advisory boards
Borison 1992
Methods Allocation: randomised.
Blindness: double.
Duration: 3 days washout period for oral medications plus 6 weeks treatment course (2
weeks for depot medications)
Setting: inpatients.
Design: parallel groups.
Participants Diagnosis: schizophrenia (DSM-III-R).
N = 160.
Age: 18-65 years.
Sex: male = 154 and female = 6.
Length of illness: ranged from 10 to 17 years.
Inclusion criteria: BPRS score more than 30.
Exclusion criteria: poor general health, cardiopulmonary disease, head traumaor epilepsy,
or drug or alcohol abuse in the last year
Interventions 1. Risperidone: dose 2 mg/day to 10 mg/day, N = 53.
2. Haloperidol: dose 4 mg/day to 20 mg/day, N = 53*.
3. Placebo: N = 54.
Outcomes Mental state.
Leaving the study early.
Global state: needing additional medication.
Adverse effects: any, gastrointestinal, central nervous system, respiratory
Unable to use:
Global state: CGI (SD not reported).
Mental state: BPRS (SD not reported), SANS (SD not reported)
Adverse effects: AIMS, ESRS (SD not reported). Use of medication for EPS is reported
as percentage, but we are unclear at which point the data was measured or theN number,
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Borison 1992 (Continued)
thus unable to convert the data into binary outcome
Physiological measures: vital signs, ECG, blood and urine chemistries (no data reported)
Notes No information available on funding, but one of the papers has a Janssen logo
*We did not use the data from this group, as the intervention is not relevant
The ’leaving the study early rate’ was high in this trial, but the overall leaving the study
early rate was less than 50%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 26/53 participants left from the risperidone
group, 37/54 left from the placebo group
Selective reporting (reporting bias) High risk All outcomes measured were reported, but
without SD.
Other bias Low risk None obvious.
Chouinard 1992
Methods Allocation: randomised.
Blindness: double blind.
Duration: 7-day single-blind placebo washout period plus 8-week treatment period
Setting: inpatients, at six centres in Canada.
Design: multicentre, parallel group.
Participants Diagnosis: chronic schizophrenia (DSM III-R).
N = 135.
Age: 19-67 years.
Sex: male and female.
Length of illness: mean ~ 2.0 years, SD ~ 3.4 years.
Inclusion criteria: total PANSS score between 60 and 120.
Exclusion criteria: pregnant or lactating women or women without adequate contra-
ception, mental disorders other than schizophrenia, neurological disorders, psychoactive
substance use or alcohol abuse
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Chouinard 1992 (Continued)
Interventions 1. Risperidone: dose 2 mg/day, N = 24.*
2. Risperidone: dose 6 mg/day, N = 22.
3. Risperidone: dose 10 mg/day, N = 22.
4. Risperidone: dose 16 mg/day, N = 24.
5. Placebo, N = 22.
6. Haloperidol: dose 20 mg/day, N = 21.
Outcomes Mental state: PANSS, BPRS.
Leaving the study early.
Global state: CGI.
Adverse effects: ESRS, UKU Side Effect Rating Scale, concomitant sedative/hypnotic
use
Unable to use:
Physiologicalmeasures: bloodpressure, heart rate in supine and standing positions, ECG,
biochemistry, hematology, urine analysis (no data reported)
Notes *Fixed dose. We included data only from the 6 mg/day arm, as this was the closest dose
to what would be used in routine clinical practice. This arm had a differential leaving
the study early rate with 45% in the risperidone arm leaving the study early compared
to 68% in the placebo arm (overall participants leaving the study early was greater than
50%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, blocks of 12.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind: “identical tablets” (p27).
Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF, ITT analysis used.
Selective reporting (reporting bias) Low risk Outcomes listed in papers all reported.
Other bias High risk Supported by a grant from the Janssen Re-
search Foundation.
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Downing 2014
Methods Allocation: multicenter, randomised.
Blindness: double blind; Quote: ’the raters were blind to the study design, entrance
criteria, and patient treatment assignment.’ p.3)
Duration: 2 weeks study entry + 7 days placebo lead-in treatment phrase + 6 weeks
treatment duration
Settings: inpatients.
Design: parallel.
Participants Diagnosis: schizophrenia (historical documentation and Structured Clinical Interview
for DSM-IV Disorders [SCID] interview).
N = 1009. (1013 participants were randomised, however, the author analysed data on
an Intention-to-treat basis)
Age: mean ~ 39.8 years, SD ~ 11.4 years.
Sex: male 647, female 362.
Length of illness: mean ~ 14.5 years, SD ~ 10.7 years.
Inclusion criteria: those with an accurate and reliable diagnosis of schizophrenia (based
upon historical documentation and Structured Clinical Interview for DSMIV Disorders
[SCID] interview), who experienced an exacerbationof their illness 2weeks prior to study
entry (Visit 1), leading to a need for intensiﬁcation of psychiatric care. Patients could be
antipsychotic treatment naive or have had prior exposure to antipsychotic medications
and were not treatment refractory in the opinion
of the investigator.
Exclusion criteria: those who had any other current Axis I psychiatric diagnoses in
addition to schizophrenia, a diagnosis
of substance dependence or substance abuse, a history of one or more seizures, answered
yes to any suiciderelated behaviors within 1 month of Visit 1, participated in any clinical
trial for which they received a studyrelated medication in the 6 months prior to Visit
1, were treatment refractory, or had demonstrated an inadequate response to treatment
with risperidone, or for whom treatment with risperidone, LY2140023, or placebo was
contraindicated
Interventions 1. Risperidone: 2 mg/d on the ﬁrst day and 4mg/d therafter, N = 142.
2. Placebo: placebo tablets or capsules identical to LY2140023 and risperidone, N = 295
3. LY2140023 low dose: twice daily, 40 mg/d, N = 292*.
4. LY2140023 high dose: twice daily, 80 mg/d, N = 280*.
Outcomes Leaving the study early.
Adverse effects**.
Unable to use
Mental state: PANSS (only means of change score were reported)
Notes *We did not use the data from these groups, as the interventions are not relevant
**For the concomitant medications rate reported in this study, we only extracted 2 drugs
mentioned in our protocol
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Quote: “multicenter, randomized, double-
blind, parallel...” (p.2)
Allocation concealment (selection bias) Unclear risk No information available.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: ’the raters were blind to the study
design, entrance criteria, and patient treat-
ment assignment.’ (p.3)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis was performed.
Selective reporting (reporting bias) Low risk All the measured outcomes were reported.
Other bias High risk All authors were from Eli Lilly and Com-
pany.
Durgam 2014
Methods Allocation: multinational, randomised.
Blindness: double blind, but unclear who is blinded.
Duration: 9 weeks duration including 7 days wash out period, 6 weeks treatment period
and 2 weeks safety follow up
Settings: inpatients, 65 study centres in the United States, India, Russia, Ukraine, and
Malaysia.
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-IV-TR).
N = 729.
Age: mean ~ 36 years, SD ~ 10.8 years.
Sex: male 502, female 227.
Length of illness: mean ~ 11.6 years, SD ~ 9.7 years.
Inclusion criteria: 18-60 years old, atients had the diagnosis for at least 1 year, current
exacerbation less than 2 weeks’ duration, and at least 1 psychotic episode requiring hos-
pitalization/antipsychotic medication change/intervention during the preceding year.
PANSS total score between 80 and 120, a score≥4 (moderate) on at least 2 of 4 PANSS
positive symptoms (delusions, hallucinatory behavior, conceptual disorganization, sus-
piciousness/persecution); CGI-S rating≥4; Body mass index (BMI) between 18 and 35.
Exclusion criteria: ﬁrst episode of psychosis; diagnosis of various DSM-IV-TR disorders
(e.g., schizoaffective, schizophreniform, bipolar I and II); alcohol/ substance abuse/de-
pendence (within 3 months); treatment-resistant schizophrenia (poor response to ≥2
antipsychotics of adequate dose and duration) or suicidal or homicidal attempt/intent
(active or preceding 2 years). Typical treatment-related, concomitant medication, and
medical/physical exclusions were applied
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Interventions 1. Risperidone: 4 mg/d , N = 140.
2. Placebo: once daily, N = 151.
3. Cariprazine low dose: 1.5 mg/d, N = 145*.
4. Cariprazine medium dose: 3 mg/d, N = 146*.
5. Cariprazine high dose: 4.5 mg/d, N = 147*.
Outcomes Mental state: no clinical response**, PANSS, Negative Symptom Assessment (NSA-16)
Leaving the study early.
Global state: Clinical Global Impressions-Improvement (CGI-I)
Adverse effects***: Treatment-emergent adverse events (TEAEs)
Unable to use:
physical examination, laboratory evaluations, vital signs, weight, and 12-lead ECG
Notes *We did not use the data from these groups, as the interventions are not relevant
**deﬁned as the decrease rate of PANSS score < 30% improvement from baseline)
***For the concomitant medications rate reported in this study, we only extracted 2
drugs mentioned in our protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Quote: “A 9-week,multinational, random-
ized, double-blind...” (p.451)
Allocation concealment (selection bias) Unclear risk No information available.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Seventy-two out of 151 participants left
the study early from placebo group, while
39 out of 140 participants left the study
early from risperidone group. Intention to
treat analysis was used to analyzed the data
and sensitivity analysis was also conducted
by using mixed effects model for repeated
measures
Selective reporting (reporting bias) Low risk All the measured outcomes were reported.
Other bias Low risk None obvious.
62Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Geffen 2010
Methods Allocation: randomised, a central randomisation scheme.
Blindness: double blind, but unclear who is blinded.
Duration: 5-14 days suspension of other antipsychotics plus 6 weeks treatment period
Settings: inpatients, 40 sites in India, Romania, and USA.
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-IV-TR).
N = 363.
Age: mean ~ 34.2 years, SD ~ 10.34 years.
Sex: male 245, female 118.
Length of illness: mean ~ 8.26 years, SD ~ 8.92 years.
Inclusion criteria: 18-65 years old, acute exacerbation within 30 days, PANSS total
score ≥ 70, at least 4 on any 2 of PANSS items (delusions, hallucinatory behaviours,
conceptual disorganization, or suspiciousness/persecution), CGI ≥ 4.
Exclusion criteria: a score of greater than 9 on the modiﬁed ISST, treatment refractory
psychosis following 2 years of exposure to a therapeutic dose of antipsychotics, substance
abuse, TD, use of mood stabilisers, history of blood cell disorder
Interventions 1. Risperidone: 2 mg/d to 8 mg/d, N = 91.
2. Placebo: no details, N = 93.
3. BL-1020 low dose: 10 mg/d, N = 90*.
4. BL-1020 high dose: 20 mg/d to 30 mg/d, N = 89*.
Outcomes Mental state.
Leaving the study early.
Global state: needing additional medication.
Adverse effects**.
Unable to use:
Clinical response. Global state: CGI-I, CGI-S. Mental state: PANSS score. Cognitive
function: Mean and SD of each outcome were not reported
Notes *We did not use the data from these groups, as the interventions are not relevant
**For the concomitant medications rate reported in this study, we only extracted 2 drugs
mentioned in our protocol
Overall leaving the study early rate is less than 50%.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed via an in-
teractive voice system.
Quote: “Randomisationwas performed us-
ing an interactive voice response system,
one randomisation scheme was generated
across all sites (i.e. a central randomisation
scheme)”. (p1169)
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Allocation concealment (selection bias) Low risk Allocation sequence was concealed by the
“voice response system”
Quote: “when the drug was dispensed, the
investigator called the interactive voice re-
sponse system to assign the treatment code.
This code number was used to identify the
medication kit to be dispensed to the pa-
tient”. (p1169)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind.
Quote: “This was a 6-week, randomised,
double-blind, placebo-controlled, parallel
group phase 2 study”. (p1168)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20 participants in risperidone group and
37 participants in placebo group did not
complete the trial, but ITT analysis was
applied
Selective reporting (reporting bias) Low risk All the measured outcomes were reported.
Other bias Low risk None obvious.
Heisterberg 2007
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Setting: no information available.
Design: multicentre, parallel groups.
Participants Diagnosis: schizophrenia as per DSM-IV-TR.
N = 599.
Age: 18-69 years.
Sex: male and female.
History: having an acute exacerbation of schizophrenia.
Inclusion criteria: baseline PANSS score of 70 to 120 and CGI score of ≥ 4.
Exclusion criteria: no information available.
Interventions 1. Risperidone: dose 6 mg/day, N = 154.
2. Placebo: N = 149.
3. Bifeprunox: N = 296.
Outcomes Adverse events: lipid parameters*, EPS.
Leaving the study early.
Unable to use:
Adverse effects: weight change (no SD reported).
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Notes Study attrition was 60% at the end of 6 weeks -- no data included in efﬁcacy analysis
*We reported this data as the paper used LOCF to account for missing values
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Quote: “...patients with acutely exacer-
bated schizophrenia were randomly as-
signed to...”
Allocation concealment (selection bias) Unclear risk No information available.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis done.
Selective reporting (reporting bias) Unclear risk Outcomes listed in the methods were re-
ported.
Other bias Low risk None obvious.
Honer 2006
Methods Allocation: randomised.
Blindness: double.
Duration: 8 weeks.
Setting: inpatient and community settings.
Design: multicentre, parallel-group study.
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV).
N = 68.
Age: 18-65 years.
Sex: male and female.
History: poor response to clozapine.
Inclusion criteria: all participants on clozapine at a stable dose of 400 mg or more for at
least 12 weeks, baseline PANSS score of 80 or greater, baseline CGI score of 4 or greater,
baseline SOFAS score of 40 or less.
Exclusion criteria: alcohol or substance misuse in the past 3 months, pregnant, breast-
feeding, people needing anticonvulsants, developmental disabilities, current treatment
with clozapine for the primary indication of movement disorder
Interventions 1. Risperidone (3 mg/day) combined with clozapine (400 mg or more/day), N = 34.
2. Placebo combined with clozapine (400 mg or more/day), N = 34
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Outcomes Mental state: PANSS.
Leaving the study early.
Global state: CGI-S.
Adverse effects: ESRS, BAS, dystonia, dyskinesia, parkinsonism, lipid proﬁle, weight,
waist circumference, BMI, fasting blood glucose, white cell count, neutrophil count
Unable to use:
Cognitive functions: frontal lobe cognitive functions (no data reported). Verbal working-
memory index (not peer-reviewed scale).
Adverse effects: UKU Side Effect Rating Scale (no data reported)
Notes Supported by Stanley Medical Research Institute. The investigators had assessed 595
people for eligibility for the study, of which 458 (77%) did not meet the inclusion criteria
and 69 (12%) declined to participate
Leaving the study early rate is less than 50%.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule with a per-
muted-block design. Quote: “randomisa-
tion was performed according to a com-
puter-generated schedule with a permuted-
block design. The ﬁxed block size was four
patients”. p473
Allocation concealment (selection bias) Low risk Quote: “the site investigators did not know
the block size. The person generating the
randomization schedule was not involved
in determining patients’ eligibility, admin-
istering treatment, or determining out-
come.” p473
Blinding (performance bias and detection
bias)
All outcomes
Low risk Triple blinding (participants, investigator,
and assessor blind) done but not tested
out. Quote: “randomly assigned to dou-
ble-blind treatment with risperidone or a
placebo of identical appearance”. p473
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT principle using mixed-model analysis.
Selective reporting (reporting bias) Unclear risk Outcomes listed in the methods were re-
ported.
Other bias Low risk Janssen-Ortho, Canada, provided the
risperidone and matching placebo and re-
viewed the protocol, but no request for
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amendment. The data were analysed and
the manuscript was written solely by the
listed authors
Marder 1994a
Methods Allocation: randomised.
Blindness: double.
Duration: 7-day single-blind placebo washout period plus 8-week treatment period
Setting: inpatients, 20 centres in USA.
Design: parallel-group study.
Participants Diagnosis: schizophrenia (DSM III-R).
N = 388*.
Age: 18-67 years.
Sex: male and female.
Inclusion criteria: total PANSS score between 60 and 120.
Exclusion criteria: pregnant or lactating women or women without adequate contra-
ception, mental disorders other than schizophrenia, neurological disorders, psychoactive
substance use or alcohol abuse, and schizoaffective disorder
Interventions 1. Risperidone: dose 2 mg/day, N = 63**.
2. Risperidone: dose 6 mg/day, N = 64**.
3. Risperidone: dose 10 mg/day, N = 65.
4. Risperidone: dose 16 mg/day, N = 64.
5. Placebo: N = 66.
6. Haloperidol: dose 20 mg/day, N = 66.
Outcomes Mental state: PANSS*.
Leaving the study early***.
Global state: CGI*.
Adverse effects: ESRS, UKU Side Effect Rating Scale*.
Notes *Data from a subset of participating centre, where leaving the study early was not reported
(risperidone N = 64; placebo N = 66)
**Fixed dose. We included data only from the 6 mg/day arm, as this was the closest dose
to what would be used in routine clinical practice. This arm had a differential leaving
the study early rate with 45% in the risperidone arm leaving the study early compared
to 68% in the placebo arm
***Data from a wider set of participating centres (risperidone N = 86; placebo N = 88)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in blocks of 12.
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Allocation concealment (selection bias) Unclear risk No information available.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis was used.
Selective reporting (reporting bias) Low risk All outcomes measured were reported.
Other bias High risk Supported by a grant from the Janssen Re-
search Foundation.
Pai 2002
Methods Allocation: randomised.
Blindness: double blind, a placebo with an identical appearance to the risperidone, but
unclear who is blinded.
Duration: 12 weeks.
Settings: not stated.
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-IV).
N = 50*.
Age: mean ~ 50.2 years, SD ~ 9.6 years.
Sex: male = 20 and female = 10.
Length of illness: mean 11.86 years, SD 10.1 years.
Inclusion criteria: age between 18 and 65 years, maintenance on conventional antipsy-
chotics for more than 1 year with an equivalent dosage of less than 200 mg/day of chlor-
promazine, BPRS total scores of less than 20, and no record of any violent or aggressive
behavior within the last 6 months, to minimise the risk of psychotic exacerbation after
withdrawing antipsychotics.
Exclusion criteria: comorbidity of organic mental disorder or major physical illness, ever
being prescribed any atypical antipsychotic, and neuroleptic depot administration within
the last 6 months
Interventions 1. Risperidone: titration period 6 weeks from 2 mg/d to 6 mg/d, then with ﬁxed dosage
of 6 mg/d for the remaining 6 weeks, N = 22.
2. Placebo: titration period 6 weeks from 2 mg/d to 6 mg/d, then with ﬁxed dosage of
6 mg/d for the remaining 6 weeks, N = 20
Outcomes Mental state: BPRS.
Leaving the study early.
Global state: needing additional medication; CGI.
Adverse effects: ESRS-parkinsonism score, ESRS-dystonia score, AIMS total score, con-
comitant with benzodiazepine, concomitant with antiparkinsonism drug
Unable to use:
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The number of participants leaving the study early in each group was not reported.
Change score of ESRS, change score of AIMS. Change scores were not used, as endpoint
scores of the same scales were available
Notes *2 of the references reported N = 50, 1 reference reported N = 49. We assume N = 50
in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information:
Quote: “subjects were randomly assigned
to the risperidone or placebo groups”. (Bai
2003, p1343)
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “double blind, a placebo with an
identical appearance to the risperidone, but
unclear who is blinded.” (p1343)
Incomplete outcome data (attrition bias)
All outcomes
High risk 42 participants completed the 12-week
study and7participantswithdrew. 4partic-
ipants left the study early due to psychotic
symptom exacerbation, another 3 partici-
pants withdrew due to a medical condition
Selective reporting (reporting bias) Low risk All the measured outcomes were reported.
Other bias Low risk None obvious.
Potkin 1997
Methods Allocation: randomised.
Blindness: double blind.
Duration: 4 weeks.
Setting: multicentre, USA.
Design: parallel.
Participants Diagnosis: schizophrenia.
N = 246.
Age: no information available.
Sex: male and female.
Inclusion criteria: PANSS score of 80 to 120, ≥ 8 on at least 2 items on the PANSS
positive subscale.
Exclusion criteria: no information available.
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Interventions 1. Risperidone: dose 4 mg/day, N = 85.
2. Risperidone: dose 8 mg/day, N = 78*.
3. Placebo: N = 83.
Outcomes Mental state: PANSS.
Leaving the study early.
Adverse effects: any adverse event.
Unable to use:
Adverse effects: ESRS (SD not reported).
Notes *We adopted data from the 4 mg arm, as it’s more representative of the dosage used in a
normal clinical setting
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further description.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information available.
Selective reporting (reporting bias) Low risk All outcomes measured were reported.
Other bias High risk Funded by Janssen Research Foundation.
Potkin 2003
Methods Allocation: randomised.
Blindness: double.
Duration: 4 weeks.
Setting: inpatients, 40 centres in USA.
Design: parallel.
Participants Diagnosis: schizophrenia and schizoaffective disorder (DSM-IV).
N = 404.
Age: the mean age for each treatment group ranged from 38.1 to 40.2 years.
Sex: male = 283, female = 121.
Length of illness: not reported.
Inclusion criteria: men and non-pregnant, non-lactating women, evidence of respon-
siveness to antipsychotic medications (were not refractory to antipsychotics and had
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previously shown an improvement with an antipsychotic drug other than clozapine and
had been an outpatient for at least 1 3-month period during the last year, PANSS score
of at least 60 and a minimum score of 4 (moderate) on at least 2 items of the psychotic
item subscale.
Exclusion criteria: history of violence, recent history of suicide attempt or serious suicide
thoughts, neurological disorders other than TD or EPS, psychoactive substance depen-
dence or history of drug or alcohol abuse within 1 month, treatment with an investiga-
tional drug within 4 weeks of the investigational period, any acute or unstable medical
condition
Interventions 1. Risperidone: dose 6 mg/day N = 99.
2. Aripiprazole: dose 20 mg/day N = 101*.
3. Aripiprazole: dose 30 mg/day N = 101*.
4. Placebo: N = 103.
Outcomes Mental State: PANSS.
Leaving the study early.
Adverse effects.
Unable to use:
Global State: CGI (no SD reported).
Mental state: BPRS, PANSS change score (no SD reported).
Adverse effects: EPS, SAS, BAS, AIMS (no data reported). Body weight, serum prolactin,
correctedQT (no SD reported). Pain was reported as “pain”, “extremity pain”, and “back
pain”; since we are unsure if participants overlapped in these categories, we selected “back
pain” to report to avoid double counting
Notes Lorazepam was used for anxiety and insomnia.
Intramuscular lorazepam was used for agitation.
Benztropine up to 6 mg per day was permitted for EPS.
Psychotropics other than those prescribed by the study protocol were prohibited
*Data from these 2 arms were not used in this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This was a randomised, 4-
week, inpatient, double-blind, placebo-
controlled, parallel-group study”. (p682)
Allocation concealment (selection bias) Unclear risk No information available.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “This was a randomised, 4-
week, inpatient, double-blind, placebo-
controlled, parallel-group study”. (p682)
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition was 40% (162/242) in this study.
Although 392participantswere included in
efﬁcacy analysis using LOCF and 403 were
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included in safety analysis, we feel that the
high attrition rate made any results from
this trial prone to bias
Selective reporting (reporting bias) Low risk All outcomes measured were reported.
Other bias High risk Supported by Bristol-Myers Squibb and
Otsuka Pharmaceutical.
Potkin 2006
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks*.
Setting: inpatients, 30 sites, USA.
Design: parallel.
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV).
N = 381.
Age: mean ~ 34.8 years, SD ~ 9.7 years.
Sex: male = 228 and female = 153.
Length of illness: not reported.
Inclusion criteria: 18-64 years old, acute exacerbation of schizophrenia of recent onset
(within 4 weeks), have a score of ≥ 4 at least 2 of the following items on the PANSS:
Hostility, Excitment, Tension, Uncooperativeness, and Poor Impulse Control, and a total
score on the 5 items of at least 17, CGI ≥ 5.
Exclusion criteria: comorbid Axis 1 diagnosis with the exception of substance abuse/
dependence, borderline personality disorder, mental retardation or clinically signiﬁcant
medical illness, also excluded were people who received risperidone or quetiapine within
7 days of baseline, clozapine within 60 days, or depot antipsychotic or electroconvulsive
therapy within the study period
Interventions 1. Risperidone: dose 4.7 ± 0.9 mg/day, N = 153.
2. Quetiapine: dose 579.5 ± 128.9 mg/day, N = 156.
3. Placebo: N = 73.
Zolpidem, zopiclone, and zaleplon used to treat insomnia.
Injectable lorazepam, sodium amytal, or midazolam used for treating agitation or rest-
lessness.
Benztropine mesylate or an equivalent treatment for movement disorder was permitted
throughout study as needed
Outcomes Mental state: PANSS.
Leaving the study early.
Global state: CGI-Severity, CGI-Change.
Adverse effects: SAS, BAS, prolactin, EPS.
Unable to use:
Readiness for discharge questionnaire (not a validated scale)
Study medication satisfaction (not a validated scale).
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Notes *2weeksmonotherapy phase followed by a 4-week additive therapy phase. In the additive
therapy phase, all the participants in the 3 groups received other antipsychotic drugs. As
the data in these two phases is reported separately, we only use the data from the 2-week
monotherapy phase
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a centralised interactive
voice response system
Quote: “A non-centralised randomisation
strategy was used to ensure that subjects
were balanced across the three treatments
within each investigate site... subjects were
assigned to a double blind treatment using
a centralized interactive voice response sys-
tem (IVRS)” (p255)
Allocation concealment (selection bias) Low risk Concealed with centralised IVRS.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind by using a centralised IVRS
(p255)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis was used.
Selective reporting (reporting bias) Low risk All outcomes measured were reported.
Other bias High risk Supported by Janssen Pharmaceutica.
Potkin 2007
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Setting: 21 sites in USA.
Design: parallel.
Participants Diagnosis: schizophrenia.
N = 180.
Age: 18 to 65 years.
Sex: not reported.
History: participants with acute exacerbation were included in the trial.
Inclusion criteria: baseline PANSS score > 60.
Exclusion criteria: recent history of suicide attempt or serious suicide thoughts, neuro-
logical disorders other than TD or EPS, psychoactive substance dependence or history
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of drug or alcohol abuse within 1 month
Interventions 1. Risperidone: dose 6 mg/day, N = 59.
2. Placebo: N = 62.
3. Asenapine: dose 10 mg/day, N = 59.
Outcomes Leaving the study early.
Adverse effects.
Unable to use:
Global state: CGI (> 50% loss to follow-up, thus data was not reported).
Mental state: PANSS (> 50% loss to follow-up, thus data was not reported)
Function: battery of neurocognitive test (no SD reported), WCST (no data reported)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk No information available.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double dummy placebo design was em-
ployed to maintain blinding. Quote:
“this double-blind, double-dummy, 3-arm,
ﬁxed-dose...” (p1493)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT for efﬁcacy data and LOCF for safety
data.
Selective reporting (reporting bias) Low risk All outcomes measured were reported.
Other bias High risk Funded by Organon USA Inc and Pﬁzer
Inc.
Yagcioglu 2005
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Setting: inpatients and outpatients, 2 sites in Turkey.
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-IV).
N = 30.
Age: 18 to 55 years.
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Sex: male = 20 and female = 10.
Length of illness: mean ~ 14.4 years, SD ~ 9.1 years.
Inclusion criteria: patients had been receiving clozapine treatment (300 mg/d to 900
mg/d) for at least 6 months prior to the study; people diagnosed as having residual
schizophrenia in whom negative symptoms were more prominent than positive symp-
toms; failed to respond adequately; positive symptoms was stable by clinical criteria and
reported in written notes for at least 3 months prior to study entry; PANSS≥ 72, CGI-
S ≥ 4, a score of at least 3 on any one of the PANSS POS items.
Exclusion criteria: concomitantly receiving mood stabilisers, including lithium carbon-
ate, antidepressants, and antipsychotic medication other than clozapine; alcohol or sub-
stance dependence; history of intolerance to risperidone for reasons other than EPS
Interventions 1. Risperidone combined with clozapine: dose 2 mg/day to 6 mg/day, N = 16.
2. Placebo combined with clozapine, N = 14.
Outcomes Clinical response*.
Leaving the study early.
Global state: CGI-S.
Functioning: GAF.
Mental state: PANSS, CDS.
Adverse effect: weight gain, serum prolactin, SAS, BAS, AIMS score
Quality of life: QLS.
Notes *no clinical improvement: PANSS positive subscale score < 20%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear how the “pre-assigned random se-
quence” was achieved. Quote: “Randomi-
sation was planned by one of the unblinded
investigators prior to the initiation of the
study in a 1:1 ratio, and pre-assigned ran-
dom sequencewas determined for each site.
The patients arriving at each site were as-
signed the study medication according to
this sequence in order with their enrol-
ment.” (p65)
Allocation concealment (selection bias) Unclear risk Not stated. Quote: “pre-assigned random
sequence was determined for each site.”
(p65)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, investigators were blinded,
no further information
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Yagcioglu 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant in the risperidone group
withdrew consent just prior to ﬁnal visit
ratings. This is unlikely to have any signif-
icant impact on the outcome assessment
Selective reporting (reporting bias) Low risk All the outcomes were reported.
Other bias Low risk None obvious.
AIMS: Abnormal Involuntary Movement Scale
BACS: Brief Assessment of Cognition in Schizophrenia
BAS: Barnes Akathisia Scale
BMI: body mass index
BPRS: Brief Psychiatric Rating Scale
CDS: Calgary Depression Scale
CGI: Clinical Global Impression
DSM: Diagnostic and Statistical Manual of Mental Disorders
ECG: electrocardiogram
EPS: extrapyramidal symptom
ESRS: Extrapyramidal Symptom Rating Scale
GAF: Global Assessment of Functioning
HAM-D: Hamilton Rating Scale for Depression
ISST: InterSePT Scale for Suicidal Thinking
ITT: intention to treat
IVRS: interactive voice response system
LOCF: last observation carried forward
PANSS: Positive and Negative Syndrome Scale
QLS: Quality of Life Scale
SANS: Scale for the Assessment of Negative Symptoms
SAS: Simpson Angus Scale
SD: standard deviation
SOFAS: Social and Occupational Functioning Assessment Scale
TD: tardive dyskinesia
WCST: Wisconsin Card Sorting Test
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adler 1999 Allocation: randomised.
Participants: people with non-organic psychosis.
Interventions: vitamin E versus placebo.
Akhondzadeh 2005 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: risperidone plus lamotrigine versus risperidone plus placebo
Akhondzadeh 2007 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: risperidone plus celecoxib versus risperidone plus placebo
Anwunah 1999 Allocation: randomised.
Participants: people with schizotypal personality disorder.
Ayd 2001 Allocation: randomised.
Participants: people with schizotypal personality disorder.
Azorin 2002 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus sertindole.
Azorin 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus sertindole.
Bai 2005 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus other atypicals (no placebo arm)
Baker 2012 Allocation: not RCT but pooled data from RCTs.
Basson 2001 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: olanzapine versus haloperidol versus risperidone
Beasley 1996 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: olanzapine versus placebo versus haloperidol.
Bondolﬁ 1998 Allocation: randomised.
Participants: people with resistant schizophrenia.
Intervention: clozapine versus risperidone.
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(Continued)
Borison 1992a Allocation: randomised.
Participants: people with chronic schizophrenia.
Intervention: risperidone versus haloperidol.
Boyer 1995 Allocation: randomised.
Participants: people with negative schizophrenia.
Intervention: amisulpride versus placebo.
Brecher 1998 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus olanzapine.
Cada 2004 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone long-acting injection versus placebo
Carson 2002 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: aripiprazole versus haloperidol versus placebo
Casey 2003 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: aripiprazole versus placebo.
Castle 2015 Allocation: not RCT but pooled data from RCTs.
Chan 2007 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus aripiprazole.
Chue 2002 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone long-acting injection versus olanzapine
Ciliberto 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone long-acting injection versus placebo
Citrome 2004 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: antipsychotic monotherapy versus antipsychotic plus valproate
Claus 1992 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus haloperidol.
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Conley 1998 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus olanzapine.
Cooper 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus olanzapine versus quetiapine
Cornblatt 2002 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: aripiprazole versus olanzapine.
Crawford 1997 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: olanzapine versus haloperidol versus placebo.
Csernansky 1999 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus haloperidol.
David 2000 Allocation: not randomised.
Davis 2001 Allocation: not randomised.
Dossenbach 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: olanzapine versus ﬂuphenazine.
Dubitsky 2002 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: aripiprazole versus risperidone.
Edgell 2000 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus olanzapine.
Fleming 2007a Allocation: randomised.
Participants: people with schizophrenia.
Intervention: asenapine versus risperidone versus placebo.
Friedman 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus haloperidol.
Gismondi 2004 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: aripiprazole versus perphenazine.
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Gregor 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: olanzapine versus haloperidol.
Harvey 2001 Allocation: randomised.
Participants: people with schizophrenia and schizoaffective disorder.
Interventions: risperidone versus olanzapine.
Hwang 2003 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus amisulpride.
Hwang 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus aripiprazole.
Kane 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone, sertindole, and aripiprazole.
Kinon 1998 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: olanzapine versus haloperidol.
Kinon 2015 Allocation: not RCT, but pooled data from ﬁve RCTs.
Lauriello 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone long-acting injection versus placebo
Lemmens 1994 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus zuclopenthixol dihydrochloride
Lieberman 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: olanzapine versus haloperidol.
Lindstrom 1994 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus haloperidol.
Loo 1997 Allocation: randomised.
Participants: people with deﬁcit schizophrenia.
Interventions: amisulpride versus placebo.
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Lopez 1996 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus haloperidol.
Lopez-Ibor 1992 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus haloperidol.
Luo 2011 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: paliperidone versus olanzapine versus placebo.
Marder 1991 Allocation: not RCT, but pooled data from two RCTs.
McClellan 2009 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus olanzapine or molindone.
McClure 2009 Allocation: randomised.
Patients: Schizotypal personality disorder.
McKenna 2004 Allocation: randomised.
Participants: people with refractory schizophrenia.
Intervention: clozapine versus clozapine plus risperidone.
Nasrallah 2004a Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone long-acting injection versus placebo
NCT 02109562 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: resperidone injections versus placebo.
NCT00034892 Allocation: randomised.
Participants: people with schizophrenia, schizophreniform disorder, and schizoaffective disorder.
Interventions: risperidone versus quetiapine versus olanzapine
NCT00088075 Allocation: randomised.
Participants: adolescents with schizophrenia.
NCT00202007 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus aripiprazole.
NCT00249119 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone long-acting injection versus placebo
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NCT00253136 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus haloperidol.
NCT00305474 Allocation: randomised.
Participants: non-psychotic relatives of people with schizophrenia
Peuskens 1995 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus haloperidol.
Peuskens 2001 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus amisulpride.
Peuskens 2001a Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus amisulpride plus haloperidol
Pikalov 2012 Allocation: not RCT, but pooled data from seven RCTs.
Rabinowitz 2001 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus haloperidol.
Rein 2002 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus amisulpride.
Revicki 1996 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: olanzapine versus haloperidol.
Riedel 2003 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone plus celecoxib versus risperidone plus placebo
Schmechtig 2010 Allocation: randomised.
Participants: health volunteers.
Siever 2002 Allocation: randomised.
Participants: people with schizotypal personality disorder.
Tollefson 1996 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: olanzapine versus risperidone.
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Tran 1997 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus olanzapine.
Tsai 2004 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone plus sarcosine versus risperidone plus placebo
Tsai 2006 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone plus D-alanine versus risperidone plus placebo
Urioste 2004 Allocation: randomised.
Participants: people with schizophrenia and schizoaffective disorder.
Intervention: risperidone long-acting injection versus placebo
Wang 2003 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone plus valproate versus risperidone plus placebo
Weickert 2003 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: antipsychotic drugs (risperidone, olanzapine, quetiapine) versus placebo
Weiden 2005 Allocation: randomised.
Participants: schizophrenia with obesity.
Intervention: sibutramin vs placebo
Wirshing 1995 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus haloperidol.
Yamawaki 1996 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone versus clocapramine (an atypical antipsychotic of the imidobenzyl class)
Zhang 2002 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone plus antioxidants versus risperidone plus placebo
Zhong 2006 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: risperidone plus buﬂomedil versus risperidone plus placebo
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Characteristics of studies awaiting assessment [ordered by study ID]
Anon 2010
Methods Allocation: no information.
Participants Diagnosis: schizophrenia.
Interventions 1. Risperidone.
2. Placebo.
Outcomes Long-term efﬁcacy.
Notes Awaiting for full text.
Bose 2010a
Methods Randomised.
Participants People with schizophrenia.
Interventions Placebo versus cariprazine versus risperidone
Outcomes no useable data reported.
Notes The paper didn’t report any data relevant to pre-deﬁned outcomes of this review. We have contacted trial authors for
further data, but haven’t received any reply
Cavazzoni 2002
Methods Randomised.
Participants People with schizophrenia.
Interventions Risperidone versus olanzapine versus clozapine versus placebo
Outcomes No useable data.
Notes The paper didn’t report any data relevant to pre-deﬁned outcomes of this review. We have contacted trial authors for
further data, but haven’t received any reply
DeMartinis 2012
Methods Randomised.
Participants People with schizophrenia.
Interventions Placebo versus risperidone versus PF-02545920.
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DeMartinis 2012 (Continued)
Outcomes No useable data reported.
Notes The paper didn’t report any data relevant to pre-deﬁned outcomes of this review. We have contacted trial authors for
further data, but haven’t received any reply
GlaxoSmithKline 2006
Methods Randomised.
Participants People with schizophrenia.
Interventions Talnetant (a neurokinin 3 receptor antagonist) versus placebo versus risperidone
Outcomes No usable data.
Notes The paper didn’t report any data relevant to pre-deﬁned outcomes of this review. We have contacted trial authors for
further data, but haven’t received any reply
Litman 2014
Methods Allocation: randomised.
Blindness: double blind.
Duration: 28 days.
Design: parallel.
Participants Diagnosis: people with schizophrenia.
N = 151.
Age: not reported.
Sex: not reported.
Interventions 1. Risperidone: 4 mg.
2. Placebo.
3. AZD8529: 40 mg.
Outcomes Unable to use:
PANSS, CGI.
Notes Full text is not available.
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NCT 00694707
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Design: parallel.
Participants Diagnosis: people with schizophrenia.
Interventions 1. Risperidone: dose 4 mg/day.
2. Placebo.
3. Cariprazine 1.5 mg/d.
4. Cariprazine 3 mg/d.
5. Cariprazine 4.5 mg/d.
Outcomes Not reported.
Notes Awaiting for full text.
NCT01086748
Methods Randomised.
Participants People with schizophrenia.
Interventions Risperidone versus placebo versus LY2140023. (no further detail of the drug was available)
Outcomes No usable data available.
Notes The paper didn’t report any data relevant to pre-deﬁned outcomes of this review. We have contacted trial authors for
further data, but haven’t received any reply
NCT01175135
Methods Randomised.
Participants People with schizophrenia.
Interventions Risperidone versus placebo versus PF-02545920. (no further detail of the drug was available)
Outcomes No useable data available.
Notes The paper didn’t report any data relevant to pre-deﬁned outcomes of this review. We have contacted trial authors for
further data, but haven’t received any reply
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NCT01363349
Methods Randomised
Participants People with schizophrenia.
Interventions Risperidone versus placebo versus BL-1020.
Outcomes No useable data*.
Notes *This trial has terminated with the following reason stated:
Pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the trial would not meet
the pre-speciﬁed primary efﬁcacy endpoint
We have contacted trial authors for data, but not received any reply yet
Nisenbaum 2013
Methods Allocation: randomised.
Blindness: double blind, but unclear who is blinded.
Duration: 6 weeks.
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-IV).
N = 100.
Age: 18-65 years old.
Sex: not reported.
Length of illness: not reported.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Interventions 1. Risperidone: 3 mg/d, N = 38.
2. Placebo: not reported, N = 78.
3. Pomaglumetad methionil: N = 83.
Outcomes Unable to use:
PANSS total score.
Notes Full text is not available.
Rujescu 2009
Methods Randomised.
Participants People with schizophrenia.
Interventions Riluzole (a drug used to treat amyotrophic lateral sclerosis) versus risperidone versus placebo
Outcomes No useable data. (The grant was terminated due to slow enrolment.)
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Rujescu 2009 (Continued)
Notes The paper didn’t report any data relevant to pre-deﬁned outcomes of this review. We have contacted trial authors for
further data, but haven’t received any reply
Vanover 2014
Methods Allocation: randomised.
Blindness: double blind.
Duration: 28 days.
Design: parallel.
Participants Diagnosis: acute exacerbated schizophrenia (DSM-IV).
N = not reported.
Age: not reported.
Sex: not reported.
Length of illness: not reported.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Interventions 1. Risperidone: 4 mg/d.
2. Placebo.
3. ITI-007 60 mg/d.
4. ITI-007 120 mg/d.
Outcomes Uable to use:
PANSS, CDSS.
Notes No full text available, we contacted the author (Kimberly Vanover, Ph.D. kvanover@intracellulartherapies.com) but
havn’t received a reply yet
Xu 2009
Methods Allocation: randomised.
Blindness: double blind, but unclear who is blinded.
Duration: 90 days.
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-IV).
N = 200.
Age: not reported.
Sex: not reported.
Length of illness: not reported.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Interventions 1. Risperidone: 3 mg/d to 6 mg/d.
2. Placebo.
3. LDXGW plus risperidone 3 mg/d to 6 mg/d.
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Xu 2009 (Continued)
4. LDXGW plus risperidone < 3 mg/d.
Outcomes Unable to use:
CGI, BPRS, SANS, SAPS.
Notes No full text available, we contacted the author but did not receive a reply
BPRS: Brief Psychiatric Rating Scale
CGI: Clinical Global Impression
DSM: Diagnostic and Statistical Manual of Mental Disorders
PANSS: Positive and Negative Syndrome Scale
SANS: Scale for the Assessment of Negative Symptoms
SAPS: Scale for the Assessment of Positive Symptoms
CDSS: the Calgary Depression Scale for Schizophrenia
Characteristics of ongoing studies [ordered by study ID]
NCT00174200
Trial name or title Study to assess differential sensitivity of 2 spatial working memory tests in people with schizophrenia treated
with risperidone
Methods Allocation: randomised.
Blindness: double.
Participants Diagnosis: people with schizophrenia.
Interventions 1. Risperidone: dose 2 mg/day.
2. Placebo.
Outcomes Cognitive functions: GMLT.
Adverse effects: ESRS.
Mental state: PANSS.
Starting date July 2007.
Contact information Pﬁzer CT.gov Call Center, Study Director, Pﬁzer.
Notes Study ID: A9001229.
ESRS: Extrapyramidal Symptom Rating Scale
GMLT: Groton Maze Learning Test
PANSS: Positive and Negative Syndrome Scale
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D A T A A N D A N A L Y S E S
Comparison 1. RISPERIDONE vs PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: no clinically
signiﬁcant response in
psychotic symptoms (deﬁned
by various scale total score
change) - short term (up to 12
weeks)
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 deﬁned by PANSS<30%
decline
3 707 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.67, 0.83]
1.2 deﬁned by PANSS/BPRS
<20% decline
6 864 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.52, 0.78]
2 Leaving the study early - short
term (up to 12 weeks)
12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 any reason 12 2261 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.62, 0.78]
2.2 due to adverse events 10 2081 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.59, 1.03]
2.3 due to lack of efﬁcacy 11 2211 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.29, 0.51]
2.4 due to noncompliance 4 534 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.33, 4.05]
2.5 lost to follow-up 6 1545 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.25, 2.56]
2.6 protocol violation 4 1257 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.39, 1.62]
2.7 reported death 10 1532 Risk Ratio (M-H, Random, 95% CI) 3.07 [0.13, 74.28]
2.8 withdrawal of consent 7 1589 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.80, 1.56]
2.9 other 3 615 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.68, 1.57]
3 Global state: 1. average endpoint
scores of CGI severity scale
(high=poor) - short term (up to
12 weeks)
3 457 Mean Difference (IV, Random, 95% CI) -0.81 [-0.89, -0.73]
4 Global state: 2. no signiﬁcant
clinical improvement CGI -
short term (up to 12 weeks)
4 594 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.57, 0.83]
5 Global state: 3. needing
additional medication - short
term (up to 12 weeks)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 benzodiazepine 1 42 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.77, 1.20]
5.2 benzodiazepine derivatives
- Lorazepam
2 228 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.68, 1.27]
5.3 benzodiazepine derivatives
- Nitrazepam
1 184 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.10, 2.72]
5.4 benzodiazepine related
drugs - Zolpidem
1 184 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.53, 1.23]
5.5 sedative/hypnotic 2 230 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.69, 1.06]
5.6 antiparkinsonian 2 172 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.79, 1.86]
5.7 psychotropics 1 186 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.45, 0.85]
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6 Mental state: 1. average
endpoint scores on various
scales on psychotic symptoms
(high=poor) - short term (up to
12 weeks)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 BPRS total 2 171 Mean Difference (IV, Random, 95% CI) -12.69 [-17.06, -8.
32]
6.2 PANSS total 3 457 Mean Difference (IV, Random, 95% CI) -17.81 [-18.17, -17.
45]
6.3 PANSS general pathology 1 44 Mean Difference (IV, Random, 95% CI) -13.20 [-20.15, -6.
25]
6.4 PANSS negative symptom 3 457 Mean Difference (IV, Random, 95% CI) -3.10 [-3.19, -3.01]
6.5 PANSS positive symptom 3 457 Mean Difference (IV, Random, 95% CI) -5.49 [-6.18, -4.80]
7 Mental state: 2. skewed data -
short term (up to 12 weeks)
Other data No numeric data
7.1 average endpoint score
BPRS total (high=poor)
Other data No numeric data
7.2 average change score of
CGI-C (larger decline=good)
Other data No numeric data
7.3 average change score of
CGI-SI (larger decline=good)
Other data No numeric data
7.4 average change score of
HAM-D-17 (larger decline=
good)
Other data No numeric data
7.5 average change score of
PANSS total (larger decline=
good)
Other data No numeric data
7.6 average change score of
PANSS negative symptom
(larger decline=good)
Other data No numeric data
7.7 average change score of
PANSS positive symptom
(larger decline=good)
Other data No numeric data
8 Adverse effects: 1a.
extrapyramidal - various effects
- short term (up to 12 weeks)
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 general - any signiﬁcant
EPS
7 1511 Risk Ratio (M-H, Random, 95% CI) 1.56 [1.13, 2.15]
8.2 general - no improvement
on AIMS score
1 42 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.15, 0.61]
8.3 general - no improvement
on BAS score
1 226 Risk Ratio (M-H, Random, 95% CI) 1.14 [1.01, 1.28]
8.4 general - needing
medication for EPS
2 94 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.78, 1.67]
8.5 speciﬁc - akathisia 5 1204 Risk Ratio (M-H, Random, 95% CI) 2.58 [1.41, 4.72]
8.6 speciﬁc - bradykinesia 2 485 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.60, 1.24]
8.7 speciﬁc - dyskinesia 1 303 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.86]
8.8 speciﬁc - dystonia 3 687 Risk Ratio (M-H, Random, 95% CI) 3.40 [0.26, 44.46]
8.9 speciﬁc - hypertonia 3 505 Risk Ratio (M-H, Random, 95% CI) 2.98 [1.35, 6.59]
8.10 speciﬁc - parkinsonism 2 485 Risk Ratio (M-H, Random, 95% CI) 7.64 [1.40, 41.59]
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8.11 speciﬁc - tardive
dyskinesia
1 303 Risk Ratio (M-H, Random, 95% CI) 6.77 [0.35, 130.03]
8.12 speciﬁc - tremor 5 1204 Risk Ratio (M-H, Random, 95% CI) 1.60 [0.89, 2.88]
9 Adverse effects: 1b.
extrapyramidal - AIMS average
endpoint score - short term (up
to 12 weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 Adverse effects: 1c.
extrapyramidal - skewed data
(various scales) - short term (up
to 12 weeks)
Other data No numeric data
10.1 average change score of
AIMS
Other data No numeric data
10.2 average change score of
CGI severity dyskinesia
Other data No numeric data
10.3 average change score of
CGI severity parkinsonism
Other data No numeric data
10.4 average change score of
ESRS
Other data No numeric data
10.5 average change score of
ESRS - akathisia
Other data No numeric data
10.6 average change score of
ESRS - dystonia
Other data No numeric data
10.7 average change score of
ESRS - dyskinesia
Other data No numeric data
10.8 average change score of
ESRS - parkinsonism
Other data No numeric data
11 Adverse effects: 2. any adverse
event - short term (up to 12
weeks)
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 any adverse event 7 1610 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.96, 1.15]
11.2 asthenia 2 639 Risk Ratio (M-H, Random, 95% CI) 1.93 [0.62, 6.02]
11.3 back pain 1 202 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.38, 2.86]
11.4 blurred vision 1 202 Risk Ratio (M-H, Random, 95% CI) 4.16 [0.47, 36.59]
11.5 cogwheel rigidity 1 226 Risk Ratio (M-H, Random, 95% CI) 5.25 [0.69, 39.88]
11.6 death 1 182 Risk Ratio (M-H, Random, 95% CI) 3.13 [0.13, 75.92]
11.7 dental disorder 1 202 Risk Ratio (M-H, Random, 95% CI) 3.64 [0.78, 17.11]
11.8 dysmenorrhoea 2 495 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.04, 30.00]
11.9 fatigue 2 558 Risk Ratio (M-H, Random, 95% CI) 2.23 [0.69, 7.22]
11.10 fever 1 130 Risk Ratio (M-H, Random, 95% CI) 9.28 [0.51, 168.90]
11.11 infection 1 202 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.10, 2.78]
11.12 salivation - increased 1 202 Risk Ratio (M-H, Random, 95% CI) 7.28 [0.38, 139.15]
11.13 pyrexia 1 182 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.45, 3.16]
11.14 pain 1 121 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.47, 5.31]
11.15 rash (skin) 1 202 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.45, 3.16]
11.16 vaginitis 1 58 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.07, 16.32]
11.17 hyperhidrosis 1 437 Risk Ratio (M-H, Random, 95% CI) 10.35 [0.50, 214.17]
12 Adverse effects: 3.
cardiovascular - short term (up
to 12 weeks)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 dizziness - orthostatic 1 44 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 69.87]
12.2 ECG abnormal 1 182 Risk Ratio (M-H, Random, 95% CI) 9.40 [0.51, 172.11]
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12.3 heart rate decreased 1 182 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.05, 5.66]
12.4 heart rate increased 1 182 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.37, 1.96]
12.5 hypotension - postural 1 44 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 69.87]
12.6 QTc > 450 milliseconds
or > 10% increase from baseline
2 380 Risk Ratio (M-H, Random, 95% CI) 8.46 [1.07, 67.07]
12.7 tachycardia 2 332 Risk Ratio (M-H, Random, 95% CI) 12.22 [2.33, 64.10]
13 Adverse effects: 4. central
nervous system - short term
(up to 12 weeks)
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 agitation 8 1388 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.75, 1.17]
13.2 anxiety 6 1225 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.73, 1.48]
13.3 dizziness 5 970 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.65, 3.05]
13.4 headache 10 1905 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.81, 1.21]
13.5 insomnia 10 1905 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.97, 1.39]
13.6 sedation 2 517 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.52, 6.50]
13.7 somnolence 6 951 Risk Ratio (M-H, Random, 95% CI) 1.61 [1.06, 2.45]
13.8 restlessness 2 619 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.49, 2.74]
14 Adverse effects: 5. endocrine -
serum prolactin increase above
reference range (23 ng/ml) -
short term (up to 12 weeks)
2 323 Risk Ratio (M-H, Random, 95% CI) 12.14 [4.38, 33.68]
15 Adverse effects: 6.
gastrointestinal system - short
term (up to 12 weeks)
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 constipation 8 1695 Risk Ratio (M-H, Random, 95% CI) 1.88 [1.19, 2.96]
15.2 diarrhoea 1 202 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.37, 2.30]
15.3 dry mouth 1 202 Risk Ratio (M-H, Random, 95% CI) 2.43 [0.65, 9.12]
15.4 dyspepsia 5 1058 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.64, 2.40]
15.5 nausea 6 1225 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.75, 1.86]
15.6 vomiting 5 1181 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.65, 2.07]
16 Adverse effects: 7a. metabolic -
weight gain - short term (up to
12 weeks)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 any gain 3 910 Risk Ratio (M-H, Random, 95% CI) 3.77 [1.34, 10.63]
16.2 >7% increase from
baseline
3 606 Risk Ratio (M-H, Random, 95% CI) 3.47 [1.64, 7.33]
17 Adverse effects: 7b. metabolic -
skewed data - average change
value on lipid proﬁle - short
term (up to 12 weeks)
Other data No numeric data
17.1 cholesterol - total Other data No numeric data
17.2 HDL Other data No numeric data
17.3 LDL Other data No numeric data
17.4 triglycerides Other data No numeric data
17.5 VLDL Other data No numeric data
18 Adverse effects: 8.
musculoskeletal system - short
term (up to 12 weeks)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 myalgia 1 202 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.12, 4.06]
18.2 Joint disorder 1 202 Risk Ratio (M-H, Random, 95% CI) 2.60 [0.52, 13.10]
19 Adverse effects: 9. physiology -
short term (up to 12 weeks)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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19.1 ALT increased 1 182 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.07, 16.45]
19.2 AST increased 1 182 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 blood CPK increased 2 619 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.23, 1.95]
19.4 blood pressure increased 1 182 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.15, 7.26]
20 Adverse effects: 10. respiratory
system - short term (up to 12
weeks)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 upper respiratory
infection
2 323 Risk Ratio (M-H, Random, 95% CI) 2.83 [1.03, 7.74]
20.2 pharyngitis 1 202 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.08, 2.10]
20.3 rhinitis 2 306 Risk Ratio (M-H, Random, 95% CI) 10.81 [2.58, 45.29]
20.4 sinusitis 1 437 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.09, 11.36]
Comparison 2. RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: no clinically
signiﬁcant response in
psychotic symptoms (deﬁned
by PANSS/BPRS<20%
decline) - short term (up to 12
weeks)
2 98 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.93, 1.42]
2 Leaving the study early - short
term (up to 12 weeks)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 any reason 3 167 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.53, 2.42]
2.2 due to adverse events 2 137 Risk Ratio (M-H, Random, 95% CI) 4.11 [0.47, 36.24]
2.3 due to lack of efﬁcacy 1 69 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.11, 2.78]
2.4 due to noncompliance 1 69 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.02, 8.61]
2.5 lost to follow-up 1 69 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.02, 8.61]
2.6 reported death 1 68 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 withdrawal of consent 3 167 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.28, 7.09]
2.8 administrative reasons 1 69 Risk Ratio (M-H, Random, 95% CI) 5.44 [0.27, 109.34]
2.9 abnormal lab results 1 69 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.02, 8.61]
3 Global state: 1. average endpoint
scores of CGI severity scale
(high=poor) - short term (up to
12 weeks)
1 65 Mean Difference (IV, Random, 95% CI) 0.51 [0.02, 1.00]
4 Global state: 2. no signiﬁcant
clinical improvement CGI -
short term (up to 12 weeks)
1 68 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.87, 1.44]
5 Global state: 3. general
functioning - average endpoint
GAF score (high=good) - short
term (up to 12 weeks)
1 30 Mean Difference (IV, Random, 95% CI) -4.5 [-8.38, -0.62]
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6 Mental state: 1. average
endpoint scores on various
scales on psychotic symptoms
(high=poor) - short term (up to
12 weeks)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 PANSS total 2 95 Mean Difference (IV, Random, 95% CI) 5.56 [1.59, 9.53]
6.2 PANSS general pathology 1 30 Mean Difference (IV, Random, 95% CI) 2.5 [0.03, 4.97]
6.3 PANSS delusion 1 30 Mean Difference (IV, Random, 95% CI) 0.70 [0.09, 1.31]
6.4 PANSS negative symptom 2 95 Mean Difference (IV, Random, 95% CI) 0.69 [-0.68, 2.05]
6.5 PANSS positive symptom 2 95 Mean Difference (IV, Random, 95% CI) 2.30 [0.98, 3.62]
7 Mental state: 2. average
endpoint scores on various
scales on psychotic symptoms
(high=poor) - medium term
(up to 26 weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 BPRS total 1 53 Mean Difference (IV, Random, 95% CI) -4.60 [-9.88, 0.68]
7.2 BPRS positive symptom 1 53 Mean Difference (IV, Random, 95% CI) -0.90 [-2.81, 1.01]
7.3 BPRS anxiety/depression
factor
1 53 Mean Difference (IV, Random, 95% CI) -1.0 [-2.80, 0.80]
7.4 SANS total 1 53 Mean Difference (IV, Random, 95% CI) -3.10 [-10.30, 4.10]
8 Mental state: 3. skewed data -
short term (up to 12 weeks)
Other data No numeric data
8.1 average endpoint score of
CDS total (high=poor)
Other data No numeric data
8.2 average endpoint score on
verbal working memory (SD,
high=good)
Other data No numeric data
9 Adverse effects: 1a.
extrapyramidal - average
endpoint SAS score - short
term (up to 12 weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 Adverse effects: 1b.
extrapyramidal - skewed data
(various scales) - short term (up
to 12 weeks)
Other data No numeric data
10.1 average endpoint score of
AIMS
Other data No numeric data
10.2 average change score of
Barnes akathisia rating scale
Other data No numeric data
10.3 average change score of
ESRS
Other data No numeric data
10.4 average change score of
ESRS - dystonia
Other data No numeric data
10.5 average change score of
ESRS - dyskinesia
Other data No numeric data
10.6 average change score of
ESRS - parkinsonism
Other data No numeric data
11 Adverse effects: 1c.
extrapyramidal - skewed data
(various scales) - medium term
(up to 26 weeks)
Other data No numeric data
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11.1 average endpoint score of
AIMS
Other data No numeric data
11.2 average endpoint score of
SAS
Other data No numeric data
12 Adverse effects: 2. any adverse
event - short term (up to 12
weeks)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 any adverse event 1 64 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.83, 1.58]
12.2 amenorrhoea 1 64 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 71.00]
12.3 asthenia 1 64 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.61, 1.91]
12.4 depression 1 64 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.61, 2.37]
12.5 emotional indifference 1 64 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.52, 2.37]
12.6 fatigue 1 64 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.61, 1.91]
12.7 failing memory 1 64 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.32, 1.41]
12.8 increased duration of
sleep
1 64 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.51, 1.97]
12.9 salivation - increased 1 64 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.81, 1.94]
13 Adverse effects: 3a.
cardiovascular - short term (up
to 12 weeks)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 dizziness - orthostatic 1 64 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.43, 2.34]
13.2 palpitation 1 64 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.27, 3.66]
13.3 tachycardia 1 64 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.27, 3.66]
14 Adverse effects: 3b.
cardiovascular - QTc interval -
short term (up to 12 weeks)
1 30 Mean Difference (IV, Random, 95% CI) -19.70 [-42.08, 2.
68]
15 Adverse effects: 4. central
nervous system - short term
(up to 12 weeks)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 sedation 1 64 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.88, 2.43]
15.2 somnolence 1 64 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.51, 1.97]
15.3 tension 1 64 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.71, 2.12]
16 Adverse effects: 5.
gastrointestinal system - short
term (up to 12 weeks)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 constipation 1 64 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.25, 2.02]
17 Adverse effects: 6a.
haematological - short term (up
to 12 weeks)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 neutrophil count 1 57 Mean Difference (IV, Random, 95% CI) 0.37 [-0.42, 1.16]
17.2 prolactin level, ng/mL 1 30 Mean Difference (IV, Random, 95% CI) 60.10 [46.52, 73.68]
17.3 white cell count 1 61 Mean Difference (IV, Random, 95% CI) 0.66 [-0.20, 1.52]
18 Adverse effects: 6b.
haematological - medium term
(up to 26 weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 prolactin level ng/mL 1 44 Mean Difference (IV, Random, 95% CI) 34.1 [17.63, 50.57]
18.2 fasting glucose 1 40 Mean Difference (IV, Random, 95% CI) -4.60 [-17.09, 7.89]
19 Adverse effects: 7a. metabolic -
weight gain - short term (up to
12 weeks)
1 64 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.40, 2.52]
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20 Adverse effects: 7a. metabolic -
weight gain - medium term (up
to 26 weeks)
1 48 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 3.96]
21 Adverse effects: 7b. metabolic -
average endpoint value on lipid
proﬁle - short term (up to 12
weeks)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 cholesterol - total (mg/
dl)
1 56 Mean Difference (IV, Random, 95% CI) -6.60 [-29.05, 15.
85]
21.2 HDL cholesterol (mg/dl) 1 52 Mean Difference (IV, Random, 95% CI) 0.0 [-8.44, 8.44]
21.3 LDL cholesterol (mg/dl) 1 53 Mean Difference (IV, Random, 95% CI) -6.90 [-26.02, 12.
22]
21.4 triglycerides (mg/dl) 1 56 Mean Difference (IV, Random, 95% CI) 6.20 [-57.57, 69.97]
22 Adverse effects: 7c. metabolic -
average endpoint value - short
term (up to 12 weeks)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 body mass index 1 63 Mean Difference (IV, Random, 95% CI) 1.70 [-0.99, 4.39]
22.2 fasting glucose (mg/dl) 1 51 Mean Difference (IV, Random, 95% CI) 16.20 [-3.12, 35.52]
22.3 waist circumference (cm) 1 61 Mean Difference (IV, Random, 95% CI) 5.10 [-4.14, 14.34]
22.4 weight gain 2 94 Mean Difference (IV, Random, 95% CI) 0.34 [-0.84, 1.53]
23 Adverse effects: 8. sleep -
skewed data - average change
score (UKU) - short term (up
to 12 weeks)
Other data No numeric data
24 Quality of life: average endpoint
score (QLS, high=good) - short
term (up to 12 weeks)
1 30 Mean Difference (IV, Random, 95% CI) 0.80 [-5.44, 7.04]
Comparison 3. SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mental state: 1. no clinically
signiﬁcant response (deﬁned by
PANSS/BPRS) - short term
(up to 12 weeks)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 deﬁned by PANSS/BPRS
<20% decline
6 864 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.52, 0.78]
1.2 deﬁned by PANSS/BPRS
<20% decline (without studies
with >50% left the study early)
3 589 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.67, 0.88]
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Analysis 1.1. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 1 Mental state: no clinically signiﬁcant
response in psychotic symptoms (deﬁned by various scale total score change) - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 1 Mental state: no clinically signiﬁcant response in psychotic symptoms (deﬁned by various scale total score change) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 deﬁned by PANSS<30% decline
Durgam 2014 78/138 120/148 45.4 % 0.70 [ 0.59, 0.82 ]
Potkin 2003 57/95 79/103 32.6 % 0.78 [ 0.64, 0.95 ]
Potkin 2006 76/152 45/71 22.1 % 0.79 [ 0.62, 1.00 ]
Subtotal (95% CI) 385 322 100.0 % 0.74 [ 0.67, 0.83 ]
Total events: 211 (Risperidone), 244 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.08, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 5.20 (P < 0.00001)
2 deﬁned by PANSS/BPRS <20% decline
Borison 1992 18/51 37/53 13.7 % 0.51 [ 0.33, 0.76 ]
Chouinard 1992 6/22 19/22 6.7 % 0.32 [ 0.16, 0.64 ]
Marder 1994a 27/63 50/64 17.9 % 0.55 [ 0.40, 0.75 ]
Potkin 1997 30/85 44/83 16.1 % 0.67 [ 0.47, 0.95 ]
Potkin 2003 57/95 79/103 23.9 % 0.78 [ 0.64, 0.95 ]
Potkin 2006 76/152 45/71 21.7 % 0.79 [ 0.62, 1.00 ]
Subtotal (95% CI) 468 396 100.0 % 0.64 [ 0.52, 0.78 ]
Total events: 214 (Risperidone), 274 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 12.27, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 4.33 (P = 0.000015)
Test for subgroup differences: Chi2 = 1.75, df = 1 (P = 0.19), I2 =43%
0.1 0.2 0.5 1 2 5 10
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Analysis 1.2. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 2 Leaving the study early - short term
(up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 2 Leaving the study early - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason
Pai 2002 3/25 5/25 0.8 % 0.60 [ 0.16, 2.25 ]
Chouinard 1992 5/22 16/22 2.0 % 0.31 [ 0.14, 0.70 ]
Geffen 2010 20/91 37/93 5.5 % 0.55 [ 0.35, 0.88 ]
Potkin 2006 27/153 28/73 5.7 % 0.46 [ 0.29, 0.72 ]
Potkin 1997 27/85 27/83 6.0 % 0.98 [ 0.63, 1.52 ]
Marder 1994a 28/64 44/66 9.5 % 0.66 [ 0.47, 0.91 ]
Borison 1992 26/51 37/53 9.7 % 0.73 [ 0.53, 1.01 ]
Potkin 2003 37/99 51/103 9.7 % 0.75 [ 0.55, 1.04 ]
Durgam 2014 39/140 72/151 10.0 % 0.58 [ 0.43, 0.80 ]
Potkin 2007 34/60 41/62 11.5 % 0.86 [ 0.65, 1.14 ]
Downing 2014 46/142 124/295 12.1 % 0.77 [ 0.59, 1.01 ]
Heisterberg 2007 74/154 100/149 17.5 % 0.72 [ 0.59, 0.87 ]
Subtotal (95% CI) 1086 1175 100.0 % 0.69 [ 0.62, 0.78 ]
Total events: 366 (Risperidone), 582 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.73, df = 11 (P = 0.20); I2 =25%
Test for overall effect: Z = 6.07 (P < 0.00001)
2 due to adverse events
Potkin 1997 6/85 0/83 1.0 % 12.70 [ 0.73, 221.87 ]
Chouinard 1992 1/22 1/22 1.1 % 1.00 [ 0.07, 15.00 ]
Potkin 2006 7/153 1/73 1.8 % 3.34 [ 0.42, 26.64 ]
Potkin 2007 4/60 7/62 5.7 % 0.59 [ 0.18, 1.91 ]
Borison 1992 6/51 7/53 7.5 % 0.89 [ 0.32, 2.47 ]
Geffen 2010 9/91 7/93 8.8 % 1.31 [ 0.51, 3.38 ]
Potkin 2003 8/99 17/103 12.4 % 0.49 [ 0.22, 1.08 ]
Durgam 2014 13/140 22/151 18.8 % 0.64 [ 0.33, 1.22 ]
0.001 0.01 0.1 1 10 100 1000
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(. . . Continued)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Downing 2014 12/142 33/295 19.8 % 0.76 [ 0.40, 1.42 ]
Heisterberg 2007 18/154 22/149 23.2 % 0.79 [ 0.44, 1.41 ]
Subtotal (95% CI) 997 1084 100.0 % 0.78 [ 0.59, 1.03 ]
Total events: 84 (Risperidone), 117 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.90, df = 9 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
3 due to lack of efﬁcacy
Chouinard 1992 1/22 10/22 1.9 % 0.10 [ 0.01, 0.72 ]
Potkin 2006 4/153 9/73 5.0 % 0.21 [ 0.07, 0.67 ]
Potkin 1997 4/85 11/83 5.3 % 0.36 [ 0.12, 1.07 ]
Geffen 2010 4/91 18/93 5.8 % 0.23 [ 0.08, 0.65 ]
Potkin 2003 8/99 17/103 8.8 % 0.49 [ 0.22, 1.08 ]
Borison 1992 8/51 20/53 10.0 % 0.42 [ 0.20, 0.86 ]
Durgam 2014 10/140 33/151 11.1 % 0.33 [ 0.17, 0.64 ]
Downing 2014 10/142 48/295 11.5 % 0.43 [ 0.23, 0.83 ]
Potkin 2007 16/60 18/62 13.3 % 0.92 [ 0.52, 1.63 ]
Marder 1994a 11/64 40/66 13.3 % 0.28 [ 0.16, 0.50 ]
Heisterberg 2007 15/154 40/149 13.9 % 0.36 [ 0.21, 0.63 ]
Subtotal (95% CI) 1061 1150 100.0 % 0.39 [ 0.29, 0.51 ]
Total events: 91 (Risperidone), 264 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 14.70, df = 10 (P = 0.14); I2 =32%
Test for overall effect: Z = 6.66 (P < 0.00001)
4 due to noncompliance
Potkin 2003 1/99 0/103 13.1 % 3.12 [ 0.13, 75.69 ]
Geffen 2010 0/91 3/93 14.9 % 0.15 [ 0.01, 2.79 ]
Chouinard 1992 1/22 2/22 21.6 % 0.50 [ 0.05, 5.12 ]
Borison 1992 9/51 4/53 50.3 % 2.34 [ 0.77, 7.12 ]
Subtotal (95% CI) 263 271 100.0 % 1.15 [ 0.33, 4.05 ]
Total events: 11 (Risperidone), 9 (Placebo)
Heterogeneity: Tau2 = 0.50; Chi2 = 4.18, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.22 (P = 0.83)
5 lost to follow-up
Durgam 2014 0/140 0/151 Not estimable
Borison 1992 0/51 2/53 10.3 % 0.21 [ 0.01, 4.22 ]
Geffen 2010 5/91 1/93 15.7 % 5.11 [ 0.61, 42.89 ]
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(. . . Continued)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Downing 2014 3/142 9/295 23.3 % 0.69 [ 0.19, 2.52 ]
Heisterberg 2007 8/154 4/149 24.5 % 1.94 [ 0.60, 6.29 ]
Potkin 2006 5/153 11/73 26.1 % 0.22 [ 0.08, 0.60 ]
Subtotal (95% CI) 731 814 100.0 % 0.79 [ 0.25, 2.56 ]
Total events: 21 (Risperidone), 27 (Placebo)
Heterogeneity: Tau2 = 1.09; Chi2 = 11.97, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 0.38 (P = 0.70)
6 protocol violation
Potkin 2006 0/153 2/73 5.6 % 0.10 [ 0.00, 1.98 ]
Durgam 2014 1/140 1/151 6.7 % 1.08 [ 0.07, 17.08 ]
Downing 2014 3/142 5/295 25.3 % 1.25 [ 0.30, 5.14 ]
Heisterberg 2007 8/154 10/149 62.5 % 0.77 [ 0.31, 1.91 ]
Subtotal (95% CI) 589 668 100.0 % 0.79 [ 0.39, 1.62 ]
Total events: 12 (Risperidone), 18 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.34, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
7 reported death
Borison 1992 0/51 0/53 Not estimable
Potkin 2007 0/59 0/62 Not estimable
Chouinard 1992 0/22 0/22 Not estimable
Potkin 2006 0/153 0/73 Not estimable
Pai 2002 0/25 0/25 Not estimable
Marder 1994a 0/64 0/66 Not estimable
Heisterberg 2007 0/154 0/149 Not estimable
Potkin 2003 0/99 0/103 Not estimable
Potkin 1997 0/85 0/83 Not estimable
Geffen 2010 1/91 0/93 100.0 % 3.07 [ 0.13, 74.28 ]
Subtotal (95% CI) 803 729 100.0 % 3.07 [ 0.13, 74.28 ]
Total events: 1 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
8 withdrawal of consent
Geffen 2010 1/91 8/93 2.6 % 0.13 [ 0.02, 1.00 ]
Borison 1992 2/51 2/53 2.9 % 1.04 [ 0.15, 7.10 ]
Chouinard 1992 2/22 3/22 3.8 % 0.67 [ 0.12, 3.61 ]
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Potkin 2006 9/153 2/73 4.7 % 2.15 [ 0.48, 9.69 ]
Durgam 2014 15/140 14/151 20.9 % 1.16 [ 0.58, 2.31 ]
Downing 2014 18/142 26/295 29.8 % 1.44 [ 0.82, 2.53 ]
Heisterberg 2007 25/154 24/149 35.3 % 1.01 [ 0.60, 1.68 ]
Subtotal (95% CI) 753 836 100.0 % 1.12 [ 0.80, 1.56 ]
Total events: 72 (Risperidone), 79 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.36, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.65 (P = 0.51)
9 other
Durgam 2014 0/140 2/151 1.9 % 0.22 [ 0.01, 4.45 ]
Potkin 2007 14/60 16/62 45.9 % 0.90 [ 0.48, 1.69 ]
Potkin 2003 20/99 17/103 52.2 % 1.22 [ 0.68, 2.20 ]
Subtotal (95% CI) 299 316 100.0 % 1.03 [ 0.68, 1.57 ]
Total events: 34 (Risperidone), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.3. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 3 Global state: 1. average endpoint
scores of CGI severity scale (high=poor) - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chouinard 1992 22 2.7 (1.1) 22 4 (1.3) 1.3 % -1.30 [ -2.01, -0.59 ]
Durgam 2014 138 -1.5 (0.1) 148 -0.7 (0.1) 95.2 % -0.80 [ -0.82, -0.78 ]
Marder 1994a 63 3 (1.3) 64 3.9 (1.2) 3.4 % -0.90 [ -1.34, -0.46 ]
Total (95% CI) 223 234 100.0 % -0.81 [ -0.89, -0.73 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.09, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 19.34 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 4 Global state: 2. no signiﬁcant clinical
improvement CGI - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 4 Global state: 2. no signiﬁcant clinical improvement CGI - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Marder 1994a 24/63 45/64 19.4 % 0.54 [ 0.38, 0.77 ]
Pai 2002 7/22 14/20 6.9 % 0.45 [ 0.23, 0.89 ]
Potkin 2003 60/99 79/103 37.0 % 0.79 [ 0.65, 0.96 ]
Potkin 2006 84/152 54/71 36.7 % 0.73 [ 0.60, 0.88 ]
Total (95% CI) 336 258 100.0 % 0.69 [ 0.57, 0.83 ]
Total events: 175 (Risperidone), 192 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.43, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 3.91 (P = 0.000091)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 1.5. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 5 Global state: 3. needing additional
medication - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 5 Global state: 3. needing additional medication - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 benzodiazepine
Pai 2002 19/22 18/20 100.0 % 0.96 [ 0.77, 1.20 ]
Subtotal (95% CI) 22 20 100.0 % 0.96 [ 0.77, 1.20 ]
Total events: 19 (Risperidone), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 benzodiazepine derivatives - Lorazepam
Borison 1992 9/22 11/22 22.6 % 0.82 [ 0.43, 1.57 ]
Geffen 2010 36/91 38/93 77.4 % 0.97 [ 0.68, 1.38 ]
Subtotal (95% CI) 113 115 100.0 % 0.93 [ 0.68, 1.27 ]
Total events: 45 (Risperidone), 49 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
3 benzodiazepine derivatives - Nitrazepam
Geffen 2010 2/91 4/93 100.0 % 0.51 [ 0.10, 2.72 ]
Subtotal (95% CI) 91 93 100.0 % 0.51 [ 0.10, 2.72 ]
Total events: 2 (Risperidone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
4 benzodiazepine related drugs - Zolpidem
Geffen 2010 26/91 33/93 100.0 % 0.81 [ 0.53, 1.23 ]
Subtotal (95% CI) 91 93 100.0 % 0.81 [ 0.53, 1.23 ]
Total events: 26 (Risperidone), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
5 sedative/hypnotic
Chouinard 1992 13/22 15/22 22.8 % 0.87 [ 0.55, 1.36 ]
Potkin 2006 75/133 35/53 77.2 % 0.85 [ 0.67, 1.09 ]
Subtotal (95% CI) 155 75 100.0 % 0.86 [ 0.69, 1.06 ]
Total events: 88 (Risperidone), 50 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
0.5 0.7 1 1.5 2
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(. . . Continued)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.41 (P = 0.16)
6 antiparkinsonian
Marder 1994a 13/64 12/66 37.0 % 1.12 [ 0.55, 2.26 ]
Pai 2002 14/22 10/20 63.0 % 1.27 [ 0.74, 2.18 ]
Subtotal (95% CI) 86 86 100.0 % 1.21 [ 0.79, 1.86 ]
Total events: 27 (Risperidone), 22 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
7 psychotropics
Potkin 2006 48/133 31/53 100.0 % 0.62 [ 0.45, 0.85 ]
Subtotal (95% CI) 133 53 100.0 % 0.62 [ 0.45, 0.85 ]
Total events: 48 (Risperidone), 31 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0031)
Test for subgroup differences: Chi2 = 8.20, df = 6 (P = 0.22), I2 =27%
0.5 0.7 1 1.5 2
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Analysis 1.6. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 6 Mental state: 1. average endpoint
scores on various scales on psychotic symptoms (high=poor) - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
Chouinard 1992 22 41.5 (12.5) 22 57.6 (15.6) 27.4 % -16.10 [ -24.45, -7.75 ]
Marder 1994a 63 44.6 (14.7) 64 56 (14.8) 72.6 % -11.40 [ -16.53, -6.27 ]
Subtotal (95% CI) 85 86 100.0 % -12.69 [ -17.06, -8.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 5.69 (P < 0.00001)
2 PANSS total
Chouinard 1992 22 72.3 (20.1) 22 98.3 (25.3) 0.1 % -26.00 [ -39.50, -12.50 ]
Durgam 2014 138 -29.6 (1.6) 148 -11.8 (1.5) 99.7 % -17.80 [ -18.16, -17.44 ]
Marder 1994a 63 77.7 (24.3) 64 95.5 (24) 0.2 % -17.80 [ -26.20, -9.40 ]
Subtotal (95% CI) 223 234 100.0 % -17.81 [ -18.17, -17.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.42, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 97.04 (P < 0.00001)
3 PANSS general pathology
Chouinard 1992 22 35.3 (10) 22 48.5 (13.3) 100.0 % -13.20 [ -20.15, -6.25 ]
Subtotal (95% CI) 22 22 100.0 % -13.20 [ -20.15, -6.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.72 (P = 0.00020)
4 PANSS negative symptom
Chouinard 1992 22 20.4 (5.7) 22 24.4 (6.9) 0.1 % -4.00 [ -7.74, -0.26 ]
Durgam 2014 138 -5.1 (0.4) 148 -2 (0.4) 99.8 % -3.10 [ -3.19, -3.01 ]
Marder 1994a 63 21.9 (7.8) 64 24.2 (6.9) 0.1 % -2.30 [ -4.86, 0.26 ]
Subtotal (95% CI) 223 234 100.0 % -3.10 [ -3.19, -3.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 65.54 (P < 0.00001)
5 PANSS positive symptom
Chouinard 1992 22 16.6 (7) 22 25.5 (8.7) 2.1 % -8.90 [ -13.57, -4.23 ]
Durgam 2014 138 -9.5 (0.5) 148 -4.1 (0.5) 91.9 % -5.40 [ -5.52, -5.28 ]
Marder 1994a 63 18.8 (8) 64 24.4 (7.8) 5.9 % -5.60 [ -8.35, -2.85 ]
-50 -25 0 25 50
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(. . . Continued)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 223 234 100.0 % -5.49 [ -6.18, -4.80 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 2.18, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 15.57 (P < 0.00001)
-50 -25 0 25 50
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Analysis 1.7. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 7 Mental state: 2. skewed data - short
term (up to 12 weeks).
Mental state: 2. skewed data - short term (up to 12 weeks)
Study Intervention Mean SD N
average endpoint score BPRS total (high=poor)
Pai 2002 Resperidone 14.7 7.4 22
Pai 2002 Placebo 19.0 12.2 20
average change score of CGI-C (larger decline=good)
Potkin 2006 Resperidone 2.4 1.23 152
Potkin 2006 Placebo 2.9 0.84 71
average change score of CGI-SI (larger decline=good)
Potkin 2006 Resperidone -1.84 1.23 152
Potkin 2006 Placebo -1.1 0.84 71
average change score of HAM-D-17 (larger decline=good)
Potkin 2006 Resperidone -5.6 4.93 152
Potkin 2006 Placebo -4.4 4.21 71
average change score of PANSS total (larger decline=good)
Potkin 2006 Resperidone -27.7 18.49 152
Potkin 2006 Placebo -20.2 16.85 71
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Mental state: 2. skewed data - short term (up to 12 weeks) (Continued)
average change score of PANSS negative symptom (larger decline=good)
Potkin 2006 Resperidone -4.0 4.93 152
Potkin 2006 Placebo -3.5 5.06 71
average change score of PANSS positive symptom (larger decline=good)
Potkin 2006 Resperidone -8.7 6.16 152
Potkin 2006 Placebo -5.3 5.9 71
Analysis 1.8. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 8 Adverse effects: 1a. extrapyramidal -
various effects - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 8 Adverse effects: 1a. extrapyramidal - various effects - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 general - any signiﬁcant EPS
Borison 1992 11/51 11/53 17.0 % 1.04 [ 0.49, 2.18 ]
Chouinard 1992 5/22 4/22 7.2 % 1.25 [ 0.39, 4.05 ]
Downing 2014 0/142 3/295 1.2 % 0.30 [ 0.02, 5.69 ]
Durgam 2014 18/140 7/151 13.5 % 2.77 [ 1.19, 6.44 ]
Heisterberg 2007 21/154 8/149 15.4 % 2.54 [ 1.16, 5.55 ]
Marder 1994a 7/64 7/66 10.0 % 1.03 [ 0.38, 2.77 ]
Potkin 2003 31/99 21/103 35.9 % 1.54 [ 0.95, 2.48 ]
Subtotal (95% CI) 672 839 100.0 % 1.56 [ 1.13, 2.15 ]
Total events: 93 (Risperidone), 61 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.48, df = 6 (P = 0.37); I2 =7%
Test for overall effect: Z = 2.72 (P = 0.0065)
2 general - no improvement on AIMS score
Pai 2002 6/22 18/20 100.0 % 0.30 [ 0.15, 0.61 ]
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 22 20 100.0 % 0.30 [ 0.15, 0.61 ]
Total events: 6 (Risperidone), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00080)
3 general - no improvement on BAS score
Potkin 2006 143/153 60/73 100.0 % 1.14 [ 1.01, 1.28 ]
Subtotal (95% CI) 153 73 100.0 % 1.14 [ 1.01, 1.28 ]
Total events: 143 (Risperidone), 60 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
4 general - needing medication for EPS
Chouinard 1992 7/22 6/22 17.2 % 1.17 [ 0.47, 2.92 ]
Pai 2002 17/25 15/25 82.8 % 1.13 [ 0.75, 1.72 ]
Subtotal (95% CI) 47 47 100.0 % 1.14 [ 0.78, 1.67 ]
Total events: 24 (Risperidone), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
5 speciﬁc - akathisia
Durgam 2014 12/140 7/151 27.4 % 1.85 [ 0.75, 4.56 ]
Geffen 2010 14/89 1/93 8.0 % 14.63 [ 1.96, 108.95 ]
Heisterberg 2007 16/154 5/149 24.8 % 3.10 [ 1.16, 8.24 ]
Potkin 2003 14/99 9/103 31.9 % 1.62 [ 0.73, 3.57 ]
Potkin 2006 11/153 1/73 7.9 % 5.25 [ 0.69, 39.88 ]
Subtotal (95% CI) 635 569 100.0 % 2.58 [ 1.41, 4.72 ]
Total events: 67 (Risperidone), 23 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 5.63, df = 4 (P = 0.23); I2 =29%
Test for overall effect: Z = 3.07 (P = 0.0021)
6 speciﬁc - bradykinesia
Geffen 2010 33/89 39/93 98.6 % 0.88 [ 0.62, 1.27 ]
Heisterberg 2007 0/154 2/149 1.4 % 0.19 [ 0.01, 4.00 ]
Subtotal (95% CI) 243 242 100.0 % 0.87 [ 0.60, 1.24 ]
Total events: 33 (Risperidone), 41 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
7 speciﬁc - dyskinesia
Heisterberg 2007 0/154 1/149 100.0 % 0.32 [ 0.01, 7.86 ]
Subtotal (95% CI) 154 149 100.0 % 0.32 [ 0.01, 7.86 ]
Total events: 0 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
0.01 0.1 1 10 100
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.69 (P = 0.49)
8 speciﬁc - dystonia
Geffen 2010 22/89 38/93 40.4 % 0.60 [ 0.39, 0.94 ]
Heisterberg 2007 11/154 1/149 32.6 % 10.64 [ 1.39, 81.42 ]
Potkin 2003 5/99 0/103 27.0 % 11.44 [ 0.64, 204.21 ]
Subtotal (95% CI) 342 345 100.0 % 3.40 [ 0.26, 44.46 ]
Total events: 38 (Risperidone), 39 (Placebo)
Heterogeneity: Tau2 = 4.20; Chi2 = 13.09, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 0.93 (P = 0.35)
9 speciﬁc - hypertonia
Geffen 2010 20/89 4/93 38.3 % 5.22 [ 1.86, 14.69 ]
Potkin 2003 9/99 6/103 40.2 % 1.56 [ 0.58, 4.22 ]
Potkin 2007 7/59 2/62 21.6 % 3.68 [ 0.80, 16.99 ]
Subtotal (95% CI) 247 258 100.0 % 2.98 [ 1.35, 6.59 ]
Total events: 36 (Risperidone), 12 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 2.87, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 2.70 (P = 0.0070)
10 speciﬁc - parkinsonism
Geffen 2010 9/89 1/93 68.7 % 9.40 [ 1.22, 72.72 ]
Heisterberg 2007 2/154 0/149 31.3 % 4.84 [ 0.23, 99.95 ]
Subtotal (95% CI) 243 242 100.0 % 7.64 [ 1.40, 41.59 ]
Total events: 11 (Risperidone), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
11 speciﬁc - tardive dyskinesia
Heisterberg 2007 3/154 0/149 100.0 % 6.77 [ 0.35, 130.03 ]
Subtotal (95% CI) 154 149 100.0 % 6.77 [ 0.35, 130.03 ]
Total events: 3 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
12 speciﬁc - tremor
Durgam 2014 10/140 5/151 21.0 % 2.16 [ 0.76, 6.16 ]
Geffen 2010 19/89 10/93 33.1 % 1.99 [ 0.98, 4.03 ]
Heisterberg 2007 7/154 7/149 21.7 % 0.97 [ 0.35, 2.69 ]
Potkin 2003 2/99 5/103 10.9 % 0.42 [ 0.08, 2.10 ]
Potkin 2006 17/153 2/73 13.2 % 4.06 [ 0.96, 17.09 ]
Subtotal (95% CI) 635 569 100.0 % 1.60 [ 0.89, 2.88 ]
0.01 0.1 1 10 100
Favours Risperidone Favours Placebo
(Continued . . . )
111Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 55 (Risperidone), 29 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 5.86, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 1.57 (P = 0.12)
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Analysis 1.9. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 9 Adverse effects: 1b. extrapyramidal -
AIMS average endpoint score - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 9 Adverse effects: 1b. extrapyramidal - AIMS average endpoint score - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pai 2002 22 9.9 (4.4) 20 15.4 (5.7) -5.50 [ -8.60, -2.40 ]
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Analysis 1.10. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 10 Adverse effects: 1c. extrapyramidal
- skewed data (various scales) - short term (up to 12 weeks).
Adverse effects: 1c. extrapyramidal - skewed data (various scales) - short term (up to 12 weeks)
Study Intervention Mean SD N
average change score of AIMS
Potkin 2006 Risperidone 0.3 2.47 153
Potkin 2006 Placebo -0.1 2.56 73
112Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Adverse effects: 1c. extrapyramidal - skewed data (various scales) - short term (up to 12 weeks) (Continued)
average change score of CGI severity dyskinesia
Chouinard 1992 Risperidone 0.3 3.3 22
Chouinard 1992 Placebo 3.5 5.3 22
average change score of CGI severity parkinsonism
Chouinard 1992 Risperidone 0.9 1.5 22
Chouinard 1992 Placebo 0.4 1.3 22
average change score of ESRS
Marder 1994a Risperidone 2.9 5.7 63
Marder 1994a Placebo 2.4 5.8 65
average change score of ESRS - akathisia
Marder 1994a Risperidone 0.6 1.1 63
Marder 1994a Placebo 0.6 1.6 65
average change score of ESRS - dystonia
Chouinard 1992 Risperidone 0.3 0.8 22
Chouinard 1992 Placebo 1.0 2.3 22
Marder 1994a Risperidone 1.3 1.3 63
Marder 1994a Placebo 1.6 1.5 64
Pai 2002 Risperidone 2.1 1.7 22
Pai 2002 Placebo 2.8 1.8 20
average change score of ESRS - dyskinesia
Chouinard 1992 Risperidone 2.6 4.5 22
Chouinard 1992 Placebo 5.7 7.2 SD
Marder 1994a Risperidone 0.6 1.1 63
Marder 1994a Placebo 0.5 1.1 65
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Adverse effects: 1c. extrapyramidal - skewed data (various scales) - short term (up to 12 weeks) (Continued)
average change score of ESRS - parkinsonism
Chouinard 1992 Risperidone 2.1 7.5 22
Chouinard 1992 Placebo 2.3 8.7 22
Marder 1994a Risperidone 0.6 1.1 63
Marder 1994a Placebo 0.5 1.1 65
Pai 2002 Risperidone 2.1 1.3 22
Pai 2002 Placebo 2.5 1.5 20
Analysis 1.11. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 11 Adverse effects: 2. any adverse
event - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 11 Adverse effects: 2. any adverse event - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any adverse event
Borison 1992 26/51 37/53 6.1 % 0.73 [ 0.53, 1.01 ]
Downing 2014 82/142 177/295 13.9 % 0.96 [ 0.81, 1.14 ]
Durgam 2014 95/140 100/151 14.5 % 1.02 [ 0.87, 1.20 ]
Geffen 2010 80/89 64/93 15.1 % 1.31 [ 1.12, 1.52 ]
Potkin 1997 77/85 72/83 19.3 % 1.04 [ 0.94, 1.16 ]
Potkin 2003 92/99 89/103 20.7 % 1.08 [ 0.98, 1.18 ]
Potkin 2006 100/153 44/73 10.4 % 1.08 [ 0.87, 1.35 ]
Subtotal (95% CI) 759 851 100.0 % 1.05 [ 0.96, 1.15 ]
Total events: 552 (Risperidone), 583 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.46, df = 6 (P = 0.02); I2 =58%
Test for overall effect: Z = 1.10 (P = 0.27)
2 asthenia
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(. . . Continued)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Downing 2014 4/142 2/295 36.4 % 4.15 [ 0.77, 22.42 ]
Potkin 2003 6/99 5/103 63.6 % 1.25 [ 0.39, 3.96 ]
Subtotal (95% CI) 241 398 100.0 % 1.93 [ 0.62, 6.02 ]
Total events: 10 (Risperidone), 7 (Placebo)
Heterogeneity: Tau2 = 0.18; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.14 (P = 0.25)
3 back pain
Potkin 2003 7/99 7/103 100.0 % 1.04 [ 0.38, 2.86 ]
Subtotal (95% CI) 99 103 100.0 % 1.04 [ 0.38, 2.86 ]
Total events: 7 (Risperidone), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
4 blurred vision
Potkin 2003 4/99 1/103 100.0 % 4.16 [ 0.47, 36.59 ]
Subtotal (95% CI) 99 103 100.0 % 4.16 [ 0.47, 36.59 ]
Total events: 4 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
5 cogwheel rigidity
Potkin 2006 11/153 1/73 100.0 % 5.25 [ 0.69, 39.88 ]
Subtotal (95% CI) 153 73 100.0 % 5.25 [ 0.69, 39.88 ]
Total events: 11 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
6 death
Geffen 2010 1/89 0/93 100.0 % 3.13 [ 0.13, 75.92 ]
Subtotal (95% CI) 89 93 100.0 % 3.13 [ 0.13, 75.92 ]
Total events: 1 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
7 dental disorder
Potkin 2003 7/99 2/103 100.0 % 3.64 [ 0.78, 17.11 ]
Subtotal (95% CI) 99 103 100.0 % 3.64 [ 0.78, 17.11 ]
Total events: 7 (Risperidone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
8 dysmenorrhoea
Downing 2014 1/142 0/295 48.6 % 6.21 [ 0.25, 151.49 ]
Potkin 2003 0/28 2/30 51.4 % 0.21 [ 0.01, 4.27 ]
Subtotal (95% CI) 170 325 100.0 % 1.10 [ 0.04, 30.00 ]
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 1 (Risperidone), 2 (Placebo)
Heterogeneity: Tau2 = 3.20; Chi2 = 2.28, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.06 (P = 0.96)
9 fatigue
Downing 2014 3/142 1/295 25.3 % 6.23 [ 0.65, 59.39 ]
Potkin 2007 6/59 4/62 74.7 % 1.58 [ 0.47, 5.31 ]
Subtotal (95% CI) 201 357 100.0 % 2.23 [ 0.69, 7.22 ]
Total events: 9 (Risperidone), 5 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 1.34 (P = 0.18)
10 fever
Marder 1994a 4/64 0/66 100.0 % 9.28 [ 0.51, 168.90 ]
Subtotal (95% CI) 64 66 100.0 % 9.28 [ 0.51, 168.90 ]
Total events: 4 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
11 infection
Potkin 2003 2/99 4/103 100.0 % 0.52 [ 0.10, 2.78 ]
Subtotal (95% CI) 99 103 100.0 % 0.52 [ 0.10, 2.78 ]
Total events: 2 (Risperidone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.44)
12 salivation - increased
Potkin 2003 3/99 0/103 100.0 % 7.28 [ 0.38, 139.15 ]
Subtotal (95% CI) 99 103 100.0 % 7.28 [ 0.38, 139.15 ]
Total events: 3 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
13 pyrexia
Geffen 2010 8/89 7/93 100.0 % 1.19 [ 0.45, 3.16 ]
Subtotal (95% CI) 89 93 100.0 % 1.19 [ 0.45, 3.16 ]
Total events: 8 (Risperidone), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
14 pain
Potkin 2007 6/59 4/62 100.0 % 1.58 [ 0.47, 5.31 ]
Subtotal (95% CI) 59 62 100.0 % 1.58 [ 0.47, 5.31 ]
Total events: 6 (Risperidone), 4 (Placebo)
Heterogeneity: not applicable
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.73 (P = 0.46)
15 rash (skin)
Potkin 2003 8/99 7/103 100.0 % 1.19 [ 0.45, 3.16 ]
Subtotal (95% CI) 99 103 100.0 % 1.19 [ 0.45, 3.16 ]
Total events: 8 (Risperidone), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
16 vaginitis
Potkin 2003 1/28 1/30 100.0 % 1.07 [ 0.07, 16.32 ]
Subtotal (95% CI) 28 30 100.0 % 1.07 [ 0.07, 16.32 ]
Total events: 1 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
17 hyperhidrosis
Downing 2014 2/142 0/295 100.0 % 10.35 [ 0.50, 214.17 ]
Subtotal (95% CI) 142 295 100.0 % 10.35 [ 0.50, 214.17 ]
Total events: 2 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 16.44, df = 16 (P = 0.42), I2 =3%
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Analysis 1.12. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 12 Adverse effects: 3. cardiovascular -
short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 12 Adverse effects: 3. cardiovascular - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 dizziness - orthostatic
Chouinard 1992 1/22 0/22 100.0 % 3.00 [ 0.13, 69.87 ]
Subtotal (95% CI) 22 22 100.0 % 3.00 [ 0.13, 69.87 ]
Total events: 1 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
2 ECG abnormal
Geffen 2010 4/89 0/93 100.0 % 9.40 [ 0.51, 172.11 ]
Subtotal (95% CI) 89 93 100.0 % 9.40 [ 0.51, 172.11 ]
Total events: 4 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
3 heart rate decreased
Geffen 2010 1/89 2/93 100.0 % 0.52 [ 0.05, 5.66 ]
Subtotal (95% CI) 89 93 100.0 % 0.52 [ 0.05, 5.66 ]
Total events: 1 (Risperidone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
4 heart rate increased
Geffen 2010 9/89 11/93 100.0 % 0.85 [ 0.37, 1.96 ]
Subtotal (95% CI) 89 93 100.0 % 0.85 [ 0.37, 1.96 ]
Total events: 9 (Risperidone), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
5 hypotension - postural
Chouinard 1992 1/22 0/22 100.0 % 3.00 [ 0.13, 69.87 ]
Subtotal (95% CI) 22 22 100.0 % 3.00 [ 0.13, 69.87 ]
Total events: 1 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
6 QTc > 450 milliseconds or > 10% increase from baseline
Geffen 2010 4/89 0/93 50.7 % 9.40 [ 0.51, 172.11 ]
Potkin 2003 3/95 0/103 49.3 % 7.58 [ 0.40, 144.91 ]
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 184 196 100.0 % 8.46 [ 1.07, 67.07 ]
Total events: 7 (Risperidone), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
7 tachycardia
Marder 1994a 3/64 0/66 31.7 % 7.22 [ 0.38, 136.96 ]
Potkin 2003 15/99 1/103 68.3 % 15.61 [ 2.10, 115.93 ]
Subtotal (95% CI) 163 169 100.0 % 12.22 [ 2.33, 64.10 ]
Total events: 18 (Risperidone), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
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Analysis 1.13. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 13 Adverse effects: 4. central nervous
system - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 13 Adverse effects: 4. central nervous system - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 agitation
Borison 1992 13/51 13/53 11.4 % 1.04 [ 0.53, 2.02 ]
Chouinard 1992 12/22 10/22 14.3 % 1.20 [ 0.66, 2.18 ]
Downing 2014 1/142 3/295 1.0 % 0.69 [ 0.07, 6.60 ]
Geffen 2010 21/89 25/93 20.1 % 0.88 [ 0.53, 1.45 ]
Marder 1994a 7/64 5/66 4.2 % 1.44 [ 0.48, 4.32 ]
Potkin 1997 19/85 24/83 18.7 % 0.77 [ 0.46, 1.30 ]
Potkin 2003 22/99 24/103 19.6 % 0.95 [ 0.57, 1.59 ]
Potkin 2007 11/59 15/62 10.6 % 0.77 [ 0.39, 1.54 ]
Subtotal (95% CI) 611 777 100.0 % 0.93 [ 0.75, 1.17 ]
Total events: 106 (Risperidone), 119 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.33, df = 7 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 anxiety
Chouinard 1992 9/22 9/22 25.1 % 1.00 [ 0.49, 2.03 ]
Downing 2014 5/142 9/295 11.0 % 1.15 [ 0.39, 3.38 ]
Durgam 2014 3/140 5/151 6.3 % 0.65 [ 0.16, 2.66 ]
Marder 1994a 5/64 1/66 2.8 % 5.16 [ 0.62, 42.93 ]
Potkin 2003 18/99 19/103 37.3 % 0.99 [ 0.55, 1.77 ]
Potkin 2007 9/59 9/62 17.4 % 1.05 [ 0.45, 2.46 ]
Subtotal (95% CI) 526 699 100.0 % 1.04 [ 0.73, 1.48 ]
Total events: 49 (Risperidone), 52 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.74, df = 5 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
3 dizziness
Durgam 2014 8/140 3/151 19.9 % 2.88 [ 0.78, 10.63 ]
Marder 1994a 6/64 0/66 6.3 % 13.40 [ 0.77, 233.08 ]
Potkin 2003 11/99 9/103 29.9 % 1.27 [ 0.55, 2.94 ]
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Potkin 2006 9/153 3/73 20.4 % 1.43 [ 0.40, 5.13 ]
Potkin 2007 4/59 9/62 23.4 % 0.47 [ 0.15, 1.44 ]
Subtotal (95% CI) 515 455 100.0 % 1.41 [ 0.65, 3.05 ]
Total events: 38 (Risperidone), 24 (Placebo)
Heterogeneity: Tau2 = 0.34; Chi2 = 7.37, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 0.87 (P = 0.39)
4 headache
Borison 1992 13/51 9/53 7.1 % 1.50 [ 0.70, 3.20 ]
Chouinard 1992 4/22 5/22 2.9 % 0.80 [ 0.25, 2.59 ]
Downing 2014 11/142 27/295 9.0 % 0.85 [ 0.43, 1.66 ]
Durgam 2014 12/140 16/151 8.0 % 0.81 [ 0.40, 1.65 ]
Geffen 2010 10/89 9/93 5.6 % 1.16 [ 0.50, 2.72 ]
Marder 1994a 10/64 3/66 2.6 % 3.44 [ 0.99, 11.92 ]
Potkin 1997 27/85 33/83 24.2 % 0.80 [ 0.53, 1.20 ]
Potkin 2003 31/99 28/103 21.9 % 1.15 [ 0.75, 1.77 ]
Potkin 2006 22/153 10/73 8.4 % 1.05 [ 0.52, 2.10 ]
Potkin 2007 13/59 17/62 10.3 % 0.80 [ 0.43, 1.51 ]
Subtotal (95% CI) 904 1001 100.0 % 0.99 [ 0.81, 1.21 ]
Total events: 153 (Risperidone), 157 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.81, df = 9 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
5 insomnia
Borison 1992 16/51 13/53 8.3 % 1.28 [ 0.69, 2.38 ]
Chouinard 1992 12/22 8/22 7.1 % 1.50 [ 0.77, 2.94 ]
Downing 2014 10/142 21/295 6.1 % 0.99 [ 0.48, 2.04 ]
Durgam 2014 21/140 11/151 6.7 % 2.06 [ 1.03, 4.11 ]
Geffen 2010 23/89 22/93 12.4 % 1.09 [ 0.66, 1.81 ]
Marder 1994a 8/64 6/66 3.2 % 1.38 [ 0.51, 3.74 ]
Potkin 1997 41/85 35/83 28.6 % 1.14 [ 0.82, 1.60 ]
Potkin 2003 20/99 23/103 11.3 % 0.90 [ 0.53, 1.54 ]
Potkin 2006 29/153 17/73 11.4 % 0.81 [ 0.48, 1.38 ]
Potkin 2007 13/59 8/62 4.9 % 1.71 [ 0.76, 3.82 ]
Subtotal (95% CI) 904 1001 100.0 % 1.16 [ 0.97, 1.39 ]
Total events: 193 (Risperidone), 164 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.10, df = 9 (P = 0.63); I2 =0.0%
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.62 (P = 0.11)
6 sedation
Durgam 2014 16/140 5/151 50.9 % 3.45 [ 1.30, 9.17 ]
Potkin 2006 10/153 5/73 49.1 % 0.95 [ 0.34, 2.69 ]
Subtotal (95% CI) 293 224 100.0 % 1.84 [ 0.52, 6.50 ]
Total events: 26 (Risperidone), 10 (Placebo)
Heterogeneity: Tau2 = 0.57; Chi2 = 3.15, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.94 (P = 0.35)
7 somnolence
Borison 1992 2/51 1/53 3.1 % 2.08 [ 0.19, 22.22 ]
Marder 1994a 2/64 0/66 1.9 % 5.15 [ 0.25, 105.31 ]
Potkin 1997 22/85 9/83 34.3 % 2.39 [ 1.17, 4.88 ]
Potkin 2003 14/99 11/103 32.0 % 1.32 [ 0.63, 2.78 ]
Potkin 2006 4/153 2/73 6.2 % 0.95 [ 0.18, 5.09 ]
Potkin 2007 9/59 8/62 22.4 % 1.18 [ 0.49, 2.86 ]
Subtotal (95% CI) 511 440 100.0 % 1.61 [ 1.06, 2.45 ]
Total events: 53 (Risperidone), 31 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.91, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
8 restlessness
Downing 2014 4/142 5/295 44.0 % 1.66 [ 0.45, 6.09 ]
Geffen 2010 5/89 6/93 56.0 % 0.87 [ 0.28, 2.75 ]
Subtotal (95% CI) 231 388 100.0 % 1.16 [ 0.49, 2.74 ]
Total events: 9 (Risperidone), 11 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 1.14. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 14 Adverse effects: 5. endocrine -
serum prolactin increase above reference range (23 ng/ml) - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 14 Adverse effects: 5. endocrine - serum prolactin increase above reference range (23 ng/ml) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Potkin 2003 90/99 11/103 66.7 % 8.51 [ 4.85, 14.93 ]
Potkin 2007 47/59 2/62 33.3 % 24.69 [ 6.28, 97.13 ]
Total (95% CI) 158 165 100.0 % 12.14 [ 4.38, 33.68 ]
Total events: 137 (Risperidone), 13 (Placebo)
Heterogeneity: Tau2 = 0.32; Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 4.80 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 15 Adverse effects: 6. gastrointestinal
system - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 15 Adverse effects: 6. gastrointestinal system - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 constipation
Borison 1992 6/51 3/53 11.7 % 2.08 [ 0.55, 7.87 ]
Downing 2014 5/142 8/295 17.2 % 1.30 [ 0.43, 3.90 ]
Durgam 2014 13/140 5/151 20.5 % 2.80 [ 1.03, 7.66 ]
Geffen 2010 5/91 2/93 8.0 % 2.55 [ 0.51, 12.84 ]
Marder 1994a 1/64 0/66 2.1 % 3.09 [ 0.13, 74.54 ]
Potkin 2003 11/99 3/103 13.4 % 3.81 [ 1.10, 13.27 ]
Potkin 2006 10/153 3/73 13.1 % 1.59 [ 0.45, 5.61 ]
Potkin 2007 4/59 6/62 14.1 % 0.70 [ 0.21, 2.36 ]
Subtotal (95% CI) 799 896 100.0 % 1.88 [ 1.19, 2.96 ]
Total events: 55 (Risperidone), 30 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.16, df = 7 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0068)
2 diarrhoea
Potkin 2003 8/99 9/103 100.0 % 0.92 [ 0.37, 2.30 ]
Subtotal (95% CI) 99 103 100.0 % 0.92 [ 0.37, 2.30 ]
Total events: 8 (Risperidone), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
3 dry mouth
Potkin 2003 7/99 3/103 100.0 % 2.43 [ 0.65, 9.12 ]
Subtotal (95% CI) 99 103 100.0 % 2.43 [ 0.65, 9.12 ]
Total events: 7 (Risperidone), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
4 dyspepsia
Downing 2014 8/142 5/295 18.2 % 3.32 [ 1.11, 9.98 ]
Marder 1994a 6/64 3/66 14.6 % 2.06 [ 0.54, 7.90 ]
Potkin 1997 8/85 9/83 21.8 % 0.87 [ 0.35, 2.14 ]
Potkin 2003 12/99 22/103 27.1 % 0.57 [ 0.30, 1.08 ]
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Potkin 2007 7/59 5/62 18.4 % 1.47 [ 0.49, 4.38 ]
Subtotal (95% CI) 449 609 100.0 % 1.24 [ 0.64, 2.40 ]
Total events: 41 (Risperidone), 44 (Placebo)
Heterogeneity: Tau2 = 0.31; Chi2 = 9.21, df = 4 (P = 0.06); I2 =57%
Test for overall effect: Z = 0.62 (P = 0.53)
5 nausea
Chouinard 1992 2/22 1/22 3.8 % 2.00 [ 0.20, 20.49 ]
Downing 2014 5/142 14/295 20.6 % 0.74 [ 0.27, 2.02 ]
Durgam 2014 8/140 5/151 17.3 % 1.73 [ 0.58, 5.15 ]
Marder 1994a 4/64 0/66 2.5 % 9.28 [ 0.51, 168.90 ]
Potkin 2003 12/99 10/103 32.9 % 1.25 [ 0.57, 2.76 ]
Potkin 2007 7/59 8/62 22.9 % 0.92 [ 0.36, 2.38 ]
Subtotal (95% CI) 526 699 100.0 % 1.18 [ 0.75, 1.86 ]
Total events: 38 (Risperidone), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.76, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
6 vomiting
Downing 2014 5/142 6/295 23.7 % 1.73 [ 0.54, 5.58 ]
Durgam 2014 4/140 5/151 19.4 % 0.86 [ 0.24, 3.15 ]
Marder 1994a 4/64 1/66 7.1 % 4.13 [ 0.47, 35.92 ]
Potkin 2003 8/99 6/103 30.7 % 1.39 [ 0.50, 3.85 ]
Potkin 2007 3/59 7/62 19.1 % 0.45 [ 0.12, 1.66 ]
Subtotal (95% CI) 504 677 100.0 % 1.16 [ 0.65, 2.07 ]
Total events: 24 (Risperidone), 25 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.11, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 0.51 (P = 0.61)
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Analysis 1.16. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 16 Adverse effects: 7a. metabolic -
weight gain - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 16 Adverse effects: 7a. metabolic - weight gain - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any gain
Downing 2014 5/142 2/295 40.6 % 5.19 [ 1.02, 26.44 ]
Durgam 2014 7/140 1/151 24.8 % 7.55 [ 0.94, 60.59 ]
Geffen 2010 3/89 2/93 34.5 % 1.57 [ 0.27, 9.16 ]
Subtotal (95% CI) 371 539 100.0 % 3.77 [ 1.34, 10.63 ]
Total events: 15 (Risperidone), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.51 (P = 0.012)
2 >7% increase from baseline
Heisterberg 2007 17/154 7/149 63.2 % 2.35 [ 1.00, 5.50 ]
Potkin 2003 11/99 2/103 23.8 % 5.72 [ 1.30, 25.17 ]
Potkin 2007 8/47 1/54 13.0 % 9.19 [ 1.19, 70.81 ]
Subtotal (95% CI) 300 306 100.0 % 3.47 [ 1.64, 7.33 ]
Total events: 36 (Risperidone), 10 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 3.25 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 1.17. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 17 Adverse effects: 7b. metabolic -
skewed data - average change value on lipid proﬁle - short term (up to 12 weeks).
Adverse effects: 7b. metabolic - skewed data - average change value on lipid profile - short term (up to 12 weeks)
Study Intervention Mean SD N
cholesterol - total
Durgam 2014 Risperidone 4.6 34.6 140
Durgam 2014 Placebo -1.3 30.4 151
Heisterberg 2007 Risperidone -2.2 31.4 154
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Adverse effects: 7b. metabolic - skewed data - average change value on lipid profile - short term (up to 12 weeks) (Continued)
Heisterberg 2007 Placebo -14.2 32.0 149
HDL
Durgam 2014 Risperidone -0.6 10.1 140
Durgam 2014 Placebo -1.1 9.4 151
Heisterberg 2007 Risperidone 2.1 10.3 154
Heisterberg 2007 Placebo -0.7 6.8 149
LDL
Durgam 2014 Risperidone 3.8 30.6 140
Durgam 2014 Placebo -0.1 25.3 151
Heisterberg 2007 Risperidone -2.8 28.8 154
Heisterberg 2007 Placebo -7.5 29.8 149
triglycerides
Durgam 2014 Risperidone 6.3 84.2 140
Durgam 2014 Placebo -3.1 59.9 151
Heisterberg 2007 Risperidone -6.7 136.2 154
Heisterberg 2007 Placebo -27.9 104.4 149
VLDL
Heisterberg 2007 Risperidone -1.4 17.7 154
Heisterberg 2007 Placebo -3.7 16.9 149
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Analysis 1.18. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 18 Adverse effects: 8. musculoskeletal
system - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 18 Adverse effects: 8. musculoskeletal system - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 myalgia
Potkin 2003 2/99 3/103 100.0 % 0.69 [ 0.12, 4.06 ]
Subtotal (95% CI) 99 103 100.0 % 0.69 [ 0.12, 4.06 ]
Total events: 2 (Risperidone), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.69)
2 Joint disorder
Potkin 2003 5/99 2/103 100.0 % 2.60 [ 0.52, 13.10 ]
Subtotal (95% CI) 99 103 100.0 % 2.60 [ 0.52, 13.10 ]
Total events: 5 (Risperidone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Chi2 = 1.17, df = 1 (P = 0.28), I2 =15%
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Analysis 1.19. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 19 Adverse effects: 9. physiology -
short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 19 Adverse effects: 9. physiology - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALT increased
Geffen 2010 1/89 1/93 100.0 % 1.04 [ 0.07, 16.45 ]
Subtotal (95% CI) 89 93 100.0 % 1.04 [ 0.07, 16.45 ]
Total events: 1 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 AST increased
Geffen 2010 0/89 0/93 Not estimable
Subtotal (95% CI) 89 93 Not estimable
Total events: 0 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 blood CPK increased
Downing 2014 4/142 15/295 88.9 % 0.55 [ 0.19, 1.64 ]
Geffen 2010 1/89 0/93 11.1 % 3.13 [ 0.13, 75.92 ]
Subtotal (95% CI) 231 388 100.0 % 0.67 [ 0.23, 1.95 ]
Total events: 5 (Risperidone), 15 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.73 (P = 0.47)
4 blood pressure increased
Geffen 2010 2/89 2/93 100.0 % 1.04 [ 0.15, 7.26 ]
Subtotal (95% CI) 89 93 100.0 % 1.04 [ 0.15, 7.26 ]
Total events: 2 (Risperidone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
Test for subgroup differences: Chi2 = 0.21, df = 2 (P = 0.90), I2 =0.0%
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Analysis 1.20. Comparison 1 RISPERIDONE vs PLACEBO, Outcome 20 Adverse effects: 10. respiratory
system - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 1 RISPERIDONE vs PLACEBO
Outcome: 20 Adverse effects: 10. respiratory system - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 upper respiratory infection
Potkin 2003 8/99 2/103 43.6 % 4.16 [ 0.91, 19.12 ]
Potkin 2007 6/59 3/62 56.4 % 2.10 [ 0.55, 8.02 ]
Subtotal (95% CI) 158 165 100.0 % 2.83 [ 1.03, 7.74 ]
Total events: 14 (Risperidone), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.043)
2 pharyngitis
Potkin 2003 2/99 5/103 100.0 % 0.42 [ 0.08, 2.10 ]
Subtotal (95% CI) 99 103 100.0 % 0.42 [ 0.08, 2.10 ]
Total events: 2 (Risperidone), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
3 rhinitis
Borison 1992 9/51 1/53 49.8 % 9.35 [ 1.23, 71.21 ]
Potkin 2003 12/99 1/103 50.2 % 12.48 [ 1.65, 94.23 ]
Subtotal (95% CI) 150 156 100.0 % 10.81 [ 2.58, 45.29 ]
Total events: 21 (Risperidone), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
4 sinusitis
Downing 2014 1/142 2/295 100.0 % 1.04 [ 0.09, 11.36 ]
Subtotal (95% CI) 142 295 100.0 % 1.04 [ 0.09, 11.36 ]
Total events: 1 (Risperidone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 9.32, df = 3 (P = 0.03), I2 =68%
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Analysis 2.1. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 1
Mental state: no clinically signiﬁcant response in psychotic symptoms (deﬁned by PANSS/BPRS<20% decline) -
short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 1 Mental state: no clinically signiﬁcant response in psychotic symptoms (deﬁned by PANSS/BPRS<20% decline) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Honer 2006 28/34 25/34 68.9 % 1.12 [ 0.87, 1.44 ]
Yagcioglu 2005 14/16 10/14 31.1 % 1.23 [ 0.84, 1.79 ]
Total (95% CI) 50 48 100.0 % 1.15 [ 0.93, 1.42 ]
Total events: 42 (Risperidone), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 2
Leaving the study early - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 2 Leaving the study early - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any reason
Bachmann 2003 8/33 8/36 78.2 % 1.09 [ 0.46, 2.57 ]
Honer 2006 2/34 2/34 15.9 % 1.00 [ 0.15, 6.70 ]
Yagcioglu 2005 1/16 0/14 5.9 % 2.65 [ 0.12, 60.21 ]
Subtotal (95% CI) 83 84 100.0 % 1.13 [ 0.53, 2.42 ]
Total events: 11 (Risperidone), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
2 due to adverse events
Bachmann 2003 2/33 0/36 52.7 % 5.44 [ 0.27, 109.34 ]
Honer 2006 1/34 0/34 47.3 % 3.00 [ 0.13, 71.15 ]
Subtotal (95% CI) 67 70 100.0 % 4.11 [ 0.47, 36.24 ]
Total events: 3 (Risperidone), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
3 due to lack of efﬁcacy
Bachmann 2003 2/33 4/36 100.0 % 0.55 [ 0.11, 2.78 ]
Subtotal (95% CI) 33 36 100.0 % 0.55 [ 0.11, 2.78 ]
Total events: 2 (Risperidone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
4 due to noncompliance
Bachmann 2003 0/33 1/36 100.0 % 0.36 [ 0.02, 8.61 ]
Subtotal (95% CI) 33 36 100.0 % 0.36 [ 0.02, 8.61 ]
Total events: 0 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
5 lost to follow-up
Bachmann 2003 0/33 1/36 100.0 % 0.36 [ 0.02, 8.61 ]
Subtotal (95% CI) 33 36 100.0 % 0.36 [ 0.02, 8.61 ]
Total events: 0 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.63 (P = 0.53)
6 reported death
Honer 2006 0/34 0/34 Not estimable
Subtotal (95% CI) 34 34 Not estimable
Total events: 0 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 withdrawal of consent
Bachmann 2003 2/33 1/36 47.2 % 2.18 [ 0.21, 22.96 ]
Honer 2006 0/34 1/34 26.1 % 0.33 [ 0.01, 7.91 ]
Yagcioglu 2005 1/16 0/14 26.8 % 2.65 [ 0.12, 60.21 ]
Subtotal (95% CI) 83 84 100.0 % 1.41 [ 0.28, 7.09 ]
Total events: 3 (Risperidone), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.09, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
8 administrative reasons
Bachmann 2003 2/33 0/36 100.0 % 5.44 [ 0.27, 109.34 ]
Subtotal (95% CI) 33 36 100.0 % 5.44 [ 0.27, 109.34 ]
Total events: 2 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
9 abnormal lab results
Bachmann 2003 0/33 1/36 100.0 % 0.36 [ 0.02, 8.61 ]
Subtotal (95% CI) 33 36 100.0 % 0.36 [ 0.02, 8.61 ]
Total events: 0 (Risperidone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 2.3. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 3
Global state: 1. average endpoint scores of CGI severity scale (high=poor) - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Honer 2006 32 5.03 (0.97) 33 4.52 (1.06) 100.0 % 0.51 [ 0.02, 1.00 ]
Total (95% CI) 32 33 100.0 % 0.51 [ 0.02, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 4
Global state: 2. no signiﬁcant clinical improvement CGI - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 4 Global state: 2. no signiﬁcant clinical improvement CGI - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Honer 2006 28/34 25/34 100.0 % 1.12 [ 0.87, 1.44 ]
Total (95% CI) 34 34 100.0 % 1.12 [ 0.87, 1.44 ]
Total events: 28 (Risperidone), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 5
Global state: 3. general functioning - average endpoint GAF score (high=good) - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 5 Global state: 3. general functioning - average endpoint GAF score (high=good) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yagcioglu 2005 16 50.3 (5.6) 14 54.8 (5.24) 100.0 % -4.50 [ -8.38, -0.62 ]
Total (95% CI) 16 14 100.0 % -4.50 [ -8.38, -0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 6
Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) - short term
(up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PANSS total
Honer 2006 32 89.8 (15.8) 33 84.8 (20.1) 20.5 % 5.00 [ -3.77, 13.77 ]
Yagcioglu 2005 16 69.7 (5.65) 14 64 (6.66) 79.5 % 5.70 [ 1.25, 10.15 ]
Subtotal (95% CI) 48 47 100.0 % 5.56 [ 1.59, 9.53 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
2 PANSS general pathology
Yagcioglu 2005 16 31.7 (3.44) 14 29.2 (3.44) 100.0 % 2.50 [ 0.03, 4.97 ]
Subtotal (95% CI) 16 14 100.0 % 2.50 [ 0.03, 4.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
3 PANSS delusion
Yagcioglu 2005 16 3.7 (1.04) 14 3 (0.64) 100.0 % 0.70 [ 0.09, 1.31 ]
Subtotal (95% CI) 16 14 100.0 % 0.70 [ 0.09, 1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
4 PANSS negative symptom
Honer 2006 32 24.7 (6.3) 33 23.6 (7.1) 17.5 % 1.10 [ -2.16, 4.36 ]
Yagcioglu 2005 16 21.7 (2.08) 14 21.1 (2.1) 82.5 % 0.60 [ -0.90, 2.10 ]
Subtotal (95% CI) 48 47 100.0 % 0.69 [ -0.68, 2.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
5 PANSS positive symptom
Honer 2006 32 20.4 (5.7) 33 18.4 (5.4) 23.9 % 2.00 [ -0.70, 4.70 ]
Yagcioglu 2005 16 16.2 (2.12) 14 13.8 (2.1) 76.1 % 2.40 [ 0.89, 3.91 ]
Subtotal (95% CI) 48 47 100.0 % 2.30 [ 0.98, 3.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 3.42 (P = 0.00062)
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Analysis 2.7. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 7
Mental state: 2. average endpoint scores on various scales on psychotic symptoms (high=poor) - medium term
(up to 26 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 7 Mental state: 2. average endpoint scores on various scales on psychotic symptoms (high=poor) - medium term (up to 26 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
Bachmann 2003 25 36.4 (9.3) 28 41 (10.3) 100.0 % -4.60 [ -9.88, 0.68 ]
Subtotal (95% CI) 25 28 100.0 % -4.60 [ -9.88, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
2 BPRS positive symptom
Bachmann 2003 25 13.2 (3.5) 28 14.1 (3.6) 100.0 % -0.90 [ -2.81, 1.01 ]
Subtotal (95% CI) 25 28 100.0 % -0.90 [ -2.81, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 BPRS anxiety/depression factor
Bachmann 2003 25 7.6 (3.1) 28 8.6 (3.6) 100.0 % -1.00 [ -2.80, 0.80 ]
Subtotal (95% CI) 25 28 100.0 % -1.00 [ -2.80, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
4 SANS total
Bachmann 2003 25 31.3 (11.9) 28 34.4 (14.8) 100.0 % -3.10 [ -10.30, 4.10 ]
Subtotal (95% CI) 25 28 100.0 % -3.10 [ -10.30, 4.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 2.00, df = 3 (P = 0.57), I2 =0.0%
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Analysis 2.8. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 8
Mental state: 3. skewed data - short term (up to 12 weeks).
Mental state: 3. skewed data - short term (up to 12 weeks)
Study Intervention Mean SD N
average endpoint score of CDS total (high=poor)
Yagcioglu 2005 Resperidone 1.6 2 16
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Mental state: 3. skewed data - short term (up to 12 weeks) (Continued)
Yagcioglu 2005 Placebo 1.4 1.9 14
average endpoint score on verbal working memory (SD, high=good)
Honer 2006 Resperidone 0.08 0.99 152
Honer 2006 Placebo 0.14 0.83 71
Analysis 2.9. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 9
Adverse effects: 1a. extrapyramidal - average endpoint SAS score - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 9 Adverse effects: 1a. extrapyramidal - average endpoint SAS score - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yagcioglu 2005 16 12.3 (1.48) 14 13.2 (1.5) -0.90 [ -1.97, 0.17 ]
-4 -2 0 2 4
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Analysis 2.10. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 10
Adverse effects: 1b. extrapyramidal - skewed data (various scales) - short term (up to 12 weeks).
Adverse effects: 1b. extrapyramidal - skewed data (various scales) - short term (up to 12 weeks)
Study Intervention Mean SD N
average endpoint score of AIMS
Yagcioglu 2005 Risperidone 1.3 0.88 16
Yagcioglu 2005 Placebo 1.0 0.86 14
average change score of Barnes akathisia rating scale
Honer 2006 Risperidone 0.5 0.7 32
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Adverse effects: 1b. extrapyramidal - skewed data (various scales) - short term (up to 12 weeks) (Continued)
Honer 2006 Placebo 0.4 0.8 33
Yagcioglu 2005 Risperidone 0.18 0.6 16
Yagcioglu 2005 Placebo 0.72 0.6 14
average change score of ESRS
Honer 2006 Risperidone 9.3 6.9 32
Honer 2006 Placebo 7.8 7.0 32
average change score of ESRS - dystonia
Honer 2006 Risperidone 0.2 0.7 32
Honer 2006 Placebo 0.1 0.5 33
average change score of ESRS - dyskinesia
Honer 2006 Risperidone 2.4 4.1 32
Honer 2006 Placebo 2.1 4.2 33
average change score of ESRS - parkinsonism
Honer 2006 Risperidone 6.7 4.3 32
Honer 2006 Placebo 5.5 4 32
Analysis 2.11. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 11
Adverse effects: 1c. extrapyramidal - skewed data (various scales) - medium term (up to 26 weeks).
Adverse effects: 1c. extrapyramidal - skewed data (various scales) - medium term (up to 26 weeks)
Study Intervention Mean SD N
average endpoint score of AIMS
Bachmann 2003 Risperidone 3.5 5.5 25
Bachmann 2003 Placebo 2.2 2.8 28
average endpoint score of SAS
Bachmann 2003 Risperidone 1.8 3.4 25
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Adverse effects: 1c. extrapyramidal - skewed data (various scales) - medium term (up to 26 weeks) (Continued)
Bachmann 2003 Placebo 1.8 2.5 28
Analysis 2.12. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 12
Adverse effects: 2. any adverse event - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 12 Adverse effects: 2. any adverse event - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 any adverse event
Honer 2006 24/32 21/32 100.0 % 1.14 [ 0.83, 1.58 ]
Subtotal (95% CI) 32 32 100.0 % 1.14 [ 0.83, 1.58 ]
Total events: 24 (Risperidone), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
2 amenorrhoea
Honer 2006 1/32 0/32 100.0 % 3.00 [ 0.13, 71.00 ]
Subtotal (95% CI) 32 32 100.0 % 3.00 [ 0.13, 71.00 ]
Total events: 1 (Risperidone), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 asthenia
Honer 2006 14/32 13/32 100.0 % 1.08 [ 0.61, 1.91 ]
Subtotal (95% CI) 32 32 100.0 % 1.08 [ 0.61, 1.91 ]
Total events: 14 (Risperidone), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
4 depression
Honer 2006 12/32 10/32 100.0 % 1.20 [ 0.61, 2.37 ]
Subtotal (95% CI) 32 32 100.0 % 1.20 [ 0.61, 2.37 ]
Total events: 12 (Risperidone), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
5 emotional indifference
Honer 2006 10/32 9/32 100.0 % 1.11 [ 0.52, 2.37 ]
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Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 32 32 100.0 % 1.11 [ 0.52, 2.37 ]
Total events: 10 (Risperidone), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
6 fatigue
Honer 2006 14/32 13/32 100.0 % 1.08 [ 0.61, 1.91 ]
Subtotal (95% CI) 32 32 100.0 % 1.08 [ 0.61, 1.91 ]
Total events: 14 (Risperidone), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
7 failing memory
Honer 2006 8/32 12/32 100.0 % 0.67 [ 0.32, 1.41 ]
Subtotal (95% CI) 32 32 100.0 % 0.67 [ 0.32, 1.41 ]
Total events: 8 (Risperidone), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
8 increased duration of sleep
Honer 2006 11/32 11/32 100.0 % 1.00 [ 0.51, 1.97 ]
Subtotal (95% CI) 32 32 100.0 % 1.00 [ 0.51, 1.97 ]
Total events: 11 (Risperidone), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
9 salivation - increased
Honer 2006 20/32 16/32 100.0 % 1.25 [ 0.81, 1.94 ]
Subtotal (95% CI) 32 32 100.0 % 1.25 [ 0.81, 1.94 ]
Total events: 20 (Risperidone), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 2.64, df = 8 (P = 0.96), I2 =0.0%
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Analysis 2.13. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 13
Adverse effects: 3a. cardiovascular - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 13 Adverse effects: 3a. cardiovascular - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 dizziness - orthostatic
Honer 2006 8/32 8/32 100.0 % 1.00 [ 0.43, 2.34 ]
Subtotal (95% CI) 32 32 100.0 % 1.00 [ 0.43, 2.34 ]
Total events: 8 (Risperidone), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 palpitation
Honer 2006 4/32 4/32 100.0 % 1.00 [ 0.27, 3.66 ]
Subtotal (95% CI) 32 32 100.0 % 1.00 [ 0.27, 3.66 ]
Total events: 4 (Risperidone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 tachycardia
Honer 2006 4/32 4/32 100.0 % 1.00 [ 0.27, 3.66 ]
Subtotal (95% CI) 32 32 100.0 % 1.00 [ 0.27, 3.66 ]
Total events: 4 (Risperidone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 2.14. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 14
Adverse effects: 3b. cardiovascular - QTc interval - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 14 Adverse effects: 3b. cardiovascular - QTc interval - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yagcioglu 2005 16 430.3 (31.2) 14 450 (31.2) 100.0 % -19.70 [ -42.08, 2.68 ]
Total (95% CI) 16 14 100.0 % -19.70 [ -42.08, 2.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 15
Adverse effects: 4. central nervous system - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 15 Adverse effects: 4. central nervous system - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 sedation
Honer 2006 19/32 13/32 100.0 % 1.46 [ 0.88, 2.43 ]
Subtotal (95% CI) 32 32 100.0 % 1.46 [ 0.88, 2.43 ]
Total events: 19 (Risperidone), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
2 somnolence
Honer 2006 11/32 11/32 100.0 % 1.00 [ 0.51, 1.97 ]
Subtotal (95% CI) 32 32 100.0 % 1.00 [ 0.51, 1.97 ]
Total events: 11 (Risperidone), 11 (Placebo)
0.5 0.7 1 1.5 2
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(. . . Continued)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 tension
Honer 2006 16/32 13/32 100.0 % 1.23 [ 0.71, 2.12 ]
Subtotal (95% CI) 32 32 100.0 % 1.23 [ 0.71, 2.12 ]
Total events: 16 (Risperidone), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
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Analysis 2.16. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 16
Adverse effects: 5. gastrointestinal system - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 16 Adverse effects: 5. gastrointestinal system - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 constipation
Honer 2006 5/32 7/32 100.0 % 0.71 [ 0.25, 2.02 ]
Subtotal (95% CI) 32 32 100.0 % 0.71 [ 0.25, 2.02 ]
Total events: 5 (Risperidone), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.53)
0.2 0.5 1 2 5
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Analysis 2.17. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 17
Adverse effects: 6a. haematological - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 17 Adverse effects: 6a. haematological - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 neutrophil count
Honer 2006 28 4.75 (1.47) 29 4.38 (1.59) 100.0 % 0.37 [ -0.42, 1.16 ]
Subtotal (95% CI) 28 29 100.0 % 0.37 [ -0.42, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 prolactin level, ng/mL
Yagcioglu 2005 16 78.3 (20) 14 18.2 (17.96) 100.0 % 60.10 [ 46.52, 73.68 ]
Subtotal (95% CI) 16 14 100.0 % 60.10 [ 46.52, 73.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.67 (P < 0.00001)
3 white cell count
Honer 2006 30 7.52 (1.7) 31 6.86 (1.73) 100.0 % 0.66 [ -0.20, 1.52 ]
Subtotal (95% CI) 30 31 100.0 % 0.66 [ -0.20, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
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Analysis 2.18. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 18
Adverse effects: 6b. haematological - medium term (up to 26 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 18 Adverse effects: 6b. haematological - medium term (up to 26 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 prolactin level ng/mL
Bachmann 2003 20 41.7 (37.4) 24 7.6 (3.9) 100.0 % 34.10 [ 17.63, 50.57 ]
Subtotal (95% CI) 20 24 100.0 % 34.10 [ 17.63, 50.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000049)
2 fasting glucose
Bachmann 2003 21 96.6 (23.5) 19 101.2 (16.5) 100.0 % -4.60 [ -17.09, 7.89 ]
Subtotal (95% CI) 21 19 100.0 % -4.60 [ -17.09, 7.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 13.47, df = 1 (P = 0.00), I2 =93%
-100 -50 0 50 100
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Analysis 2.19. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 19
Adverse effects: 7a. metabolic - weight gain - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 19 Adverse effects: 7a. metabolic - weight gain - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Honer 2006 7/32 7/32 100.0 % 1.00 [ 0.40, 2.52 ]
Total (95% CI) 32 32 100.0 % 1.00 [ 0.40, 2.52 ]
Total events: 7 (Risperidone), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 20
Adverse effects: 7a. metabolic - weight gain - medium term (up to 26 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 20 Adverse effects: 7a. metabolic - weight gain - medium term (up to 26 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bachmann 2003 0/24 2/24 100.0 % 0.20 [ 0.01, 3.96 ]
Total (95% CI) 24 24 100.0 % 0.20 [ 0.01, 3.96 ]
Total events: 0 (Risperidone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 21
Adverse effects: 7b. metabolic - average endpoint value on lipid proﬁle - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 21 Adverse effects: 7b. metabolic - average endpoint value on lipid proﬁle - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 cholesterol - total (mg/dl)
Honer 2006 28 182.2 (43.6) 28 188.8 (42.1) 100.0 % -6.60 [ -29.05, 15.85 ]
Subtotal (95% CI) 28 28 100.0 % -6.60 [ -29.05, 15.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 HDL cholesterol (mg/dl)
Honer 2006 26 42.1 (13.9) 26 42.1 (17) 100.0 % 0.0 [ -8.44, 8.44 ]
Subtotal (95% CI) 26 26 100.0 % 0.0 [ -8.44, 8.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 LDL cholesterol (mg/dl)
Honer 2006 27 97.7 (35.5) 26 104.6 (35.5) 100.0 % -6.90 [ -26.02, 12.22 ]
Subtotal (95% CI) 27 26 100.0 % -6.90 [ -26.02, 12.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
4 triglycerides (mg/dl)
Honer 2006 28 215.9 (118.6) 28 209.7 (124.8) 100.0 % 6.20 [ -57.57, 69.97 ]
Subtotal (95% CI) 28 28 100.0 % 6.20 [ -57.57, 69.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 2.22. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 22
Adverse effects: 7c. metabolic - average endpoint value - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 22 Adverse effects: 7c. metabolic - average endpoint value - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 body mass index
Honer 2006 32 28.3 (6.2) 31 26.6 (4.6) 100.0 % 1.70 [ -0.99, 4.39 ]
Subtotal (95% CI) 32 31 100.0 % 1.70 [ -0.99, 4.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
2 fasting glucose (mg/dl)
Honer 2006 26 118.9 (46.8) 25 102.7 (18) 100.0 % 16.20 [ -3.12, 35.52 ]
Subtotal (95% CI) 26 25 100.0 % 16.20 [ -3.12, 35.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
3 waist circumference (cm)
Honer 2006 29 103.1 (20.3) 32 98 (16) 100.0 % 5.10 [ -4.14, 14.34 ]
Subtotal (95% CI) 29 32 100.0 % 5.10 [ -4.14, 14.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
4 weight gain
Yagcioglu 2005 16 68.6 (1.68) 14 68.3 (1.65) 98.5 % 0.30 [ -0.89, 1.49 ]
Honer 2006 32 86.5 (21) 32 83.4 (18.4) 1.5 % 3.10 [ -6.57, 12.77 ]
Subtotal (95% CI) 48 46 100.0 % 0.34 [ -0.84, 1.53 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
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Analysis 2.23. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 23
Adverse effects: 8. sleep - skewed data - average change score (UKU) - short term (up to 12 weeks).
Adverse effects: 8. sleep - skewed data - average change score (UKU) - short term (up to 12 weeks)
Study Intervention Mean SD N
Yagcioglu 2005 Risperidone 0.7 0.36 16
Yagcioglu 2005 Placebo 0.2 0.37 14
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Analysis 2.24. Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 24
Quality of life: average endpoint score (QLS, high=good) - short term (up to 12 weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE
Outcome: 24 Quality of life: average endpoint score (QLS, high=good) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yagcioglu 2005 16 55.8 (8.84) 14 55 (8.57) 100.0 % 0.80 [ -5.44, 7.04 ]
Total (95% CI) 16 14 100.0 % 0.80 [ -5.44, 7.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours risperidone Favours placebo
150Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition),
Outcome 1 Mental state: 1. no clinically signiﬁcant response (deﬁned by PANSS/BPRS) - short term (up to 12
weeks).
Review: Risperidone versus placebo for schizophrenia
Comparison: 3 SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition)
Outcome: 1 Mental state: 1. no clinically signiﬁcant response (deﬁned by PANSS/BPRS) - short term (up to 12 weeks)
Study or subgroup Risperidone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 deﬁned by PANSS/BPRS <20% decline
Borison 1992 18/51 37/53 13.7 % 0.51 [ 0.33, 0.76 ]
Chouinard 1992 6/22 19/22 6.7 % 0.32 [ 0.16, 0.64 ]
Marder 1994a 27/63 50/64 17.9 % 0.55 [ 0.40, 0.75 ]
Potkin 1997 30/85 44/83 16.1 % 0.67 [ 0.47, 0.95 ]
Potkin 2003 57/95 79/103 23.9 % 0.78 [ 0.64, 0.95 ]
Potkin 2006 76/152 45/71 21.7 % 0.79 [ 0.62, 1.00 ]
Subtotal (95% CI) 468 396 100.0 % 0.64 [ 0.52, 0.78 ]
Total events: 214 (Risperidone), 274 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 12.27, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 4.33 (P = 0.000015)
2 deﬁned by PANSS/BPRS <20% decline (without studies with >50% left the study early)
Potkin 1997 30/85 44/83 15.6 % 0.67 [ 0.47, 0.95 ]
Potkin 2003 57/95 79/103 50.3 % 0.78 [ 0.64, 0.95 ]
Potkin 2006 76/152 45/71 34.1 % 0.79 [ 0.62, 1.00 ]
Subtotal (95% CI) 332 257 100.0 % 0.77 [ 0.67, 0.88 ]
Total events: 163 (Risperidone), 168 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Chi2 = 2.16, df = 1 (P = 0.14), I2 =54%
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A D D I T I O N A L T A B L E S
Table 1. Risperidone reviews
Comparison Reference
Oral risperidone vs other atypical drugs Gilbody 2000; Komossa 2007
vs olanzapine Jayaram 2006
vs typical drugs Kennedy 2000; Hunter 2003
Depot risperidone Hosalli 2003
Risperidone dose Li 2009
Risperidone for acute aggression Ahmed 2011
Table 2. Global Assessment of Functioning scale
Score Judgement
91-100 Superior functioning in a wide range of activities, life’s problems never seem to get out of hand, is sought out by others
because of his or her many qualities. No symptoms
81-90 Absent or minimal symptoms, good functioning in all areas, interested and involved in a wide range of activities, socially
effective, generally satisﬁed with life, no more than everyday problems or concerns
71-80 If symptoms are present they are transient and expectable reactions to psychosocial stresses; no more than slight impairment
in social, occupational, or school functioning
61-70 Some mild symptoms OR some difﬁculty in social, occupational, or school functioning, but generally functioning pretty
well, has some meaningful interpersonal relationships
51-60 Moderate symptoms OR any moderate difﬁculty in social, occupational, or school functioning
41-50 Serious symptoms OR any serious impairment in social, occupational, or school functioning
31-40 Some impairment in reality testing or communication OR major impairment in several areas, such as work or school,
family relations, judgement, thinking, or mood
21-30 Behavior is considerably inﬂuenced by delusions or hallucinations OR serious impairment in communications or judgment
OR inability to function in all areas
11-20 Some danger of hurting self or others OR occasionally fails to maintain minimal personal hygiene OR gross impairment
in communication
1-10 Persistent danger of severely hurting self or others OR persistent inability to maintain minimum personal hygiene OR
serious suicidal act with clear expectation of death
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Table 2. Global Assessment of Functioning scale (Continued)
0 Not enough information available to provide GAF.
Table 3. Reviews suggested by excluded studies
Broad category of
comparison
Intervention Control Excluded study/studies Existing Cochrane re-
views
Augmentation [of] risperidone by antioxidants Zhang 2002 -
buﬂomedil Zhong 2006
celecoxib Riedel 2003
D-alanine Tsai 2006
sarcosine Tsai 2004
valproate Wang 2003
clozapine risperidone McKenna 2004,
Peuskens 2001a
Long-acting
preparation
depot risperidone versus olanzapine Chue 2002 Hosalli 2003
placebo Cada 2004, Ciliberto
2005, Lauriello 2005,
Nasrallah 2004a,Urioste
2004, NCT00249119
Experimental com-
pound
risperidone versus BL-1020 NCT01363349a -
LY2140023 NCT01086748a
PF-02545920 DeMartinis 2012a,
NCT01175135a
Versus another an-
tipsychotic
risperidone versus amisulpride Hwang 2003, Rein
2002, Peuskens 2001
Komossa 2010;
Komossa 2007
aripiprazole Dubitsky 2002, Chan
2007, Hwang 2005,
NCT00202007, Kane
2005
Khanna 2014; Komossa
2007
asenapine Fleming 2007a Komossa 2007
cariprazine Bose 2010b Protocol underway
153Risperidone versus placebo for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Reviews suggested by excluded studies (Continued)
clozapine Bondolﬁ 1998, Cavaz-
zoni 2002a
Komossa 2007
clocapramine Yamawaki 1996 -
haloperidol Claus 1992, Friedman
2000, Lindstrom 1994,
Lopez 1996, Lopez-Ibor
1992, NCT00253136,
Peuskens
1995, Rabinowitz 2001,
Wirshing 1995, Borison
1992a, Csernansky 1999
Hunter 2003
molindone McClellan 2009 Bagnall 2007
olanzapine Tollefson 1996,
Edgell 2000, Tran 1997,
Conley 1998, Harvey
2001, Brecher 1998,
McClellan 2009, Cavaz-
zoni 2002a, Cooper
1997, NCT00034892
Komossa 2007; Jayaram
2007
quetiapine Cooper 1997,
NCT00034892
Asmal 2013; Komossa
2007
sertindole Kane 2005 Komossa 2009;
Komossa 2007
zuclopenthixol
dihydrochloride
Lemmens 1994 Hunter 2003; Kumar
2005
Not risperidone amisulpride versus placebo Boyer 1995, Loo 1997 Mota 2002
aripiprazole haloperidol Carson 2002 Bhattacharjee 2008
olanzapine Cornblatt 2002 Khanna 2014
perphenazine Gismondi 2004 Bhattacharjee 2008
placebo Carson 2002, Casey
2003
Belgamwar 2011
haloperidol placebo Beasley 1996, Carson
2002, Crawford 1997
Adams 2013
olanzapine ﬂuphenazine Dossenbach 1997 Duggan 2005
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Table 3. Reviews suggested by excluded studies (Continued)
haloperidol Beasley 1996, Crawford
1997, Gregor 2000,
Kinon 1998, Lieberman
2005, Revicki 1996
paliperidone Luo 2011 Komossa 2007;
Nussbaum 2012
placebo Beasley 1996, Crawford
1997, Luo 2011
Protocol underway
paliperidone placebo Luo 2011 Nussbaum 2012
Single vs polyphar-
macy
risperidone versus amisulpride + haloperi-
dol
Peuskens 2001a -
Miscellaneous antipsychotic drugs versus miscellaneous (risperi-
done, olanzapine, queti-
apine)
Weickert 2003
risperidone valproate
+ miscellaneous antipsy-
chotic drugs
Citrome 2004
riluzole (a drug used to
treat amyotrophic lateral
sclerosis)
Rujescu 2009a
talnetant (a
neurokinin 3 receptor
antagonist)
GlaxoSmithKline 2006a
Table 4. Suggested design of study
Methods Allocation: randomised, clearly described and concealed.
Blinding: double, tested.
Duration: 1 year or more.
Participants Diagnosis: schizophrenia, schizotypal, schizoaffective, delusional disorder, acute psychosis, comorbid alcohol prob-
lems, and substance misuse.
N = 300.
Age: adults.
Sex: men or women.
History: perhaps once an early episode of moderate severity has subsided and after a period of stable washout of the
medications used during the acute phase, living anywhere and not just in hospital
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Table 4. Suggested design of study (Continued)
Interventions 1. Risperidone: dose 4 mg/day or above.
2. Placebo.
Outcomes Healthy days.
Mental state: improved to important degree.
Global state: improved to important degree, relapse.
Service use: in hospital.
Social functioning: employment status, relationships.
Quality of life: improved to important degree.
Economic outcomes: cost.
Notes Free of all industry inﬂuence.
A P P E N D I C E S
Appendix 1. Previous search
The previous search phrases for the register via MeerKat (February 2008) were as follows:
[risperidone* or Risperdal* in title or *risperidone* or *risperdal* in abstract, index terms of REFERENCE] or [risperidone* in
interventions of STUDY]
This register is compiled by systematic searches of major databases and theirmonthly updates, handsearches, and conference proceedings
(see group module).
Appendix 2. Previous methods
Data collection and analysis
Selection of studies
We (RR, MJ) independently inspected all reports of identiﬁed studies. Any disagreements were resolved by consensus; where doubts
remained, we acquired the full article. We independently decided whether these studies met the review criteria. We did not intend to
blind the names of authors, institutions, and journal of publication. Again, we resolved any disagreements by consensus. When this
was not possible, we sought further information and, in the interim, added these trials to the Studies awaiting classiﬁcation list. RR
and MJ independently inspected citations from the subsequent updated search (December 2007) and identiﬁed the relevant abstracts.
We obtained and inspected full reports of the abstracts meeting the review criteria.
Data extraction and management
1. We (RR, MJ) independently extracted data and resolved any disagreements by discussion. When this was not possible, we sought
further information from the trial authors.
1.1 Binary data
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When summation was appropriate, with binary outcomes such as improved/not improved, we calculated the risk ratio statistic with a
95% conﬁdence interval and used a random-effects model. In addition, as a measure of efﬁciency, we estimated the number needed to
treat to beneﬁt or the number needed to treat to harm from the pooled totals.
1.2. Continuous data
1.2.1 Normally distributed data
Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to
non-parametric data, we applied the following standards to all data before inclusion: (a) standard deviations (SD) and means reported
in the paper were obtained from the authors; (b) when a scale starts from the ﬁnite number 0, the SD, when multiplied by 2, is less
than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution) (Altman 1996); (c)
if a scale started from a positive value (such as Positive and Negative Syndrome Scale, which can have values from 30 to 210), the
calculation described above was modiﬁed to take the scale starting point into account. In these cases skew will be present if 2 SD > (S
- S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a ﬁnite start and endpoint,
and these rules can be applied to them. When continuous data are presented on a scale that includes a possibility of negative values
(such as change on a scale), it is difﬁcult to tell whether data are non-normally distributed (skewed) or not. We presented skewed data
in the ’Other data’ tables rather than included in the analysis.
For change data (endpoint minus baseline), the situation is even more problematic. In the absence of individual participant data, it
is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we
presented the change data in order to summarise the available information. In doing this, we assumed that data was not skewed or
that the analyses can cope with the unknown degree of skew. Again, without individual participant data it was impossible to test this
assumption. Where both change and endpoint data were available for the same outcome category, we presented only the endpoint
data. We acknowledge that by doing this, much of the published change data can be excluded, but our argument is that endpoint
data is more clinically relevant and that if change data were to be presented along with endpoint data, it would give undeserved equal
prominence to both. We contacted the authors of studies that only reported change for endpoint ﬁgures.
1.2.2 Summary statistic
For continuous outcomes, we estimated a weighted mean difference between groups. Again, this was based on the random-effects
model, as this took into account any differences between studies even if there was no statistically signiﬁcant heterogeneity. We did not
consider continuous data presented without use of summary statistics (that is mean, SD, standard error, median, interquartile range),
although we noted the existence of these data in the text.
Assessment of risk of bias in included studies
Again working independently, review authors assessed risk of bias using the tool described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008). This tool encourages consideration of how the sequence was generated, how allocation was
concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting, and other biases. We excluded
studies where allocation was clearly not concealed.
We removed trials with high risk of bias (deﬁned as at least three out of ﬁve domains categorised as ’no’) from the ’included’ category.
When the raters disagreed, the ﬁnal rating was made by consensus with the involvement of another review author. Where details of
randomisation and other characteristics of trials were inadequate, we contacted authors of the studies to obtain further information.
We reported non-concurrence in quality assessment.
Measures of treatment effect
Many rating scales are available to measure outcomes in mental health trials (Marshall 2000). These scales vary in quality, and many
are poorly validated. It is generally accepted that measuring instruments should have the properties of reliability (the extent to which a
test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure). Before
publication of an instrument, most scientiﬁc journals insist that its reliability and validity be demonstrated to the satisfaction of referees.
As a minimum standard, we excluded data from unpublished rating scales. In addition, the rating scale was either: (i) a self report; or
(ii) completed by an independent rater or relative. If continuous data were presented from different scales rating the same outcome, we
presented all data without summation and inspected the general direction of effect.
Unit of analysis issues
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To facilitate comparison between trials, we intended to convert variables (such as days in hospital) that can be reported in different
metrics (mean days per year, per week, or per month) to a common metric (for example mean days per month). We converted weight
gain reported in pounds to kilograms where possible.
Dealing with missing data
Where possible, we analysed the data on an intention-to-treat basis and assumed that those who had not been accounted for had the
less positive outcome. We did not include this rule for the outcome of ’death’. We intended to test this assumption with a sensitivity
analysis. For continuous data, which was impossible to manage in this way, we presented only the ’completer’ data. Wherever feasible,
we converted the continuous scores to dichotomous data.
If, for a given outcome (except adverse effects), more than 50% of the total numbers randomised were not accounted for, we did not
present the results, as such data are impossible to interpret with authority. If, however, more than 50% of those in one arm of a study
were lost, but the total loss was less than 50%, we marked such data with ’*’ to indicate that such result may well be prone to bias.
Assessment of heterogeneity
Firstly, we considered all the included studies within any comparison to judge clinical heterogeneity. We then visually inspected the
graphs in order to investigate the possibility of statistical heterogeneity; to supplement this we used, primarily, the I2 statistic, which
provides an estimate of the percentage of variability due to heterogeneity rather than due to chance alone. Where the I2 estimate
was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (Higgins 2003). If
inconsistency became high, we did not summate data, but presented it separately, and we investigated the reasons for heterogeneity.
Assessment of reporting biases
In order to investigate the likelihood of overt publication bias, we entered all data from all identiﬁed and selected trials into a funnel
graph (trial effect against trial size) (Egger 1997).
Data synthesis
Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for
risperidone. Studies increasingly employ ’cluster randomisation’ (such as randomisation by clinician or practice), but analysis and
pooling of clustered data pose problems. Firstly, authors often fail to account for intraclass correlation (ICC) in clustered studies, leading
to a ’unit of analysis’ error (Divine 1992), whereby P values are spuriously low, conﬁdence intervals are unduly narrow, and statistical
signiﬁcance gets overestimated. This causes type I errors (Bland 1997, Gulliford 1999).
Where clustering was not accounted for in primary studies, we presented the data in a table with a (*) symbol to indicate the presence
of a probable unit of analysis error. In subsequent versions of the review, we will seek out ﬁrst authors of studies to obtain ICC of their
clustered data and use accepted methods to adjust for this (Gulliford 1999). Where clustering has been incorporated into the analysis of
primary studies, we also presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect. We have
sought statistical advice and have been advised that the binary data presented in a report should be divided by a ’design effect’. This
is calculated using the mean number of participants per cluster (m) and the ICC Design effect = 1 + (m - 1)*ICC (Donner 2002). If
the ICC was not reported, we assumed it to be 0.1 (Ukoumunne 1999). If cluster studies had been appropriately analysed, taking into
account ICCs, and relevant data documented in the report, we synthesised these with other studies using the generic inverse variance
technique.
Subgroup analysis and investigation of heterogeneity
If data were clearly heterogeneous, we checked that they had been extracted and entered correctly, and that we had made no unit of
analysis errors. If the high levels of heterogeneity remained, we did not undertake a meta-analysis at this point, because if there is
considerable variation in results, and particularly if there is inconsistency in the direction of effect, it may be misleading to quote an
average value for the intervention effect. We prespeciﬁed no characteristics of studies that may be associated with heterogeneity except
quality of trial method.
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Sensitivity analysis
If studies had high attrition rates, we analysed the effect of including these studies in a sensitivity analysis, but we did not include any
ﬁgures with more than 50% attrition in the analysis of efﬁcacy. Where a trial was described as ’double-blind’, but it was implied that
the study was randomised, we intended to include such studies in the sensitivity analysis, but we did not come across any such studies.
F E E D B A C K
Response to comments, 21 February 2013
Summary
Hutton 2012 has highlighted the following issues regarding this review:
1. ’Fixed effect’ analysis was used instead of ’random effects’ analysis for the outcome of 20% change in total PANSS/BPRS scores.
2. Should not have included Marder 1994a in our analysis, as the overall attrition rate for this study was over 50%.
3. Should not have included Borison 1992 study in our analysis, as an internal conﬁdential report by Janssen Pharmaceuticals reports
a different leaving the study early rate than that of the original published paper.
4. It is incorrect to derive standard deviation from standard error in Chouinard 1992, and data were entered wrong way round for
two outcomes: endpoint Brief Psychiatric Rating Scale (BPRS) total score and Positive and Negative Syndrome Scale (PANSS) positive
symptom score.
5. Honer 2006 should not have contributed to outcome ’no clinically signiﬁcant improvement (CGI-S)’, as they had used only PANSS
scores.
Reply
Thank you for your comments.
We have now repeated the analysis for the outcome 20% change in total PANSS/BPRS score by using ’random effects’ model instead
of ﬁxed effects. With the ’ﬁxed effects’ analysis RR was 0.7 favouring risperidone and with ’random effect’ analysis the RR is 0.68
favouring risperidone and hence there is no change in the overall outcome.
As regards the Marder 1994a study, it has an overall attrition rate of over 50%. However this study has three arms of risperidone and
we included data from only the 6mg arm as this was closest to what is clinically most commonly used. This intervention arm of 6mg
per day of risperidone had an attrition rate of 45% (page 828, American Journal of Psychiatry, 151:6 June 1994). The attrition rate for
this particular arm was less than 50% and hence this was included.
The attrition rate in Borison 1992 as reported by the original published paper is zero. This did appear too good to be true, however
our attempts to contact the authors were unsuccessful and we did not have access to any other data. We would be keen to have a look
at the internal conﬁdential report by Janssen if this indeed reports a different drop out rate and would be grateful if anyone with access
to this can forward the data to the authors.
For data extraction from theChouinard 1992 study, we have used formula recommended by theCochraneHandbook to derive Standard
Deviation Higgins 2008. The authors checked Chouinard 1992 data and are assured that we have reported it accurately in our review.
The paper reports the ﬁgures for the number of patients showing more than 20% improvement in BPRS/PANSS but in our review
we have extrapolated the ﬁgures for ’<20% decrease in PANSS/BPRS total score’. Although the primary publication for Honer 2006
reports only the PANSS scores, we found additional published data (International Congress of Schizophrenia Research 2005, page 487)
which provides data on CGI-S scores.
Contributors
Dr Ranganath Rattehalli and Dr Mahesh Jayaram
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Response to email, 3 March 2013
Summary
Paul Hutton from the Psychosis Research Unit, Psychology Department, Greater Manchester West Mental Health Trust, UK, has
sent an email to the authors of this review wherein he claims that the review authors should not have included the two clozapine
augmentation studies in the review (Yagcioglu 2005 and Honer 2006), or should have analysed these separately.
Reply
We acknowledge that the two clozapine augmentation studies could have been analysed separately. We have thus now analysed our
results with and without these two studies, and the results of this sensitivity analysis are as follows.
2.1 Leaving the study early - for any reason
With the clozapine augmentation studies the results are: 11 RCTs, N = 1363, RR 0.7 (0.57, 0.86), favours risperidone. Without the
clozapine augmentation studies the results are: 9 RCTs, N = 1265, RR 0.69 (0.56, 0.85), still favours risperidone. Exclusion of clozapine
augmentation studies makes no difference to this outcome.
2.2 Leaving study early - due to adverse effects
With the clozapine augmentation studies the results are: 6 RCTs, N = 829, RR 1.09 (0.43, 2.74), not statistically signiﬁcant. Without
the clozapine augmentation studies the results are: 5 RCTs, N = 761, RR 1.03 (0.38, 2.81), still not statistically signiﬁcant. Exclusion
of the clozapine augmentation studies makes no difference to this outcome.
2.3 Leaving the study early - due to withdrawal of consent
With the clozapine augmentation studies the results are: 4 RCTs, N = 368, RR 1.2 (0.44, 3.28), not statistically signiﬁcant. Without
the clozapine augmentation studies the results are: 3 RCTs, N = 300, RR 1.39 (0.48, 4.00), still not statistically signiﬁcant. Exclusion
of the clozapine augmentation study makes no difference to this outcome.
2.4 Global state - no clinically signiﬁcant improvement (CGI-Severity)
With the clozapine augmentation studies the results are: 3 RCTs, N = 397, RR 0.8 (0.55, 1.15), not statistically signiﬁcant. Without the
clozapine augmentation studies the results are: 2 RCTs, N = 329, RR 0.67 (0.46, 0.98), favours risperidone. Exclusion of the clozapine
augmentation study changes the result in favour of risperidone for this outcome.
2.5 Global state - average endpoint score (CGI-Severity)
With the clozapine augmentation studies the results are: 4 RCTs, N = 266, WMD -0.29 (-1.18, 0.59), not statistically signiﬁcant.
Without the clozapine augmentation studies the results are: 2 RCTs,N = 171,WMD-1.01 (-1.38, -0.64), favours risperidone. Exclusion
of the clozapine augmentation study changes the result in favour of risperidone for this outcome.
2.6 Global state - average endpoint score (GAF score)
Akdede 2006 (clozapine augmentation study) is the only study favouring risperidone for this outcome.
2.7 Mental state - < 20% decline on PANSS total change score
With the clozapine augmentation studies the results are: 4 RCTs, N = 407, RR 0.64 (0.39, 1.04), not statistically signiﬁcant. Without
the clozapine augmentation studies the results are: 3 RCTs, N = 339, RR 0.54 (0.4 0.74), favours risperidone. Exclusion of clozapine
augmentation study changes the result in favour of risperidone for this outcome.
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2.8 Mental state - < 20% decrease in PANSS/BPRS total change score
With the clozapine augmentation studies the results are: 7 RCTs, N = 856, RR 0.7 (0.62, 0.79), favours risperidone. Without the
clozapine augmentation studies the results are: 6 RCTs, N = 788, RR 0.66 (0.58, 0.76), favours risperidone. Exclusion of clozapine
augmentation study makes no difference to this outcome.
2.9 Mental state - average endpoint score (PANSS Total score)
With the clozapine augmentation studies the results are: 4 RCTs, N = 266, WMD -7.55 (-22.04, 6.95), not statistically signiﬁcant.
Without the clozapine augmentation studies the results are: 2 RCTs, N = 171, WMD -20.13 (-27.33, ...), favours risperidone. Exclusion
of the clozapine augmentation studies changes the result in favour of risperidone for this outcome.
2.10 Mental state - average endpoint score (PANSS General score)
With the clozapine augmentation studies the results are: 2 RCTs, N = 74, WMD -5 (-20.37, 10), not statistically signiﬁcant. Without
the clozapine augmentation studies the results are: 1 RCT, N = 44, WMD -13.2 (-20.15, ...), favours risperidone. Exclusion of the
clozapine augmentation study leaves only one RCT for this outcome, which is in favour of risperidone.
2.11 Mental state - average endpoint score (PANSS Negative symptom score)
With the clozapine augmentation studies the results are: 4RCTs,N =266,WMD -0.9 (-3.06, 1.27), not statistically signiﬁcant.Without
the clozapine augmentation studies the results are: 2 RCTs, N = 171, WMD -2.84 (-4.96, -0.73), favours risperidone. Exclusion of the
two clozapine augmentation studies changes this outcome in favour of risperidone.
2.12 Mental state - average endpoint score (PANSS Positive symptom score)
With the clozapine augmentation studies the results are: 4 RCTs, N = 266, WMD 1.67 (-2.93, 6.28), not statistically signiﬁcant.
Without the clozapine augmentation studies the results are: 2 RCTs, N = 171, WMD 1.52 (-12.69, 15.73), still not statistically
signiﬁcant. Exclusion of the two clozapine augmentation studies does not change this outcome.
Thus, in summary, exclusion of the two clozapine augmentation studies either makes no difference to the main outcomes or shifts the
results slightly more in favour of risperidone on some of the outcomes related to mental state. These augmentation studies contribute
to less than 20% of the data, and we feel that it is only fair to include them in the review, as in real life many more people with
schizophrenia are going to be on a combination of antipsychotics.
Contributors
Dr Ranganath Rattehalli and Dr Mahesh Jayaram
WH A T ’ S N E W
Date Event Description
13 September 2016 New citation required but conclusions have not
changed
Results of update searching added to review. Five new
trials added to included studies table. Data from these
new trials did not change overall results or conclusions
of review
19 October 2015 New search has been performed Update search run and 25 references assessed, 2 new
studies included
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(Continued)
15 October 2013 Amended Update search carried out 2013, 69 references assessed,
3 new studies included
15 March 2013 Feedback has been incorporated Comments reported inHutton 2012 regarding includ-
ing trials with high attrition addressed, sensitivity anal-
ysis completed and added to feedback section. Overall
results and conclusion of review are unaffected
H I S T O R Y
Date Event Description
3 March 2013 Amended See feedback section for amendments.
21 February 2013 Amended See feedback section for details.
C O N T R I B U T I O N S O F A U T H O R S
RR: Initiated the review, developed the background and protocol, selected studies and extracted data, and wrote the ﬁndings of the
original 2008 review, helped with 2015 update writing.
SZ: Screened search results, extracted data for the 2015 update search and wrote the report.
BL: Screened search results and extracted data for the 2015 update search.
MJ: Helped with developing the background and protocol, cross checked data extraction, and wrote the ﬁndings of the original 2008
review, draft checking 2015 update.
JX: Screened search results, extracted data, and participated in report writing for the 2015 update.
SS: Screened and data extraction for 2013 search.
D E C L A R A T I O N S O F I N T E R E S T
RR: none known.
SZ: none known.
BL: none known.
MJ: none known.
JX: none known.
SS: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• Leeds Partnerships NHS Foundation Trust, UK.
External sources
• University of Nottingham, UK.
• Cochrane Collaboration Programme Grant 2011, UK.
Reference number: 10/4001/15
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The methods section of the protocol was updated to reﬂect the Cochrane Schizophrenia Group’s standardised method section (see
Appendix 2 for previous methods). We altered the structure of the protocol outcomes to match the structure in the data and analyses
table; however, we have not changed outcomes.
N O T E S
None
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Antipsychotic Agents [∗administration & dosage; adverse effects]; Placebos [therapeutic use]; Publication Bias;
Randomized Controlled Trials as Topic; Risperidone [∗administration & dosage; adverse effects]; Schizophrenia [∗drug therapy]
MeSH check words
Humans
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